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3ABSTRACT
Prolonged arterial occlusion results in ischaemic cell death. Reperfusion is necessary to
prevent irreversible tissue infarction, but paradoxically contributes to some cell death.
The composite ischaemia-reperfusion (IR) injury, contributes to tissue damage in
common clinical conditions, and reducing IR injury remains a validated therapeutic
target.
Ischaemic preconditioning (IPC) attenuates IR injury and is elicited by non-lethal
periods of ischaemia in advance of a prolonged arterial occlusion. IPC also exerts a
systemic protective effect, remote ischaemic preconditioning (RIPC), which is believed
to occur through activation of humoral and neural pathways.
Experiments in this thesis investigated IPC and RIPC using four in vivo models. Firstly,
in a rat model of stroke caused by transient occlusion of the middle cerebral artery,
RIPC induced by limb ischaemia reduced infarct size. Secondly, in healthy volunteers
in vivo, vascular occlusion caused endothelial IR injury of the brachial artery and this
model was used to determine whether physical exercise elicited a protective phenotype
similar to RIPC. In these experiments, only IPC has an effect to reduce IR injury.
Thirdly, the inflammatory response to cantharidin was used in healthy volunteers to
model the innate immune response, and to compare the anti-inflammatory effects of
aspirin and IPC. Aspirin reduced inflammation in subjects with an early resolution
phenotype, but IPC had no effect on the immune response. Fourthly, the effect of IPC
on the response to exercise was investigated in healthy cyclists. IPC did not alter
exercise capacity but increased skeletal muscle oxygenation in humans during an
incremental exercise test. The results in this thesis complement certain previous
observations and provide evidence of heterogeneity in the protective phenotype of IPC
and RIPC.
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1.1. Background
Cardiovascular disease has a high morbidity and mortality in the developed world. The
2006 death rate for cardiovascular disease in the USA was 263 per 100,000 (1), and
currently accounts for 1 in 3 deaths in the UK (191,000 deaths/year) (2). Atherosclerotic
cardiovascular disease often results in either total or partial arterial occlusion, and
presents clinically as an acute ischaemic event such as myocardial infarction
(124,000/year in the UK) or stroke (152,000/year in the UK) (3). Despite improvements
in treating cardiovascular disease over the past 30 years, reducing the burden further
requires improved prevention of atherosclerotic cardiovascular events, and improved
treatment when these events occur.
In addition to acute ischaemic emergencies, ischaemia occurs during elective surgical
procedures, such as coronary artery bypass graft surgery and organ transplantation. In
both of these examples of emergency and elective cases, arterial flow to an organ or
tissue is critically reduced, and this limits supply of oxygen and glucose, and removal of
waste metabolites. Treatments of ischaemia, including bypass, percutaneous coronary
intervention, and thrombolysis, rely on rapid restoration of oxygenated blood flow to
the ischaemic tissue, which is vital in ensuring cell viability. Reperfusion however is
commonly described as a “double-edged sword”. Whilst vital for tissue recovery,
reperfusion paradoxically contributes to cellular injury (4). The resultant damage from a
combined ischaemic event and treatment by reperfusion, is known collectively as an
ischaemia-reperfusion (IR) injury.
One of the most widely studied interventions to reduce IR injury is ischaemic
preconditioning (IPC). Ischaemia acts as physiological hormesis; whilst a prolonged
episode causes cellular injury, brief non-lethal bouts are well tolerated, and can induce a
protective phenotype against subsequent ischaemic injury. During IPC, a tissue or organ
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is exposed to brief periods of non-lethal intermittent ischaemia and reperfusion prior to
the prolonged ischaemic event (5). Furthermore IPC is believed to induce a systemic
protective effect, such that tissues distant to the site of IPC also become protected
against IR injury (6). IPC and variants thereof are currently undergoing human clinical
trials for a variety of ischaemic conditions (7).
The pathophysiology of IR injury involves a complex interaction between numerous
mechanisms, and hence results from in vitro studies are often not replicated in vivo.
Furthermore findings in animal experiments often fail to provide sufficient efficacy and
safety when studied in human clinical trials (8). This highlights the importance of well-
designed animal models, and the necessity for human in vivo models to ensure that early
findings have the potential to contribute as useful clinical treatments.
My PhD comprises an investigation into the mechanisms of IPC. I have utilised four in
vivo models (one rat model, three human models) to describe the effects of IPC on
stroke, the vascular endothelium, acute inflammation, and muscle oxygenation. This
thesis describes two years and five months of research.
1.2. Ischaemia-reperfusion injury
The injury resulting from a prolonged arterial occlusion and subsequent reperfusion is
termed ischaemia-reperfusion (IR) injury. Below are described the mechanisms which
contribute to the pathophysiology of IR injury, firstly during ischaemia, and secondly
during reperfusion.
1.2.1. Ischaemic injury
Arterial occlusion reduces the delivery of oxygen to tissues, and the removal of toxic
waste metabolites. The cellular response to ischaemia is to reduce energy consumption,
and to switch towards oxygen-independent energy pathways. From the onset of acute
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ischaemia cells become reversibly injured. As ischaemia is prolonged, cellular injury
becomes irreversible, resulting in a complete tissue infarction, which can be lethal to the
organ.
Given that ischaemic heart disease has a high worldwide mortality, and that several
well-categorised in vitro and in vivo animal models of myocardial IR injury exist, most
of the mechanistic changes understood to occur during ischaemia are based upon
observations from myocardial experiments. In describing the mechanism of injury this
report primarily details cells in the ischaemic myocardium, before specifically reporting
the endothelial, cerebral, and skeletal musculature response to ischaemia.
1.2.1.1. Mechanism of ischaemic injury
Cells with a high metabolic demand, such as cardiomyocytes, have poor tolerance to
ischaemia. The degree of injury is dependent on the totality of the occlusion, the
duration of the occlusion, and the volume of tissue supplied by the occluded vessel.
Animal studies have shown that after forty minutes of coronary artery occlusion, 28%
of the area at risk is irreversibly injured, rising to 70% after three hours (9). The
mechanism by which ischaemia induces cell death involves a series of intracellular
changes (see Figure 1.1).
Healthy cardiomyocytes use oxidative phosphorylation of fatty acids and carbohydrates
to supply energy in the form of adenine triphosphate (ATP). During ischaemia,
insufficient oxygen supply leads to a series of downstream effects which are detrimental
to cell viability. During early coronary ischaemia (15-20 seconds from onset), any
oxygen available as oxyhaemoglobin in capillaries is exhausted, NADH2 / NAD+ ratio
increases (10), and ATP and phosphocreatine are depleted (11). Anaerobic metabolism
is required to generate additional ATP (12).
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To compensate for a halting of oxidative phosphorylation, ATP demand is reduced by
decreasing membrane potential and cessation of cardiomyocyte contractions.
Nonetheless demand outstrips supply. Additional ATP is provided as NADH is oxidised
to NAD+, and by lactate dehydrogenase catalysing the reduction of pyruvate to lactate.
The ATP-dependent phosphorylation of fructose-6-phosphage to fructose-1,6-
diphosphate is necessary for continued glycolysis, but stops when ATP becomes
critically low (11).
Lack of blood flow during ischaemia also prevents the removal of waste metabolites
from tissue. This increases concentration of several glycolytic products including
glucose-6-phosphate, alpha glycerol phosphate, and glucose-1-phosphate. In addition
intracellular accumulation of adenine diphosphate (ADP) is detrimental to cell survival.
ADP is converted to ATP and adenosine monophosphate (AMP), and AMP to
hypoxanthine. Hypoxanthine along with lactate, acyl carnitine, CoA and H+ accumulate
and contribute to structural changes that result in cellular necrosis (10).
The catabolism of ATP, creatine phosphate and glycogen in the ischaemic cell rapidly
increases the number of molecules within it, increasing the osmotic load (10). Water
moves along the osmotic gradient, and causes cell swelling. Osmolar load changes alter
intracellular ion concentrations, notably resulting in potassium ions being exported
extracellularly, potentially contributing to ischaemic cardiac arrhythmias.
Lactate produced during glycolysis lowers intracellular pH and further disrupts the ionic
balance within the cell. Reduced activity of the ATP-sensitive Ca2+ channel, causes
subsequent increase in intracellular calcium. The ATP-dependent Na+ / K+ exchanger
slows, possibly due to reactive oxygen species (ROS) accumulation (13), resulting in an
increase in intracellular Na+ (14).
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During the initial 30-40 minutes of myocardial ischaemia, alterations to intracellular
chemistry lead to changes in cell structure. By this point many cells will have suffered
irreversible injury, primarily due to mitochondrial swelling, loss of glycogen stores,
aggregation of nuclear chromatin, and sarcolemmal disruption. Sarcolemmal injury
occurs due to the cytoskeletal and membrane disruption that follows catabolite
accumulation. This is believed to be a trigger of cardiomyocyte death, because the
sarcolemma releases critical intracellular enzymes into the extracellular space (10).
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Figure 1.1 Mechanism of ischaemic injury. Ischaemia causes hypoxia and a low flow state. This
results in rapid depletion of adenine triphosphate (ATP), the development of anaerobic metabolic
pathways, and an accumulation of toxic metabolites. The depletion of ATP disrupts ATP-dependent
ion channels, resulting in an increase in intracellular Na+ and Ca2+, and hence cell swelling. This in
combination with toxic reactive oxygen species (ROS), adenine diphosphate (ADP) metabolites, acyl
carnitine, CoA and an acidosis, causes structural changes in the mitochondria, leading to
irreversible cellular necrosis.
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1.2.1.2. Endothelial ischaemic injury
The cellular response to ischaemia in the endothelium resembles that in the
myocardium. It appears that in the myocardial microvasculature, the endothelium is
more tolerant of ischaemia than cardiomyocytes, most likely due to a reduced energy
demand when compared with surrounding cells (10). As such during myocardial
ischaemia, endothelial destruction does not occur until substantial irreversible
cardiomyocyte injury has occurred (10). The resistance to ischaemia by endothelial cells
is supported by human studies showing that endothelial dysfunction induced by IR
injury is transient, and restored by 60 minutes of reperfusion (15). In peripheral conduit
arteries the exact changes during ischaemia are less well characterised than the
myocardium, but endothelial cells are known to suffer from metabolic and ionic
imbalance, structural damage, and cell swelling in a similar manner to cardiomyocytes
(14).
The endothelium is crucial in the maintenance of vascular tone by release of
endogenous mediators. In response to ischaemia there is a reduced production of
vasodilator and cytoprotective substances, such as nitric oxide (NO) and prostacyclin;
an increase in vasoconstrictors, such as thromboxane A2 and endothelin-1; and an
increase in pro-inflammatory mediators such as cytokines and adhesion molecules (16).
Prolonged ischaemia can cause structural alterations to endothelial cells, resulting in
endothelial protrusions that may contribute to myocardial no-reflow, a phenomenon
associated with reperfusion injury (17).
1.2.1.1. Cerebral ischaemic injury
Cerebral neurons and glia, like cardiomyocytes, have a high demand for glucose and
oxygen. Cells undergo changes similar to those described above, with the addition of
some specific neuronal alterations. Cerebral artery occlusion is characterised by two
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ischaemic regions. Firstly, a core of absolute no-flow that undergoes a rapid irreversible
necrotic cell death. Secondly, an ischaemic penumbra, a region of low flow around the
ischaemic core that retains partial blood supply through the collateral vasculature, and
therefore undergoes a slower progression to cell death (18).
In the ischaemic core, lactate and other metabolites accumulate, resulting in acidosis,
ionic imbalance, oedema, and necrosis. In addition the energy deficit causes neurons to
depolarise, which activates voltage-gated ion channels. Channels release excitatory
neurotransmitters, such as glutamate, into the extracellular space, which cause
stimulation of glutamate receptors on other neurones. This process is known as
excitotoxicity, and results in a considerable increase in intracellular Na+, Cl- and Ca2+
concentrations, and subsequent cytotoxic oedema (19). As extracellular glutamate
concentration increases, it moves into the penumbral regions, and propagates a wave of
peri-infarct depolarisation (18).
1.2.1.2. Exercise-induced ischaemia
Some of these changes during ischaemia are mimicked by the effects of physical
exercise of muscle. Exercise increases the requirement for high energy phosphate within
myocytes. An increase in oxidative phosphorylation using the mitochondrial electron
transport chain accounts for this, but relies on adequate oxygen supply. When exercise
is performed at an increasing work rate, a mismatch occurs between oxygen demand
and supply, such that aerobic metabolism alone can no longer maintain sufficient supply
of ATP, and anaerobic metabolism is required to contribute to ATP requirements. This
point is known as the anaerobic threshold, and is characterised by an exponential
increase in carbon dioxide elimination, despite a constant increase in oxygen
consumption. Anaerobic metabolism occurs by the splitting of phosphocreatine and
anaerobic glycolysis. During high-intensity exercise this results in a number of
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detrimental intracellular pathways, which are comparable to those occurring during low-
flow ischaemia.
If glycolysis occurs at a rate which is faster than the tricarboxylic acid cycle can process
pyruvate, then lactate will accumulate intracellularly in proportion relative to pyruvate
production (20). The fundamental advantage of lactate production is that it allows for
the reoxidation of NADH and H+ to NAD+, and thereby continues ATP production
despite anaerobic conditions. However lactate production increases H+ ions, which
require intracellular buffering from circulating hydrogen bicarbonate (HCO3-). As work
rate continues to increase, a threshold is reached whereby the buffering capacity of
HCO3- is no longer sufficient to prevent the increase in intracellular H+. This results in a
number of adaptive physiological changes, including an increase in ventilatory drive,
consumption of muscle glycogen, plasma electrolyte concentration, and a metabolic
acidosis.
As in low-flow ischaemia, exercise-induced anaerobic metabolism results in an
increased production of metabolic intermediates, such as alanine, alpha-glycerol
phosphate, and pyruvate. These contribute to muscular fatigue obtained from exercising
above the anaerobic threshold, and result in a reduction in power output (21). The
mechanism that governs the halting of intense exercise varies between individuals is
highly contentious, but believed to be a combination of central fatigue governed by the
central neuronal response to intense exercise, and peripheral fatigue due to intracellular
changes in the musculature (22). Place et al. summarised four major causes of
peripheral muscular fatigue: an increase in intracellular inorganic phosphate
concentration, an increase in reactive oxygen and nitrogen species (ROS), an increase in
extracellular potassium, and a decrease in pH (21). This peripheral fatigue is
comparable to low-flow ischaemia, because as described in 1.2.1.1, acidosis, altered
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osmolar load, and ROS also contribute to the cellular dysfunction attributed to
ischaemic injury. The metabolic effects of exercise differ in one important way from
those of ischaemia, in that there is continual washout of metabolites.
1.2.1.3. Treatment of ischaemic injury
Treatment of ischaemia relies on rapid restoration of blood flow prior to irreversible
injury. This is achieved clinically by thrombolysis, arterial bypass, or percutaneous
intervention. Despite improvements in reducing the duration from onset of ischaemia to
treatment, it is often the case that by the point of revascularisation, patients have already
suffered substantial ischaemic injury. Treatment with reperfusion is crucial in the
prevention of irreversible changes, but a paradoxical reperfusion injury inhibits
recovery.
1.2.2. Reperfusion injury
The theory that reperfusion might contribute to the overall injury was first proposed by
Jennings et al. who observed that a short duration of ischaemia followed by reperfusion
induced a greater infarct than a longer duration of ischaemia without reperfusion (23). It
is further supported by the reduction in infarct size caused by a variety of interventions
timed to occur at reperfusion and hence unable to influence ischaemia, such as
ischaemic postconditioning (IPostC) (24). Numerous therapeutic options have been
developed to reduce reperfusion injury, yet despite promising results in preclinical
studies, in clinical trials none have shown sufficient efficacy and safety to be
incorporated into recommended revascularisation therapy (25–27).
Below are described the mechanisms of reperfusion injury. Again, the majority of
evidence is from cardiac studies, but comparisons are drawn between these
observations, and the cerebral and endothelial response to reperfusion.
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1.2.2.1. Mechanism of reperfusion injury
Reperfusion injury might be considered as a flood following a drought: despite having
all the necessary ingredients for recovery, their presence is overwhelming, and
accentuates injury in an already fragile cell population. During reperfusion, rapid
oxygen flux activates a number of detrimental pathways, and exaggerates components
of cellular injury suffered during ischaemia (Figure 1.2). Dysfunctional cardiomyocytes
release ROS from their mitochondria, which result in the denaturing of critical enzymes,
membrane failure, nucleic acid damage, reduced NO bioavailability (28), and opening
of the mitochondrial permeability transition pore (mPTP).
Other factors also play a role in promoting cellular injury during reperfusion. The Na+
overload during ischaemia causes Na+ / Ca2+ exchange during reperfusion, and results in
a rise in intracellular calcium (29). Calcium causes a rapid attraction of actin and
myosin molecules, inducing myofibrillar hypercontraction and ATP depletion (28),
contributing to the breakdown of mitochondrial structure (30). In addition, the rapid
restoration of physiological pH appears to exaggerate injury; given that reperfusion with
an acidic buffer can reduce mPTP opening, and some protective techniques slow the
return to a normal pH (28).
Reperfusion causes the opening of the mPTP, which is widely regarded as a crucial step
in irreversible cellular injury (4). The opening of the mPTP causes uncoupled oxidative
phosphorylation, mitochondrial swelling and rupture (28). Loss of mitochondria will
quickly result in necrotic cell death, whereas inhibition of mPTP opening during
reperfusion reduces injury (31).
Reperfusion injury causes cell death by three methods. This is primarily by necrosis,
following mitochondrial rupture. Recent evidence has also suggested that cell death by
autophagy and apoptosis may be important during reperfusion. Apoptosis is an ATP-
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dependent programmed cell death, and follows extracellular activation of a caspase
pathway by membrane receptors, or intracellular activation through the mPTP (30). The
finding that inhibiting caspase pathways reduces infarct size supports a role for
apoptosis in reperfusion injury (32). Autophagy and the ubiquitin proteasome system
target proteins for degradation as part of regular protein renewal in cells, a process
shown to be upregulated in reperfusion (33).
Another pathological process that complicates reperfusion is the no-reflow
phenomenon; despite conduit vessel reperfusion, blood flow does not always return to
the microvasculature, and ischaemia persists (34). Cells remaining in these ischaemic
zones will continue to progress towards necrosis. The cause of no reflow is in part due
to the previously described ischaemia-induced endothelial disruption. However, it is
likely to be heavily influenced by the plugging of capillaries by the infiltration of the
microcirculation of neutrophils, platelets, and mixed cell aggregates. Furthermore, the
production of vasoconstrictors such as endothelin-1 by dysfunctional endothelial cells is
likely to restrict return of flow.
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Figure 1.2 Mechanism of reperfusion injury. Reperfusion induces a rapid reoxygenation, resulting
in production of reactive oxygen species (ROS), which lead to deoxyribonucleic acid (DNA) damage
and protein degradation. This, in combination with rapid changes in pH, cell swelling following ion
imbalance, and hypercontraction of myofibrils, leads to the opening of the mitochondrial
permeability transition pore (mPTP), a trigger for subsequent cell death. There is a contribution of
the innate immune response, which results in disruption of endothelial cells and microvascular
plugging. This contributes to the no-reflow phenomenon and subsequent cell death.
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1.2.2.2. Inflammatory response to reperfusion
During IR, tissues develop a proinflammatory state and an immune response similar to
that designed for killing invading pathogens. Cytokines, complement, lipid mediators
and ROS are released during ischaemia and early reperfusion, and promote endothelial
rolling, adherence, and transmigration of neutrophils into reperfusing tissue (35). This
occurs by an increased expression of P-selectin and intercellular adhesion molecule-1
(ICAM-1) on endothelial cells. Increased rolling promotes neutrophil adhesion
molecule expression, such as the CD11b/CD18 glycoprotein complex. Our group has
previously shown that limb IR injury increases expression of CD11b on circulating
neutrophils (15).
Neutrophils are believed to contribute to tissue injury by release of enzymes and ROS
within the extracellular space, by plugging the microvasculature and contributing to no-
reflow, and promoting further neutrophil infiltration and activation. Enzymes released
by neutrophils include elastases, collagenase, gelatinase, and acid hydrolases, which
catalyse the degradation of the extracellular matrix comprising collagen, elastic, and
glycoproteins (36).
Furthermore leukocytes release pro-inflammatory cytokines including IL-1ß, IL-8, and
TNF-α. These cytokines act in a positive feedback, encouraging further leukocyte 
trafficking. Cytokines also act upon resident cells to activate apoptotic and necrotic
pathways. Complement pathways are also activated during reperfusion, contributing to
further leukocyte trafficking and cell death (37).
Recently, interest has grown into a high molecular weight protein complex, known
collectively as the inflammasome. This is believed to govern the sterile inflammatory
response to reperfusion by influencing cytokine release and activation of caspases.
Kawaguchi et al. emphasised an important role for cardiac fibroblasts in governing the
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response to myocardial IR injury (38). They then showed that ROS and K+ efflux in
fibroblasts causes the activation of IL-1ß, a process dependent on the inflammasome.
1.2.2.3. Endothelial reperfusion injury
Reperfusion injury reduces both receptor-dependent and receptor-independent
endothelial function. Experiments in isolated animal coronary arteries show that
following reperfusion, there is a reduction of endothelium-dependent vasodilatation, but
not endothelium-independent vasodilatation, suggesting that the endothelium is much
more susceptible to IR than surrounding smooth muscle (39,40).
Human in vivo studies from our group have shown that limb IR reduces endothelium-
dependent dilatation in response to intra-arterial ACh (41). This dysfunction appears to
be transient, with recovery by 60 minutes (15). Indeed, endothelial cells from canine
coronary arteries appear to take much longer to recover from IR (42).
The cause of transient endothelial dysfunction in humans remains uncertain. This may
be attributable to a reduced substrate bioavailability in the nitric oxide pathway,
supported by evidence that administration of L-arginine preserves endothelial function
following myocardial infarction in dogs (43). Alternatively organ bath studies have
suggested that neutrophil adhesion and migration contributes to dysfunction (44).
Reperfusion stimulated neutrophil migration disrupts the binding of the endothelium to
the basement membrane, and causes inter-endothelial cell gap formation, increasing the
permeability of the vasculature (28).
ROS are also likely to be a key contributor to post-IR endothelial dysfunction. ROS are
known to substantially increase following reperfusion, and their inhibition can prevent
experimental endothelial dysfunction (45). Chronic granulomatous disease patients have
a genetic mutation in NADPH oxidase subunits, and subsequently have negligible
oxidase activity in neutrophils. A recent study showed that these patients are resistant to
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endothelial IR injury, when compared to matched controls, supporting a role for ROS in
mediating endothelial IR injury (46).
1.2.2.1. Cerebral reperfusion injury
Reperfusion following cerebral ischaemia results in similar changes to those in the
heart. Intracellular ROS concentration increases, damaging neuronal organelles, causing
the opening of the mPTP and a release of proapoptotic molecules and critical
intracellular enzymes. Inflammation is also likely to contribute to reperfusion injury in
stroke. As in the heart, leukocytes are activated and infiltrate the cerebral parenchyma to
subsequently release pro-inflammatory cytokines and chemokines. Inhibiting tumour
necrosis factor (TNF)-α, a pro-inflammatory cytokine, with TNF binding protein can 
reduce experimental infarct size following middle cerebral artery occlusion (47).
In addition to the neuronal changes, reperfusion of the cerebral vasculature can cause
destruction of the blood-brain barrier (BBB). The BBB is a cellular matrix comprised of
tight junctions between endothelial cells, and is crucial in providing homeostatic control
within the brain by restricting movement of high molecular weight proteins. During
cerebral IR injury, the BBB degrades, primarily due to the detrimental effect of matrix
metalloproteases, oxidative stress, thrombin and bradykinin on the tight junctions (48).
This allows for a subsequent movement of high molecular weight proteins into the brain
parenchyma, causing a vasogenic oedema. Furthermore, BBB destruction allows for the
movement of leukocytes into the tissue. The now fragile vascular wall is also at an
increased risk of reperfusion-induced haemorrhage.
1.2.2.2. Reperfusion following high intensity exercise
Following intense exercise, subsequent power output is reduced. This is supported from
studies on individual myocytes, which show that following continued stimulation,
maximal force will decline (49). The drop in function following intense exercise is
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comparable to the post-ischaemic loss of cellular function attributable to reperfusion
injury. Following the cessation of exercise, the cellular demand for high energy
phosphate is dramatically reduced. As with post-occlusive reperfusion, the metabolic
changes that contribute to peripheral muscular fatigue during exercise, such as
metabolic acidosis, presence of waste metabolites, and increased extracellular
potassium, are rapidly reversed (50). However despite this, force generation in
recovering muscles remains reduced.
The cause of decreased force generation, as with classical reperfusion injury, appears
due to the rapid ROS production in recovering myocytes (21). This is supported by
evidence from Bruton et al. (51). They showed that mice overexpressing superoxide
dismutase, which converts superoxide to hydrogen peroxide, had decreased sensitivity
to calcium concentration. The lower sensitivity to calcium results in a decreased force
output, suggesting that the presence of highly-reactive peroxide molecules contribute to
muscular fatigue. Further studies have suggested that a range of ROS might contribute
to exercise fatigue, without causing changes in calcium sensitivity (49). These results
suggest that, as in classical reperfusion, the post-exercise delay in force recovery could
be attributable to the detrimental effects of ROS on intracellular mechanisms.
1.2.2.3. Treatment of reperfusion injury
A large number of therapeutic interventions to treat reperfusion injury have been trialled
in both animal and human studies. These have been summarised in several reviews
(4,28,30), and include ROS scavengers, inhibitors of Na+/H+ exchange (52), NO donors
(53), and mPTP inhibitors (26). Unfortunately, none have successfully shown sufficient
efficacy and safety to be incorporated into current revascularisation therapy, and
additional therapies are needed to tackle this clinical conundrum.
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Another protective phenomenon is ischaemic conditioning. Application of intermittent
non-lethal ischaemia applied prior to (preconditioning), during (perconditioning), or
immediately following (postconditioning) a prolonged ischaemia is believed to induce a
protective state against reperfusion injury. Ischaemic preconditioning, the intervention
of interest in my PhD, is discussed in more detail below.
1.3. Ischaemic preconditioning
Unlike specifically targeted therapies, ischaemic preconditioning (IPC) is a protective
phenomenon that influences multiple factors involved in the pathogenesis of IR injury.
IPC was first observed by Murry et al., who exposed canine hearts to brief, intermittent
episodes of IR (four cycles of five minutes ischaemia followed by five minutes of
reperfusion) prior to a sustained (40 minutes) ischaemic insult, reperfusion and 4 days
of recovery (5). IPC substantially reduced infarct size, and this effect has since been
replicated in many mammalian species, and more recently in a number of clinical trials
(7).
IPC was originally believed to target ischaemic injury, given that IPC reduced the rate
of ATP depletion, and H+ and lactate accumulation in the ischaemic myocardium (54).
However, recent studies have shown that if intermittent ischaemia is applied at the point
of reperfusion (IPostC), this also reduces infarct size. Given that IPostC can have no
effect on cell behaviour during ischaemia, and yet reduces infarct size, it suggests that
reperfusion injury is also a likely target for IPC (24). Furthermore inhibition of
adenosine and bradykinin receptors at the point of reperfusion prevents IPC without
influencing ischaemia. There remains uncertainty in the exact mechanism of IPC, but
current theory is described below.
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1.3.1. Local ischaemic preconditioning
Local ischaemic preconditioning (IPC) is the most widely studied type of conditioning
stimulus. It is defined as the application of intermittent IR to an organ or tissue that will
subsequently undergo a prolonged IR injury. IPC takes effect during an initial or early
window, lasting for one to two hours after the stimulus; and a second or late/delayed
window of protection, emerging 12 hours after the stimulus, and lasting for up to and
over 72 hours (55).
The mechanism of early IPC can be described as having three phases: an initial trigger
phase stimulated by the binding of endogenous autacoids to G-protein coupled receptors
(GPCRs); a second mediator phase where intracellular pathways transfer the protective
signal from membrane receptors to sites within the cell; and finally end effectors, which
render the cell tolerant to IR injury (Figure 1.3). The second window of protection is
believed to recruit similar pathways as the early window, and is associated with
synthesis of protective proteins following gene transcription.
1.3.1.1. Triggers of ischaemic preconditioning
Intermittent ischaemia is believed to stimulate the release of a number of endogenous
factors including adenosine, bradykinin and opioids, which bind to GPCRs on the cell
surface membrane, namely adenosine A1, bradykinin B2, and δ-opioid receptors. 
GPCRs are coupled to G proteins, which cause cyclic adenosine monophosphate
(cAMP) production, or activate phospholipase C and protein kinase C (PKC) (56).
Following adenosine receptor activation, phospholipase C generates diacylglycerol,
which activates PKC. Bradykinin and opioid receptors activate phosphatidyl inositol-3
kinase (PI3 kinase). Protein kinase B (Akt) is then phosphorylated, activating
endothelial nitric oxide synthase (eNOS), which forms NO. This stimulates guanylyl
cyclase to produce cyclic GMP, which in turn stimulates protein kinase G (PKG) (56).
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In addition, α and ß adrenoceptors may also trigger IPC, which is supported by evidence 
that α adrenoceptor agonists confer protection against subsequent IR injury using a PKC 
dependent mechanism (57). Adrenoceptors are GPCRs, and activate similar G protein
coupled effects to those described above. There is therefore much redundancy in the
pathway, and many of the components are targeted by drugs in clinical use for other
indications.
1.3.1.2. Mediators of ischaemic preconditioning
Protein kinase A (PKA), PKC and PKG are key intracellular mediators of IPC, though
the exact mechanism of action is uncertain. PKG is involved in the opening of the
mitochondrial ATP-dependent potassium (mKATP) channel (58). ROS are believed to
mediate IPC by increasing the opening of mKATP channels in a positive feedback loop
with mitochondrial PKC-ε, and also by inhibiting the opening of the mPTP (56). In 
addition IPC activates the reperfusion injury salvage kinase (RISK) pathway, which
involves a number of survival kinases such as PI3 kinase, Akt, Jun N-terminal kinases
(JNKs), and mitogen-activated protein kinases (MAPK) including p38MAPK,
extraregulated kinase 1/2 (Erk 1/2), and MAPK-activated protein kinase-2 (59). The
role for the RISK pathway is supported by evidence showing that inhibiting kinase
phosphorylation prevents IPC-induced cardioprotection (60).
1.3.1.3. End effectors of ischaemic preconditioning
The RISK pathway and other mediators effect protection by targeting several elements
of the detrimental IR cascade. This includes preventing the opening of the mPTP
through inhibition of GSK-3β, activation of PI3 kinase, or eNOS stimulation with NO 
release (31,61). Again, there is redundancy in these pathways, but it is generally
accepted that central to the effector mechanism of IPC is the prevention of reperfusion-
induced closure of the mitochondrial KATP channels and subsequent opening of the
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mPTP. Whilst there remains gaps in the mechanism, it is known that IPC limits Ca2+
accumulation in the mitochondria (62), inhibits GSK-3β (63), activates the RISK 
pathway, and recruits eNOS (64), which are individually known to reduce mPTP
opening. Mitochondrial KATP channels are involved in the prevention of membrane
uncoupling and stabilisation of the mitochondrial membrane (65), ROS production (56),
and inhibition of mPTP opening (56). PI3K and p38 MAPK activate glucose transporter
4 (GLUT4), resulting in an improved glucose uptake.
40
Figure 1.3 Mechanism of local ischaemic preconditioning. Intermittent cycles of ischaemia and
reperfusion stimulate G-protein coupled receptors including adenosine A1, bradykinin B2, δ-opioid, 
and α and β adrenoceptors. These trigger intracellular mediators, in particular the reperfusion 
injury salvage kinase (RISK) pathway, reactive oxygen species (ROS), calcium ions (Ca2+),
endothelial nitric oxide synthase (eNOS), and other kinases (PKC-ε, GSK-3ß, PKG). The effect is a 
reduction in the opening of the mitochondrial permeability transition pore (mPTP), increased
opening of the mitochondrial potassium (mKATP) channel, and activating the GLUT-4 transporter.
These factors enhance tolerance to subsequent IR injury, by improving glucose uptake, and
inhibiting cell death and inflammation.
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1.3.1.4. Anti-inflammatory effects of ischaemic preconditioning
As discussed, reperfusion is associated with an acute, sterile inflammatory response. If
IPC acts primarily on reperfusion, it is reasonable to hypothesise that IPC may alter the
immune responses associated with reperfusion. Stimulation of eNOS, a mediator of
IPC, results in the production of nitric oxide (NO), which is known to be anti-
inflammatory.
The hypothesis that IPC is anti-inflammatory is supported by evidence from animal
studies. Szabo et al. found that IPC prevents the IR-induced increase in leukocyte
rolling and adhesion in rat tibial microcirculation, and prevents the increase in CD11b
and ICAM-1 expression on leukocytes and peripheral tissue respectively (66). Erling et
al. observed that IPC prevented the increase in leukocyte activation, and expression of
selectins and ICAM-1, induced by mesenteric IR injury (67). Inhibiting chemosensitive
C–fibres or calcitonin gene-related peptide receptors can prevent these anti-
inflammatory effects of IPC (68).
In humans, the evidence for IPC influencing leukocyte trafficking is limited to
observations made from in vitro neutrophil studies. Our group has previously shown
that following upper limb IR injury, CD11b expression is increased in circulating
neutrophils, and is prevented by IPC (15). The mechanism behind this might be due to
interaction between neutrophils and endogenous autacoids, notably opioids and
bradykinin (69,70). There is also evidence that IPC may prevent the no-reflow
phenomenon by attenuating circulating monocyte-platelet aggregates (71).
Shimizu et al. performed an in vitro study phenotyping circulating human neutrophils
following application of IPC (72). They observed a reduced adhesion of neutrophils to
wells coated in fetal bovine serum, 24 hours after IPC stimulation. IPC also reduced
neutrophil apoptosis, and increased in N-formyl-methionyl-leucyl phenylalanine-
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stimulated CD63 and CD66b expression. However there were no changes in neutrophil
CD11b expression, NADPH oxidase activity, phagocytosis, and cytokine expression
following IPC. To date no study has investigated whether IPC modulates the human
inflammatory response in vivo.
1.3.2. Remote ischaemic preconditioning
IPC also confers a systemic protective effect against IR injury. Przyklenk et al. observed
in dogs that the region of myocardium supplied by the left anterior descending coronary
artery could be protected from IR injury by IPC applied to the territory supplied by the
circumflex artery (6). This result has been reproduced by several groups, and it is now
understood that IPC applied to one tissue can prevent another from prolonged IR injury,
a property known as remote ischaemic preconditioning (RIPC) (6). RIPC has since been
shown to protect against IR injury in the heart (6), brain (73), kidney (74), skeletal
muscle (75) and liver (76).
The observation that RIPC could be induced by intermittent IR of the limb (41), gave an
opportunity to translate this systemic protective effect into human clinical trials (77).
Intermittent limb ischaemia as a stimulus for RIPC is appealing as an intervention
because it is non-invasive, simple to administer, and inexpensive.
1.3.2.1. Transferring the protective stimulus
In effecting protection, RIPC is believed to recruit similar intracellular pathways to
local IPC, involving signalling kinases that act upon KATP channels and the mPTP to
render the cell resistant to IR injury (78). The most intriguing element of RIPC is the
pathway that transfers protection from the ischaemic stimulus to the site of injury. The
current literature supports three hypotheses: that transfer of protection is mediated by
neural, humoral and immunological mechanisms. The evidence supporting each
hypothesis is described below.
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The release of adenosine and bradykinin at the site of RIPC stimulus are believed to
activate neural mechanisms. Evidence that the autonomic ganglion blocker trimetaphan
can inhibit RIPC suggests the autonomic nervous system is involved (79). Recently
Mastitskaya et al. have shown that the cardioprotection afforded by RIPC relies on
intact activity of vagal pre-ganglionic neurones (80). They showed that RIPC as a
therapy against rat myocardial IR injury was abolished by systemic muscarinic blockade
using atropine, or by specific inhibition of vagal pre-ganglionic neurones. Another
group have shown that protection afforded by limb RIPC can be prevented by femoral
nerve transection (81).
The evidence for a humoral pathway is based on the observation that transfusing the
blood of a preconditioned animal into that of a non-preconditioned animal can transfer
the protective effect (82). Furthermore the dialysate of plasma from preconditioned
rabbits or humans can effect protection against an experimental cardiac IR injury (83).
This effect is abrogated by naloxone, suggesting that endogenous opioids are important
in the humoral pathway.
As described, IPC modifies the inflammatory response to IR injury. Given that both IPC
and RIPC reduce leukocyte rolling, it is possible that circulating leukocytes might
transfer the protective effect (67). The modified neutrophil function observed by
Shimizu et al. was from leukocytes acquired from the contralateral arm to that receiving
intermittent ischaemia (72). RIPC also upregulates the pro-resolution cytokine
interleukin-10 (84). Inhibition of cyclooxygenase 1 and 2 by SC-560 and rofecoxib
respectively can inhibit RIPC in a model of gastric IR injury (85).
It is therefore possible that RIPC uses a multifaceted approach, with neural, humoral
and anti-inflammatory factors overlapping to confer protection against IR. This is
supported by evidence that inhibition of several alternative pathways can attenuate
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RIPC. As with IPC there may also be mechanistic differences in the two windows of
protection. Furthermore, it is likely that differences exist between the transfer of
protection in RIPC between rodents and higher mammals.
1.3.2.2. Remote ischaemic preconditioning in experimental stroke
Preconditioning has been shown to protect against experimental rodent stroke (86).
Initially this was evident using local IPC, by non-lethal occlusions of the middle
cerebral artery (MCA) prior to prolonged IR (87). More recently it has been shown that
RIPC induced by iliac or femoral artery occlusion, can reduce infarct size during
cerebral ischaemia, in both a four-vessel occlusion method (88), and a permanent MCA
occlusion (73). However, it is uncertain whether RIPC is effective in a transient model,
which as described is more representative of human stroke.
The mechanism of cerebral protection is similar to that described in cardiac studies.
Firstly there are two windows of protection (86,89). Secondly RIPC involves neural and
humoral pathways, given that both ganglion blockade by hexamethonium, and
antagonism of adenosine receptors inhibits cerebral protection by RIPC (90).
Furthermore inhibition of NOS, a mediator of the preconditioning pathway, by L-
NAME abrogates cerebral protection (88). Further work is required to investigate how
RIPC modifies the MCA model in varying experimental conditions, including the
occlusion strategy (permanent vs transient), anesthetic regime (inhaled vs injectable),
and strength of RIPC stimulus.
1.3.3. Exercise as a preconditioning stimulus
In humans, performing regular physical exercise is associated with reduced mortality
from cardiovascular events (91,92). This was believed to be related to exercise-induced
reduction in traditional risk factors, such as obesity, hypertension,
hypercholesterolaemia, and insulin resistance. More recently however, exercise has
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been shown to protect against myocardial IR injury irrespective of these risk factors
(93).
McElroy et al. reported that after 5 weeks of swim training, infarct size was reduced by
30% in rodent myocardial IR injury (93). This observation has been reproduced in
several studies using alternative exercise training programs (94,95). The mechanism of
training-induced preconditioning as a protective stimulus involves increased heat shock
proteins, NO production, antioxidants, endoplasmic reticulum stress proteins,
cyclooxygenase-2, development of collateral vasculature, and mitochondrial adaptation
(reviewed by Kavazis et al. (96) and Powers et al. (97)).
1.3.3.1. Acute exercise preconditioning
A single bout of exercise increases heart rate, activates the sympathetic nervous system,
and releases endogenous factors, including opioids, nitric oxide, α-adrenoceptor 
agonists, and bradykinin. High intensity exercise causes high flow ischaemia of
exercising muscle, where oxygen supply is insufficient to meet metabolic demand. In
animal models evidence suggests that exercise-induced preconditioning (ExPC) to
reduce IR injury can be achieved by just a few days of exercise training (98), or even
from a single exercise bout (99,100).
That ExPC activates IPC pathways is supported by results from Domenech et al., who
found that 5 cycles of 5 minutes exercise followed by 5 minutes of rest can reduce
canine myocardial IR injury, and like IPC it offered two windows of protection (99).
Acute ExPC, like IPC, appears to involve mKATP channels and PKC (100,101).
In humans, studies have shown that exercise-induced myocardial ischaemia causes
preconditioning, which is known as the “warm up phenomenon” (102). It has been
documented for over 50 years that angina patients have fewer ischaemic symptoms in
the second of two consecutive exercise stress tests, where exercise is limited by
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myocardial pain or ECG changes (103). This exercise-induced high flow ischaemia has
been shown to exhibit protection against interventional myocardial ischaemia over a
comparable time window to IPC (104,105).
Moreover IPC can be compared to high-intensity interval training (HIIT). Brief,
intermittent, high intensity exercise performed regularly reduces the risk of
cardiovascular death in men and women (106). HIIT is known to increase intracellular
kinase activity (such as p38 MAPK) (107), which is comparable to the intracellular
mechanisms of IPC.
Like IPC, ExPC confers a systemic protective effect. Exercise induces protection in
organs which are known to have minimal response to acute exercise, such as the brain.
Jia et al. showed that 3 weeks of exercise training improves rat cerebral tolerance to IR
(108). Evidence for systemic ExPC effects in humans is limited. Tyldum et al. showed
that intake of a high fat meal induces endothelial dysfunction in healthy volunteers
(109). This was prevented by an intense lower limb exercise protocol, performed 12-16
hours prior to the meal.
Brief exercise as a preconditioning stimulus is of interest in clinical settings, such as
elective surgery. The long term health benefits of exercise in reducing cardiovascular
risk factors have been widely reported (92), but if ExPC is known to reduce humans IR
injury, this could promote the uptake of exercise in the wider population, and help to
lower the burden of cardiovascular disease.
1.3.4. Ischaemic preconditioning as a treatment for IR injury in humans
In the past 10 years, IPC and RIPC have been suggested as treatments for IR injury in
humans. Evidence for this is supported by experimental in vivo studies and randomised
controlled clinical trials, which are described below.
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1.3.4.1. Human ischaemia reperfusion injury studies
Our research group has developed a model of limb IR injury, by using vascular
assessment tools to ascertain the effects of IR on endothelial function in vivo
(15,41,79,110–112). Prolonged upper arm cuff inflation to a suprasystolic pressure
followed by reperfusion induces a transient endothelial dysfunction in conduit and
resistance vessels. Endothelial function has been assessed in two ways, firstly as a
reduction in endothelium-dependent dilatation of resistance vessels in response to intra-
arterial administration of acetylcholine (41). Secondly as a reduction in endothelium-
dependent dilatation of conduit vessels in response to a hyperaemic stimulus, a
phenomenon known as flow mediated dilatation (FMD) (15). This model has served to
identify a number of interventions that reduce human IR injury, including IPC (15),
RIPC (79), local and remote IPostC (111), nitrates (113) and HMG CoA reductase
inhibitors (114).
1.3.4.1. Clinical trials of local ischaemic preconditioning
Local IPC has been trialled in a number of clinical conditions including cardiac surgery
(7), liver transplantation (115) and lower limb orthopaedic surgery (116). A meta-
analysis of randomised controlled trials of IPC in coronary surgery (23 trials, 933
patients) found a significant reduction in the number of ventricular arrhythmias,
inotrope use, and length of intensive care stay in patients compared with controls (7).
However a Cochrane review and meta-analysis of the benefits of IPC in liver resections
(4 trials, 271 patients) found insufficient evidence to support a protective effect (117).
Unfortunately meta-analyses of small trials cannot account for publication bias, and
large, randomised controlled trials demonstrating clinically useful effects of IPC are
needed before it can be adopted in clinical practice.
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1.3.4.2. Clinical trials of remote ischaemic preconditioning
As described, the non-invasive nature of limb RIPC is appealing for use in patients. To
date several small clinical trials have shown an improvement in clinical endpoints by
RIPC, in coronary artery bypass graft surgery (118) aortic aneurysm repair (119), and
acute kidney injury (120). However a meta-analysis of vascular or endovascular trials (4
trials, 115 patients) up to July 2011 found no difference between RIPC and control
(121). Once again, large randomised trials are necessary to clarify the presence of a
clinical benefit. A search of www.clinicaltrials.gov in August 2012 for remote ischemic
preconditioning found 26 trials currently recruiting, suggesting that these questions will
be answered within the next few years.
1.3.5. Ischaemic preconditioning and skeletal muscle function
Skeletal muscles are tolerant of brief low-flow ischaemia, most likely due to the
necessity to readily perform anaerobic metabolism during intense exercise. Studying
how IPC influences skeletal muscles can act as a proxy for how IPC affects vital organs
such as the heart, during IR injury. Saito et al. found that IPC can improve the oxygen
supply to the musculature during sciatic nerve stimulation of the gastrocnemius of rats
(122). In addition muscle re-oxygenation following occlusion is improved by prior IPC
in rats (123) and humans (124).
Methods for improving muscle function are of great interest in sport science. This is
especially true for novel interventions that take advantage of the innate physiology. The
oxygen transport system during exercise is critical in determining athletic performance,
and interest has grown into interventions that can legally modify the rate-limiting steps,
such as high-altitude training. Oxygen delivery is dependent on arterial oxygen
saturation, haemoglobin concentration, arterial partial pressure of oxygen, muscle blood
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flow, and muscle oxygen extraction (22), and studies use assessments of oxygen
delivery (ܸ̇O2) and consumption as outcomes to relate to exercise performance.
Blood flow restriction in combination with exercise (known as KAATSU training) is
known to encourage training effects on skeletal muscles, and to improve cardiovascular
response to an orthostatic stimulus (125). Until recently however, no published studies
had investigated whether IPC alone can improve muscle function in humans. Groot et
al. recorded that IPC improves human exercise performance on an exhaustive cycling
exercise (126). They observed that suprasystolic cuff inflations consisting of three
cycles of 5 minutes ischaemia followed by 5 minutes reperfusion on both lower limbs,
improved exercise performance in a subsequent incremental exercise test. IPC improved
maximal oxygen delivery (ܸ̇O2 max) by 3% and maximal power output (WR max) by 1.6%
in 15 well trained cyclists (126).
Crisafulli et al. performed a similar experiment, whereby subjects were randomised to
control, IPC or a submaximal exercise and IPC combination, prior to an incremental
exercise test (127). Both IPC and the exercise and IPC combination increased maximal
power output (4%), total exercise time, maximal ventilation, and maximal heart rate,
when compared to control. Unlike the previous study, they did not observe any change
in ܸ̇O2 max with IPC. Further evidence suggests that upper limb IPC can improve
performance in a standardised swimming test (128). However Clevidence et al. found
no effect with IPC on either submaximal or maximal testing for ventilatory or
performance outcomes (129). Whilst evidence suggests that IPC may improve muscular
function, differences exist in the literature as to whether this is reflected in an improved
exercise performance.
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1.4. Scope of thesis
In this thesis I plan to investigate the mechanisms of IPC using in vivo models of IR
injury. Firstly, by using a rat model to study the effects of RIPC on a cerebral IR injury
caused by transient occlusion of the middle cerebral artery following reperfusion.
Secondly, by using a human vascular model to study the effects of IPC, RIPC and ExPC
on endothelial IR injury. Thirdly, by using a human skin blister model to study the anti-
inflammatory effects of IPC. Finally, by using a human exercise test to investigate the
effects of IPC on muscular oxygenation and exercise performance.
1.5. Hypotheses
 Remote ischaemic preconditioning protects against cerebral ischaemia-
reperfusion injury in rats.
 Exercise and ischaemic preconditioning protect against endothelial ischaemia-
reperfusion injury in humans.
 Ischaemic preconditioning reduces leukocyte trafficking to an inflammatory
stimulus in humans.
 Ischaemic preconditioning increases skeletal muscle oxygenation and improves
exercise performance in humans.
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2. GENERAL METHODS
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2.1. In vivo assessment of cerebral ischaemia-reperfusion
injury in rats
2.1.1. Background
Human ischaemic stroke is typically associated with thromboembolism, which results in
arterial occlusion within the cerebral circulation. To identify and characterise novel
therapies for human stroke, it is crucial to begin with an adequate animal model. Stroke
models allow researchers to investigate potential treatments for efficacy and safety prior
to human clinical trials. However, as with many animal in vivo models, stroke studies
are often limited by being unrepresentative of the disease in question and by exhibiting
a large within-population variability.
Studying stroke in rodents has become increasingly popular since the development of
genetically modified mice, and the general trend towards conducting fewer experiments
in higher mammals. However despite a variety of therapies showing promise in murine
stroke models, the majority have failed to translate to clinical practice in humans, and
currently the only licensed therapeutic agents to treat ischaemic stroke in the UK are the
recombinant tissue plasminogen activator alteplase, the thienopyridine clopidogrel, and
aspirin (130).
Two factors that differ between human and experimental animal stroke continue to
hamper the translation of therapies from animals to human. Firstly, most human strokes
will undergo a period of occlusion, followed by reperfusion, either due to thrombolytic
therapy (131) or the development of collateral flow (132), whereas many experimental
stroke models consist of ischaemia only. Secondly, human strokes are usually less than
10% of the hemispheric volume, whereas animal studies often tend to involve at least
30% of the hemispheric volume (133).
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Research to date using animals has had three main objectives. Firstly, to improve the
understanding of the pathophysiology of stroke, the cellular changes which occur during
it and in particular the elements that contribute to cell death or towards cell
preservation. Secondly to understand which risk factors contribute to stroke. Finally, to
test novel interventions that aim to develop new treatments against human stroke. These
objectives have been studied in a variety of stroke models, which others have
comprehensively reviewed (see Durukan & Tatlisumak, 2007 (134) and Carmichael,
2005 (133)). To investigate the role of ischaemic preconditioning in stroke a focal
ischaemia-reperfusion model was used, that involved the temporary occlusion of the
middle cerebral artery.
2.1.1.1. Middle cerebral artery occlusion
A number of different methods exist for inducing a murine ischaemic stroke, including
craniectomy, embolic, endothelin-1 induced, photothrombosis and middle cerebral
artery (MCA) occlusion stroke models (134). The current study, used an intraluminal
suture MCA occlusion method (135), which has become the most widely used stroke
model (136). It is less traumatic than alternatives, has a low within-population
variability, and by allowing for reperfusion is more representative of human ischaemic
stroke, which itself regularly involves occlusion of the MCA (137). The intraluminal
suture model involves the insertion of a monofilament into the internal carotid artery,
such that it occludes the MCA. This can be manipulated using occlusion of the
contralateral carotid artery to reduce flow within the circle of Willis whilst the patent
vertebral arteries ensure flow is maintained to the contralateral hemisphere.
2.1.1.2. Histological analysis
An assessment of infarct size can be determined by magnetic resonance imaging, or by
histological staining. Given the necessity to rapidly produce results during method
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development, and the logistical challenge of using magnetic resonance imaging, this
study used a common histological method. Brain slices were stained using 2,3,5-
triphenyltetrazolium (TTC). TTC identifies live tissue by producing a red precipitate in
cells with active mitochondria. This results in a distinct contrast between infarcted and
non-infarcted tissue, which can be measured by imaging software (Figure 2.2).
Histological variables include the number and thickness of the slices, the duration of
dye exposure, the scanning hardware, the imaging software and the outlining technique.
In addition, previous murine stroke experiments have observed that a cerebral infarct is
associated with extensive vasogenic oedema within the tissue, which can introduce bias
within the data, and should be accounted for when interpreting infarct size (138).
Several equations have been suggested for calculating the infarct size (138,139), the
majority of which use a correcting factor for oedema.
2.1.2. Experimental set up
All procedures were carried out in the UCL Centre for Advanced Biomedical Imaging,
in a temperature controlled surgical facility. All surgical procedures were conducted by
a UCL research technician, who has over twenty years of experience in performing in
vivo animal research. I conducted the study design, provided technical support during
the procedures, and performed all image analysis. All research was conducted according
to the UK Home Office Guidelines under the 1986 Animals (Scientific Procedures) Act,
and all procedures were outlined in the Home Office project license 70/6919.
Experimental protocols are described in section 3.2.
2.1.2.1. Animal preparation
Male, Sprague Dawley rats (aged 10-12 weeks; Charles River Ltd, Margate, UK) were
housed in filter cages in diurnal conditions for at least 24 hours prior to surgery. Rats
weighed 180-220 g immediately prior to surgery, to reduce variability in cerebral artery
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luminal diameters. Rats of smaller size were at risk of the filament piercing the cerebral
vasculature, and in those of a larger size it was more likely that blood would flow
around the filament.
2.1.2.2. Surgical procedure
Experimental stroke was induced using an intraluminal filament to cause a unilateral
stroke of the region of the cerebral hemisphere supplied by the MCA. Rats were
maintained using injectable anaesthesia in the majority of studies. Anaesthesia was
induced with a mixture of 0.24 mg/kg fentanyl and 7.5 mg/kg fluanisone (Hypnorm,
Vetaphama, UK), and 1.5 mg/kg midazolam hydrochloride (Hypnovel, Roche Products
Ltd, UK) given in a 300 µl fluid volume as an intra-peritoneal (i.p.) injection.
Midazolam, a short acting benzodiazepine, enhances the action of gamma-aminobutyric
acid (GABA), the primary inhibitory neurotransmitter, on the GABA receptors in the
neurones. Fentanyl, an opioid, primarily acts upon µ opioid receptors, and is used as an
analgesic and anaesthetic agent. Fluanisone, a butyrophenone, is an antipsychotic and
used to sedate the animal, and for maintenance of anaesthesia with fentanyl, to
potentiate the anaesthetic and analgesic effect. Continued anaesthesia was maintained
with 0.12 mg/kg fentanyl and 3.75 mg/kg fluanisone, administered as an i.p. injection
every 30-60 minutes. Throughout surgery the body temperature was maintained at 37°C
by use of a feedback regulated heating pad and the animals were carefully monitored to
ensure suitable anaesthesia and respiratory function.
The surgical procedure is demonstrated in Figure 2.1. Firstly the neck flap was shaved,
followed by a ventral midline neck incision, and the left and right common carotid
arteries (CCA) were identified. The bifurcation of the right CCA into the internal and
external carotid arteries was located, followed by the bifurcation of the pterygopalatine
artery from the right internal carotid artery. A vascular clip was attached just proximally
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to the first bifurcation of the right CCA, and a tie placed at the proximal end, to inhibit
blood flow to the site of filament entry. The right CCA was then opened using vascular
scissors, and a silicon rubber-coated monofilament (size 4-0, diameter with coating 0.35
± 0.02 mm, filament length 30 mm, Doccol Corporation, USA) was advanced into the
arterial lumen and directed into the internal carotid artery, such that the silicone tip of
the filament rested within the circle of Willis, and blocked the entry of blood into the
MCA. To aid positioning over the MCA, the monofilament had been pre-marked with a
silver line 13 mm from the tip, such that the filament was assumed to be correctly
positioned when the silver line reached just superiorly to the bifurcation of the
pterygopalatine artery. At this point the filament was secured, and maintained in
position for 60 minutes. In studies requiring a contralateral occlusion the left CCA was
occluded using a vascular clip, and then released when necessary.
Reperfusion of the MCA was achieved by retracting the monofilament and by releasing
the right CCA. This returned flow to the cerebral circulation, and the neck was closed
up and animals recovered from anaesthesia in a temperature controlled (37°C) recovery
box. Following recovery animals were returned to their filter cage, and monitored for
evidence of recovery and neurological symptoms.
57
Figure 2.1 Experimental procedures for middle cerebral artery occlusion surgery. Initially the left
(A) and right (B) common carotid arteries (CCA) were identified and isolated. A vascular clip was
then placed just inferiorly to the bifurcation of the right CCA into the internal and external carotid
artery (C). The right CCA was tied and a small incision made in the arterial wall (D) to allow for
monofilament insertion. The filament was advanced into the internal carotid artery, and the
position checked above the bifurcation of the pterygopalatine artery (E). The left CCA was
occluded using a vascular clip (F). Dissection of the palate and viewing the ventral aspect of the
brain confirmed that the filament occluded the MCA (G). RIPC was induced by tightening of a
cable tie (H) at the top of the right thigh, and occlusion confirmed by a colour change in the
ischaemic right paw (I).
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2.1.2.3. Brain isolation
After 24 hours of recovery, animals were anesthetised (0.16 mg/kg fentanyl, 5 mg/kg
fluanisone, 1 mg/kg midazolam hydrochloride i.p.) and culled by a schedule 1
procedure before decapitation. The skin around the head was extended back over the
eyes, and the skull washed with water to remove blood and hair. The skull was opened
using straight iris scissors from the entrance of the spinal cord to the eye sockets. A
coronal cut was made between the eye sockets, and the crown of the skull was removed.
The lateral edges of the skull were held back using a rongeur, and the brain was excised
along the ventral aspect from caudal to rostral, to release the cranial nerves and
vasculature. The brain was immediately placed on a 4 cm diameter filter paper disc, and
two to three drops of lubricating oil (3 in 1, USA) were dropped on the top of the brain
to aid slicing.
2.1.2.4. Histological staining of infarcted tissue
The brain was sliced from caudal to rostral into 1 mm slices using a tissue slicer
(McIlwain Tissue Chopper, Mickle Laboratory Engineering Co. Ltd, UK). The sliced
brain was immediately transferred to plate containing the staining dye (2% w/v TTC
solution, Sigma Aldrich, USA) for 20 minutes at room temperature, where the slices
were separated in a caudal to rostral fashion, ensuring that the slices arranged with the
rostral side facing superiorly. Slices were then transferred to a fixing solution
(formaldehyde 4% aqueous solution, VWR, USA) for 20 minutes. Slices were briefly
dried using an absorbent paper, arranged vertically on a clear plastic sheet, and scanned
(PIXMA MX700 2400 dpi, Canon, Japan) using a black background in preparation for
image analysis.
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2.1.2.5. Remote ischaemic preconditioning
Remote ischaemic preconditioning (RIPC) was induced by use of a cable tie to inhibit
arterial flow to the right lower limb (Figure 2.1). The cable tie was tightened at the level
of the hip to ensure that a large volume of thigh muscle received RIPC. Cable tie
tightening initially resulted in neuromuscular injury in some cases, as animals were
observed to be limping during recovery. This was avoided by passing a thin plastic tube
through the cable tie, such that during tightening the pressure was spread evenly across
the limb. Vascular occlusion was confirmed by observing that the skin became blue
during cuff tightening.
2.1.2.6. MK-801
MK-801, ((+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d) cyclohepten-5,10-imine
maleate) is a known neuroprotective agent (140,141), which was used as a positive
control in this study. It is a noncompetitive antagonist for the N-methly-D-aspratate
(NMDA) receptor, which inhibits the release of glutamate into the extracellular space
during ischaemia (see 1.2.1.1). Glutamate accumulation causes excitotoxicity and is
associated with cell swelling and neuronal death. MK-801 has been shown to reduce
infarct size in several rat stroke models, though it is associated with side effects
including sedation and respiratory depression. MK-801 (Sigma-Aldrich, USA) was
administered as a 3 mg/kg i.p. injection 15 minutes prior to monofilament insertion
occlusion.
2.1.3. Image analysis
Brain slice images were saved in the tagged image file format (TIFF) and analysed
using a public domain Java-based image processing program (Image J v1.44, National
Institutes of Health, USA). Images were initially zoomed to 300%, and the images were
adjusted to ensure that the maximal contrast between the infarcted and the non-infarcted
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tissue was observed. Three outlines were drawn on each slice: around the infarcted
territory, the entire ipsilateral hemisphere, and the entire contralateral hemisphere. Care
and attention was taken to ensure that the exact outline of each slice was followed, and
the area was saved. All analyses were performed by myself, to avoid potential inter-
analyser variability.
Figure 2.2 Image analysis technique for rodent brain slices. Slices were arranged vertically and
scanned with a black background (A), before the contrast was adjusted (B). Each slice (middle
cerebral artery territory slice shown) is then zoomed to 300% (C), and the areas of the infarcted
territory (D), the entire ipsilateral hemisphere (E) and the entire contralateral hemisphere (F) are
measured free hand using imaging software. Yellow line indicates measured area.
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2.1.4. Interpretation of results
Analysis of acquired data was performed using graphing software (GraphPad Prism,
GraphPad Inc, USA). Equation 2.1 was used to calculate the hemispheric lesion volume
and to account for oedema (139,142,143). Briefly a correction factor was applied to the
lesion area, and then expressed as a percentage of the contralateral hemisphere. Lesion
size is expressed as an area of a single slice in the MCA territory (see Figure 2.2 C-F),
and as a volume to establish infarct volume throughout the cerebral hemispheres, by
calculating the mean of 8-10 slices. Coefficient of variation was calculated using
Equation 2.2. Sample sizes were calculated using statistical software (Power and
Sample Size Calculations, Dupont & Plummer, v3.0, (144)).
Equation 2.1 Calculation to account for oedema within the infarcted territory.
Equation 2.2 Calculation of coefficient of variation.
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2.2. In vivo assessment of endothelial function in humans
2.2.1. Background
The endothelium is a dynamic organ, consisting of a single layer of cells lining the
vasculature, which play a crucial role in maintaining homeostasis. Endothelial cells
release endogenous vasodilators, inhibit thrombosis and regulate the movement of
leukocytes from the circulation into peripheral tissues. In a number of clinical
conditions the endothelium is known to become dysfunctional, which is associated with
a reduction in the release of endogenous mediators, and the development of a pro-
thrombotic state. Endothelial dysfunction is associated with progression of
atherosclerosis (145) and may be of value in predicting cardiovascular events in some
patient groups (146,147).
In response to shear stress, endothelial cells release factors including nitric oxide, dilator
prostaglandins and endothelium-derived hyperpolarizing factor, which cause smooth
muscle relaxation and hence vasodilatation. Researchers have attempted to quantify this
dilatation for use as an additional prognostic tool in atherosclerosis, and to assess
endothelial function in vivo for other diseases. Several in vivo assessments currently
exist, including invasive techniques such as resistance vessel dilatation in response to
intra-arterial acetylcholine as assessed by venous plethysmography (148), quantitative
coronary angiography (149); and non-invasive methods such as flow mediated
dilatation (150), peripheral arterial tonometry (151), laser Doppler flowmetry (152) and
pulse wave velocity (153).
2.2.1.1. Flow mediated dilatation
Celermajer et al. showed that measuring the increase in brachial artery diameter in
response to hyperaemia (flow mediated dilatation, FMD) might be a valid measure of
endothelial function in humans (150), which studies in this PhD have utilised. FMD is a
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non-invasive, reproducible ultrasound technique, which assesses change in peripheral
conduit artery diameter (2-5 mm, typically brachial, radial or femoral artery) in response
to a transient hyperaemia. Reactive hyperaemia that follows brief distal limb arterial
occlusion, results in a 7-fold increase in brachial artery flow and causes vasodilatation
(154). FMD is primarily dependent on NO production, given that L-NMMA, an
inhibitor of nitric oxide synthase, almost entirely abolishes FMD with no effect on
blood flow (155). Other endogenous vasodilators such as endothelium-derived
hyperpolarizing factor (EDHF) and prostacyclin may also contribute to FMD (154,156).
The technique requires a high degree of ultrasonographer skill, and a number of groups
have reviewed the technical aspects of FMD, and have agreed on guidelines that should
be followed during the assessment (157–159). This is needed to achieve a low within-
subject variability (160,161). FMD is typically performed by ultrasound of the brachial
or radial artery in a longitudinal plane, using a high frequency ultrasound probe. Vessel
diameter is recorded before and after a five minute arterial occlusion, usually distally to
the arterial section of interest. FMD is expressed as the difference between baseline and
the maximum dilatation following hyperaemia, with respect to baseline diameter.
Alternative assessments include absolute dilatation, the time required to reach maximal
dilatation, and the area under the diameter-time curve (161).
FMD is the most commonly used assessment of endothelial function because it is
inexpensive, repeatable, and non-invasive. For this reason it has lent itself well to large
population-based studies (162), and to repeated studies on healthy volunteers (15). FMD
is reduced in patients with endothelial dysfunction such as diabetes mellitus (163,164),
and in recent years FMD has also been used as a surrogate marker for cardiovascular
disease in clinical trials (reviewed by Charakida et al. (165)).
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To investigate the mechanisms of preconditioning, our research group has developed a
non-invasive human in vivo model using endothelial function as the primary outcome
(15). We have previously shown that twenty minutes of upper limb ischaemia, followed
by twenty minutes of reperfusion causes a reduction in endothelial function in conduit
and resistance vessels, quantified by a reduction in FMD in the brachial (79) and radial
(15) artery, and in the acetylcholine-stimulated increase in forearm blood flow (112).
Given the low within-subject variability and practicality associated with FMD, this
technique was used to assess endothelial function in the current investigation.
2.2.1.2. Low-flow mediated constriction
During distal occlusion, conduit arterial flow is reduced by approximately 70%, and the
artery vasoconstricts (low-flow mediated constriction, L-FMC) (154). This was
originally believed to only occur in patients with hypercholesterolaemia, and not in a
healthy population (166). However Spieker et al. showed in a healthy population, that a
significant constriction occurs in the radial artery, and is of a similar degree to the
dilatation (167). Recent interest has developed from the observation that radial artery L-
FMC is as repeatable as FMD, and like FMD, is reduced in patients with coronary
artery disease. It has been suggested that L-FMC may complement FMD, possibly by
providing an estimate of basal endothelial function (154).
If L-FMC is repeatable and related to FMD, then it supports the notion that L-FMC
could have an additive role in the in vivo assessment of endothelial function. Recently
groups have shown that FMD and L-FMC correlate (168,169), and thus L-FMC may
represent the flip-side of FMD, whereby a reduction in flow causes an endothelium-
dependent reduction in diameter; the opposite to the dilatation seen in response to
hyperaemia. However at present this remains speculation. Unlike FMD, L-FMC is not
abolished by L-NNMA (155), and variably dependent on prostaglandins, EDHF and
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endothelin-1 (154,167). Alternatively L-FMC could be a myogenic or neurogenic
response to arterial occlusion or a composite of several pathways. Further work is
required to assess whether L-FMC, like FMD, is an endothelium dependent
phenomenon. One way of addressing this question is to investigate how L-FMC is
modified by IR injury.
2.2.2. Experimental set up
Experimental protocols are described in 3.2.2 and 4.2.3. Studies were approved by the
Joint UCL/UCLH Committees on the Ethics of Human Research (Committee A), with
the reference 09/H0714/67, and conducted within the guidelines of the Declaration of
Helsinki. All studies were conducted in a temperature controlled laboratory (24-26°C)
in the Clinical Research Facility, University College Hospital. Healthy males (aged 18-
45 years) were recruited by using an advertising email directed to students at UCL and
by word of mouth. Females were not included due to the potential variation of
endothelial function with the menstrual cycle (170), and the necessity to repeat studies
more often than once every 28 days. Participants were excluded if they were younger
than 18 years old, or older than 45 years old. All current or previous smokers, those
taking regular medication, and subjects with a recent history of a vascular or
inflammatory disorder were excluded. Participants were asked to refrain from moderate
exercise and alcohol intake for at least 24 hours, and caffeine and high fat meals for at
least four hours prior to each study. Subjects provided written consent prior to
experimental procedures.
2.2.2.1. Brachial artery flow mediated dilatation
International guidelines for FMD have been followed for experimental studies (157).
Training was given by two experienced vascular scientists. FMD in the brachial artery
was assessed as described previously (79). Experimental set up is shown in Figure 2.3.
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Briefly participants were positioned supine on an adjustable hospital bed for at least 10
minutes prior to the start of ultrasound recording, and were asked to remain still
throughout the study. The right arm was rested in an arm holder, with the forearm
slightly raised using a foam pad to aid comfort. An 8.5 cm wide pneumatic cuff was
placed 2 cm distal to the medial epicondyle of the right forearm. Right index finger skin
temperature was maintained between 28-32°C, using a heated bean bag to warm the
hand if necessary.
A B-mode ultrasound scan of the brachial artery was obtained in a longitudinal section
between 5 and 10 cm proximal to the antecubital fossa. The ultrasound probe was a 13.0
MHz linear-array transducer connected to an Aloka SSD-5000 ultrasound system
(Aloka Hitachi, Japan). For repeated tests previous subject recordings were reviewed
prior to image acquisition, and both ultrasound probe position and baseline diameter
were matched where possible.
Image quality was maintained using an adjustable probe holder (Vascular Imaging,
Netherlands). Fine adjustments with the probe holder in the coronal and sagittal plane
maintained a constant, focused image of the upper and lower walls, and counteracted
any movement caused by cuff inflation. Longitudinal, ECG-gated, end-diastolic images
were acquired, and recorded onto DVD.
For each FMD protocol, recording lasted 11 minutes in duration. Following one minute
of rest, the distal cuff was inflated to 300 mmHg using an automatic cuff inflator
(Logan Research Ltd, UK), which caused a low-flow state within the arterial lumen.
After five minutes of occlusion the cuff was released. This resulted in a reactive
hyperaemia and a subsequent dilatation. The arterial diameter was measured for a
further five minutes. Blood flow velocity was continuously monitored by pulsed-wave
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Doppler. Blood pressure was assessed immediately prior to each ultrasound recording
using an automated blood pressure cuff on the left arm (Dinamap, GE Healthcare, UK).
2.2.2.1. Radial artery flow mediated dilatation
To assess FMD in the radial artery, the distal cuff was placed on the wrist, and the right
forearm was fixed in position using a compression pillow (PRA Plastics &
Development Ltd, UK) to reduce arterial movement during cuff inflation. A B-mode
ultrasound scan was then obtained in a longitudinal section between 5 and 15 cm distal
to the antecubital fossa for the radial artery assessment. For repeated tests the previous
participant recordings were again reviewed prior to image acquisition, and both
ultrasound probe position and baseline diameter were matched where possible. The
timing protocol, and cuff pressures were identical for radial and brachial FMD.
2.2.2.2. Ischaemia-reperfusion injury
For the induction of IR injury, a 6.5 cm wide cuff was applied to the right upper arm,
and inflated to 200 mmHg using an automated cuff inflator (Hokanson, USA).
Ischaemia was confirmed by an absence of a flow signal at the level of the brachial or
radial artery. For the IR injury protocols refer to section 4.2.3.3.
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Figure 2.3 Experimental set up for vascular ultrasound studies. Subjects laid supine whilst the right
arm was imaged (A). The FMD cuff was applied below the medial epicondyle for the FMD protocol.
A proximal cuff was fitted below the shoulder for inducing IR and IPC. In the radial studies a
compression pillow maintained arm stability (B), whilst in the brachial studies the arm was
supported by an arm holder and foam pad (C).
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2.2.2.3. Local ischaemic preconditioning
For the induction of IPC a 6.5 cm wide cuff was applied to the right upper arm, and
inflated to 200 mmHg using an automated cuff inflator (Hokanson, USA). Ischaemia
was confirmed by an absence of a flow signal at the level of the brachial or radial artery.
For IPC protocols refer to section 5.2.3.2.
2.2.2.4. Remote ischaemic preconditioning
For the induction of RIPC a 6.5 cm wide cuff was applied to the left upper arm, and
inflated to 200 mmHg using an automated cuff inflator (Hokanson, USA). Ischaemia
was confirmed by the absence of a radial pulse. For RIPC protocols refer to section
5.2.3.1.
2.2.2.5. Exercise preconditioning
To assess the effect of exercise preconditioning (ExPC) on IR injury, subjects
performed a ramp exercise protocol using an electronically braked cycle ergometer
(Lode, Netherlands). Following a four minute warm up of unloaded cycling (0 W), an
exercise protocol based on weight and age was used to steadily increase cycle resistance
(20-40 W/min, Equation 2.3) (20), whilst cycling at a constant cadence (60 revolutions
per min, rpm). Exercise continued until physical exhaustion, or until subjects were
unable to maintain a cadence of above 50 rpm despite encouragement. Heart rate was
recorded throughout. For ExPC protocol refer to section 5.2.3.3.
Equation 2.3 Calculation of work rate increments for exercise preconditioning study.
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2.2.3. Analysis of acquired ultrasound images
2.2.3.1. Analysis of diameter changes
Images were acquired in real-time during FMD recording using automated software
(Brachial Tools, Medical Imaging Applications, USA). The software obtained images
once every 3 seconds across a 3 cm longitudinal section. Data analysis was performed
using specialist software (Brachial Analyser, Medical Imaging Applications, USA).
Initially, a region of interest was chosen with an optimum image quality, defined by an
obvious definition between the arterial intima and the lumen, which was free from
anatomical artefacts (see Figure 2.4A). During analysis FMD traces were scrutinised,
and were excluded if necessary due to poor image quality or the presence of artefacts
(see Figure 2.4B&C). Furthermore studies were excluded if, post hyperaemia, the vessel
failed to return to within 0.2 mm of the baseline diameter, or if there was a difference in
baseline diameter of greater than 0.2 mm between scans performed before and after the
IR injury intervention.
ABC71
Figure 2.4 Typical ultrasound image and brachial and radial artery diameter responses during flow
mediated dilatation protocol. Vessel diameter was measured in a longitudinal section every three
seconds, using edge-detection software (A). This produced graphs for the 11 minute recording
period in the brachial (B) and radial arteries (C). The radial artery was narrower, and had a
greater mean L-FMC% that the brachial artery, whilst FMD is similar.
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2.2.3.2. Analysis of the velocity-time integral
Arterial blood flow velocity was analysed from the pulsed wave Doppler flow signal.
Each cardiac cycle produced a velocity-time profile, displayed as a spectral Doppler
curve. Calculating the area under the curve gives a velocity-time integral (VTI), which
is approximately the distance covered by a pulse of blood in one cardiac cycle. Given a
constant heart rate and arterial diameter, VTI can be considered as proportional to flow
(flow = velocity x π r2). Thus VTI was used as a convenient proxy for flow, consistent
with previous studies (111,112).
For this thesis, VTI was calculated at baseline, during low flow and during high flow
(Figure 2.5). Images collected during recording were retrospectively analysed for VTI.
Individual images were identified, and envelopes were manually traced using the free-
hand function in commercially available imaging software (Image J v1.44, National
Institutes of Health, USA). Baseline VTI was calculated as the mean of three
consecutive velocity-time profiles, 30 seconds prior to distal cuff inflation. Low-flow
VTI was calculated as the mean of three consecutive velocity-time profiles, taken 30
seconds prior to distal cuff deflation. High-flow VTI was calculated as the mean of the
three greatest velocity-time profiles, which occurred within the first 10 seconds of cuff
release.
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Figure 2.5 Image analysis technique for velocity-time integral assessment. Representative image is
shown of the Doppler velocity-time envelope in the brachial artery. Profiles were displayed for each
cardiac cycle during flow mediated dilatation recording. Imaging software was used to free-hand
(yellow line) outline the envelope during rest (baseline, A), distal cuff occlusion (low flow, B), and
following cuff release (high flow, C). Area under the curve measurements were expressed as the
velocity-time integral (VTI) in meters.
2.2.3.3. Variability of the image analysis
Repeated recordings were made to assess the variability of the diameter and flow
analysis techniques. To assess the variability associated with the image analysis
technique, I analysed 11 brachial artery ultrasound scans on two occasions (Figure 2.6).
FMD, L-FMC, baseline diameter and velocity time integral (VTI) were highly
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repeatable. There was no evidence of systematic bias between the repeated analyses,
given that the differences were evenly spread around 0 on Bland-Altman plots.
To assess between-analyser variability, I then analysed 18 brachial artery ultrasound
scans that were also analysed by an experienced ultrasonographer (Figure 2.7). The
coefficient of variation indicated that analysis of baseline diameter, FMD and L-FMC
are more variable when assessed by two investigators instead of one. Furthermore there
was some evidence of systematic bias between analysers for baseline diameter, though
this had no effect on FMD or L-FMC. This was most likely due to a calibration
differences between analysers. Given this, results in this thesis were analysed by myself
as a single investigator, to limit analysis variability.
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BL diameter
(mm)
FMD
(%)
L-FMC
(%)
BLVTI
(m)
LF VTI
(m)
HF VTI
(m)
mean 3.62 8.38 2.29 0.071 0.019 0.316
between subject SD 0.33 2.36 2.87 0.023 0.006 0.047
within subject SD 0.01 0.29 0.14 0.003 0.001 0.006
Mean CV (%) 0.2 3.4 6.1 3.7 3.29 2.01
ICC 1.00 0.99 1.00 0.99 0.99 0.98
mean difference 0.00 -0.07 0.03 -0.004 0.000 0.004
difference SD 0.02 0.57 0.26 0.005 0.001 0.017
n 11 11 11 11 11 11
Figure 2.6 Within-analyser variability of ultrasound images. 11 brachial artery flow mediated
dilatation scans were analysed on two separate occasions. Table summarises statistical results.
Bland-Altman plots are shown for baseline diameter (A), flow mediated dilatation (FMD) (B), low-
flow mediated constriction (L-FMC) (C), baseline velocity-time integral (VTI) (D), high flow VTI
(E) and low flow VTI (F). There was no evidence of systematic bias. Dotted lines represent 95%
limits of agreement.
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BL diameter
(mm)
FMD
(%)
L-FMC
(%)
Mean 3.90 6.12 2.87
between subject SD 0.32 3.37 2.01
within subject SD 0.06 0.54 1.09
Mean CV (%) 1.5 8.8 38.1
ICC 0.97 0.98 0.77
mean difference -0.08 0.02 -0.08
difference SD 0.08 1.06 2.09
n 18 18 14
Figure 2.7 Between-analyser variability of ultrasound images. 18 brachial artery flow-mediated
dilatation scans were analysed by two investigators. Table summarises statistical results. L-FMC
could not be measured in 4 images. Bland-Altman plots are shown for baseline diameter (A), flow
mediated dilatation (FMD) (B) and low-flow mediated constriction (L-FMC) (C). There was some
evidence of bias for baseline diameter. Dotted lines represent 95% limits of agreement.
2.2.4. Interpretation of results
Data were analysed by myself using analysis software (GraphPad Prism, Graph Pad Inc,
USA). FMD was calculated as the difference between baseline diameter, and the highest
three consecutive values following cuff release. L-FMC was calculated as the difference
between baseline diameter and the final 30 seconds prior to cuff deflation. Both FMD
and L-FMC were expressed as the percentage change from baseline. Baseline, high flow
and low flow VTI are expressed as absolute values in metres. High and low flow VTI
included a correction for heart rate.
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2.3. In vivo assessment of acute inflammation in humans
2.3.1. Background
To investigate the effect of IPC on the human inflammatory response it was necessary
to use a quantitative assessment of acute inflammation. As discussed, IPC influences
human leukocyte function in vitro, but it remains uncertain whether altering immune
function occurs in vivo, and thus whether this is an important part of the mechanism by
which IPC reduces IR injury. A number of human in vivo models of acute inflammation
exist, which include the negative pressure skin blister model (171), the systemic
inflammatory reaction following endotoxin inhalation (172), and the cantharidin-
induced skin blister model (173).
As an experimental technique for categorising inflammation, the cantharidin skin blister
is advantageous in that, unlike endotoxin inhalation, it assesses a local response. In
addition our group has previously shown it is non-invasive, has a low within-person
variability, and can be maintained to categorise both the acute and resolving
inflammatory response in healthy volunteers (174). It also has few side effects, and a
retrospective analysis of topical cantharidin administration identified erythema (37%),
mild to moderate pain (14%), a transient burning sensation (10%), and a post-
inflammatory hypo or hyperpigmentation (8%) as being the major unwanted side effects
(175).
Cantharidin, a protein phosphatase inhibitor (3,6 epoxy-1,2-dimethylcyclohexane-1,2-
dicarboxylic anhydride), is obtained from beetles of the order Coleoptera and the family
Meloidae, which induce skin blistering on contact with skin. Cantharidin has been used
historically as a treatment for helminths and ulcers, and as an aphrodisiac (176).
However when swallowed it induces pharyngeal blistering, vomiting, and haematemesis
(177). Cantharidin is currently used as a treatment for plantar warts (178), and has been
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suggested as a novel therapy for acquired perforating dermatosis (179). When applied
topically to the skin, cantharidin is absorbed into the epidermis by the lipid layers of the
cellular membranes (176). This results in an initial suprabasal acantholysis, followed by
an extensive acantholysis down to the level of the sebaceous glands (180).
In cantharidin blister studies to date, leukocytes that enter the fluid-filled space have
been enumerated, and a differential acquired by histologically staining cells, or by
labelling cells with fluorescent antibodies and performing flow cytometry. Furthermore
cytokines, chemokines and inflammatory lipids that accumulate in the fluid may be
assessed by performing an enzyme-linked immunosorbent assay (ELISA). This study
has investigated blisters at two time points, 24 and 72 hours. At 24 hours inflammatory
blister leukocytes are primarily neutrophils, but by 72 hours the neutrophils are reduced,
which coincides with an increase in macrophages (181).
2.3.2. Experimental set up
The study was approved by the UCL ethics committee, reference 2907/02, and
conducted within the guidelines of the Declaration of Helsinki. Healthy males (aged 18-
45 years) were recruited from researchers within the UCL Division of Medicine and
from UCL students using an advertising poster and by word of mouth. Participants
provided written consent prior to experiments. Subjects were excluded if they had a
history of an acute or chronic inflammatory, vascular or gastrointestinal disorder, recent
immunisation, or had any known adverse response to aspirin. Participants were asked to
avoid non-steroidal anti-inflammatory medication for at least 72 hours, to avoid all
medication (including caffeine and alcohol) for at least 24 hours, and intense exercise
for at least 24 hours prior to each blister application. Following blister application,
participants were asked to avoid alcohol, caffeine, medication and moderate intensity
exercise until the final blister was aspirated.
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2.3.2.1. Blister induction
Table 2.1 lists the materials required to induce two cantharidin blisters. Blisters were
induced as previously described by our group (Figure 2.8) (174,181). Initially the skin
was prepared by choosing two parallel sites approximately 30-70 mm from the elbow
crease on the ventral aspect of the forearm. The sites had 20-40 mm between them,
depending on forearm width. Any hairs in a 3 cm diameter of the area chosen were
trimmed, and the area cleaned with 70% alcohol. Two 10 mm diameter filter paper discs
were positioned in the centre of each blister site. 12.5 µl of 0.1% cantharidin was then
pipetted onto each disc. The paper discs were then covered with 16 mm diameter film
discs, and then the foam pads were positioned superiorly, such that each film disc was
protected by two foam pads. The pads were covered with an adhesive dressing, which
was applied at a constant pressure and without extensive forearm skin depression to
minimise blister volume variability. Participants were advised to keep the dressing dry
by covering during bathing.
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Table 2.1 Materials required for each participant to receive forearm skin blisters. Below are shown
materials required for application and aspiration of two cantharidin skin blister, at 24 and 72
hours.
Material Supplier
Filter paper punched into 10 mm diameter discs (Whatman®
grade 1)
2 discs Whatman International Ltd, Maidstone, UK)
Laboratory film punched into 16 mm diameter discs (ParafilmTM) 2 discs Alpha Laboratories, Eastleigh, UK
Foam pads cut into 30 mm diameter discs (Activheal® Non-
adhesive foam pad, 10 x10 cm)
4 discs Advanced Medical Solutions Ltd, Winsford, UK
0.1% cantharidin (0.7% Cantharone® diluted in acetone) 25 µl Dormer Laboratories Inc., Toronto, Canada
Adhesive dressing (IV 3000TM, 10x14 cm) 1 dressing Smith & Nephew, Hull, UK
Film dressing (Mepore® Film & Pad, 9x10 cm) 2 dressings Mӧlnlycke Heath Care, Gothenburg, Sweden 
Ulcer dressing (Comfeel® Plus, Ulcer Dressing, 10x10 cm) 1 dressing Coloplast, Peterborough, UK
Cap from 30 ml Specimen Tube 1 cap Sterilin, Newport, UK
Support bandage (Tubigrip® size C, medium elbow) 15cm Mӧlnlycke Heath Care, Gothenburg, Sweden 
Surgical tape cut into 10 cm strips (MicroporeTM) 10 strips 3M Healthcare, Loughborough, UK
Alcohol wipe 3 wipes UHS, Enfield, UK
Disposable Haemocytometer (C-Chip) 2 slides Digital Bio, Seoul, Korea
0.4% trypan blue stain 20 µl Life Technologies Ltd, Paisley, UK
3% sodium citrate, dissolved in 0.9% sodium chloride 100 µl Sigma Aldrich, Gillingham UK
26 gauge sterile needle 2 needles Sigma Aldrich, Gillingham UK
1 ml syringe 2 syringes Terumo, Egham, UK
Roswell Park Memorial Institute (RPMI) media (Gibco®) 2 ml Life Technologies Ltd, Paisley, UK
1.5 ml microcentrifuge tubes 4 tubes Appleton Woods, UK
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Figure 2.8 Induction of cantharidin blister. Photos show experimental set up for induction of
cantharidin skin blisters (182). Initially 12.5 µl of 0.1% cantharidin were pipetted onto filter paper
discs (A). These were covered by film discs and foam pads (B–D). Finally an adhesive dressing was
used to fix the position (E-F). Dressings were then kept in position for 24 hours.
2.3.2.2. Blister aspiration at 24 and 72 hours
Participants returned to the laboratory at 24 and 72 hours following blister patch
application for blister aspiration (Figure 2.9). The adhesive dressing, followed by the
foam, film and paper discs were carefully removed, the integrity of blisters was
assessed, and the diameter recorded. The blister that had been assigned to aspiration at
24 hours was then pierced at the lateral border with a sterile needle, and a syringe was
rolled across the blister pushing the fluid onto the skin. The fluid was aspirated from the
skin, and transferred to a centrifuge tube containing 50 µl of 3% sodium citrate. The
tube was immediately weighed, and centrifuged (2000 g. , 5 minutes, 10°C). The
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supernatant was removed and aliquoted, before being frozen at -80°C for further
analysis. The cell pellet was resuspended in 0.1-1 ml of RPMI buffer, depending on the
size of the pellet.
Following blister aspiration, the area was cleaned with a 70% alcohol swab, and
covered with a sterile dressing. The remaining intact 72 hour blister was then given a
protective cover so that it was secured for the remaining 48 hours (Figure 2.10). Initially
a 2 cm hole was cut into an ulcer dressing, which was shaped to fit around the
remaining blister. A thin strip of the ulcer dressing was cut to cover the rim of a
specimen tube cap, which was secured over the blister using medical tape. Finally the
cap and dressings were covered with a support bandage. At 72 hours, participants
returned to the laboratory. The bandage, cap and dressings were removed, and again the
blister was inspected for integrity, before being aspirated as at 24 hours.
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Figure 2.9 Aspiration of cantharidin blister. Blisters were aspirated at 24 and 72 hours following
application (182). Initially blisters were inspected for integrity and measured for size (A). Blisters
were then aspirated at the lateral border using a sterile needle (B). A syringe was rolled across the
blister to push out the contents, whilst the fluid was aspirated using a pipette (C and D).
84
Figure 2.10 Protecting the cantharidin blister from 24 to 72 hours. Aspirated 24 hour blisters were
cleaned and covered with a sterile dressing (A) (182). Then an ulcer dressing is fitted around the
remaining intact blister (B and C), before it is secured by a protective cap (D and E), and finally by
a support bandage (F). The remaining blister was aspirated at 72 hours.
2.3.2.3. Cell counting
To enumerate blister leukocytes and assess viability, 10 µl of the cell suspension was
mixed with 10 µl 0.4% trypan blue solution (Sigma Aldrich, UK). Trypan blue is not
absorbed by cells with an intact cell membrane, and hence is used to exclude dead cells.
10 µl of this mixture was then pipetted into the enclosed chamber of a disposable
manual haemocytometer (Digital Bio, Korea) and cells were enumerated using a light
microscope (Primo Vert, Zeiss, Germany). The total blister cell count was calculated
using Equation 2.4.
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Equation 2.4 Calculation of total blister cell count. Cells are expressed as the absolute total cell
count or as the cell concentration within the blister fluid.
2.3.2.4. Collection and preparation of human peripheral blood
Peripheral blood was drawn from the antecubital vein of participants using a 21G
butterfly needle (Vacuette®, Greiner, Austria), and collected in tubes containing
ethylenediaminetetraacetic acid (EDTA), which when blood was added formed an
EDTA concentration of 1.8 mg per ml, to prevent the sample from clotting. Plasma was
isolated by centrifuging blood collection tubes at a high velocity (3000 g., 10 min,
10°C). Plasma supernatant was then aliquoted and immediately stored at -80°C for later
analysis.
To isolate leukocytes, venous blood was exposed to a hypotonic solution, followed by a
hypertonic correction to induce red cell lysis, whilst maintaining the integrity of the
peripheral blood leukocytes. To achieve this 5 ml of venous blood were added to 45 ml
of distilled water (1:10) for 17 seconds only. Then, 5 ml of 9% NaCl solution were
added, immediately returning the blood mixture to an isotonic solution, and preventing
leukocytes from losing membrane integrity. After 5 minutes the mixture was
centrifuged (500 g. , 5 min, 10°C), followed by aspiration of the supernatant, and the
remaining cell pellet was resuspended in 500 µl hypotonic ACK lysing buffer (Lonza,
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Switzerland) for 3 minutes, to ensure lysis of the remaining red blood cells. After 3
minutes 1 ml of flow cytometry buffer (1% fetal calf serum, 2 mM EDTA in 1 x
phosphate buffered solution, PBS) was added, and the mixture was centrifuged (500 g. ,
5 min, 10°C). Cells were then resuspended in 2 ml of flow cytometry buffer, resulting in
an approximate leukocyte concentration of 12.5 x 106 cells/ml.
2.3.3. Flow cytometry
2.3.3.1. Background
Fluorescent labelling of cells using flow cytometry allows researchers to quantify
relative expression of specific receptors on cell populations. This is of particular use in
the setting of the cantharidin blister, because it provides a rapid, accurate differential of
leukocytes, and can be compared with circulating leukocytes. One previous cantharidin
blister study has used flow cytometry for cell identification (181). However this study
planned to make use of modern equipment using the BD LSR FortessaTM system, to
label each cell mixture with seven antibodies. This allowed for cell differentiation in
every blister and venous sample, and to determine cell activation by using major
histocompatibility complex class II (MHC class II) expression. Training was given by
an experienced post-doctoral research fellow.
2.3.3.2. Leukocyte preparation for flow cytometry
Blister leukocytes were prepared for flow cytometry by centrifuging cells (2000 g. , 5
min, 10°C), and resuspending cell pellets in flow cytometry buffer. 40 µl of cell
suspension were used at each time point, and given an approximate concentration of
0.05 – 0.5 x 106 cells / 40 µl.
Working dilutions of each antibody was determined by titration and assessment of
expression on circulating leukocytes. The list of antibodies used, including information
on the fluorescent conjugate, concentration, and population of labelled cells are given in
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Table 2.2. 40 µl of cell suspension was incubated with 60 µl antibody mixture on a 96-
well plate for 25 minutes on ice in the dark. Samples were then washed 3 times by
adding 150 µl flow cytometry buffer, centrifuged (800 g. , 3 min, 10°C), before being
resuspended in 400 µl fixing buffer (0.1% paraformaldehyde in PBS), and transferred to
a 1.1 ml microtube. Samples were analysed using the LSRFortessaTM flow cytometer
(BD, USA) within 7 days of cells being fixed.
Table 2.2 Antibodies used to characterise leukocyte populations. Antibodies were acquired from
bioscience manufacturers. 1 BD, 2 AbD Serotec, 3 eBioscience, all USA.
Antigen Clone
Fluorescent
conjugate
Volume
(µl / test)
Stock concentration
(µg/ml)
Cell population labelled
CD31 UCHT1 APC 10 3 T-lymphocytes
CD141 M5E2 Alexa Fluor® 700 2.5 200 Monocytes/Macrophages
CD161 3G8 FITC 20 50 Granulocytes
CD191 SJ25C1 PE-CyTM7 2.5 6 B-lymphocytes
CD561 B159 PerCP-CyTM5.5 2.5 25 Natural-killer cells
CD1631 M130 PE 20 6.25 Monocyte/Macrophages
HLA-DR1 L243 V450 2.5 50 MHC Class II+ cells
CD332 WM53 PE 10 100 All myeloid lineage cells
CD11b3 ICRF44 PE-CyTM7 2.5 200 Myeloid lineage cells
CD151 H198 PerCP-CyTM5.5 5 25 Granulocytes
2.3.3.3. Flow-assisted cell sorting
In three subjects, cells were sorted for histological staining and morphological
assessment. Samples were prepared as previous, except that the final resuspension was
in 400 µl of flow cytometry buffer. The resuspended cell suspension was analysed using
the FACS Aria flow cytometer (BD, USA) within 2 hours of preparation. Cells were
sorted according to the standardised gating strategy (see 2.3.3.5).
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2.3.3.4. Histological staining and slide preparation
Sorted populations were processed for microscopy. Slides were prepared by
centrifuging the sorted cell suspension using a cytospin and subsequently staining using
a modified Wright’s staining procedure (Shandon Kwik-Diff, Thermo Fisher, UK).
Stained cells were viewed by microscopy (200 x, Olympus BX41, Olympus, Japan),
and photographed using imaging software (Image Pro 6.3, MediaCybernetics, USA).
2.3.3.5. Data analysis
Data were analysed using the FlowJo software (FlowJo v7.6.1, Tree Star Inc, USA).
Briefly cell populations were identified within dot plots based upon size, granularity and
fluorescence. Due to the lack of published data on blister cell differentiation by flow
cytometry, a novel gating strategy was designed to identify individual cell populations.
The gating was almost identical for both circulating and blister populations. Positive
antibody expression was identified by performing florescence-minus-one (FMO)
controls, which contain all antibodies except for one. FMO controls are typically used to
identify populations that are positive and negative for the antibody of interest (183).
Gating strategy is described in section 6.3.2. Populations are labelled according to
relative fluorescence intensity, indicated by superscript text i.e. xhi = high expression,
xdim = medium expression, xlo = low or no expression.
2.3.4. Tumour-necrosis-factor-alpha and interleukin-10 assay
To assess the concentration of tumour-necrosis-factor-alpha (TNF-α) and interleukin-10 
(IL-10) in the blister fluid and plasma, a series of enzyme linked immunosorbent assays
(ELISAs) were performed. TNF-α assay (Human TNF-alpha DuoSet, R&D Systems, 
USA) and IL-10 assay (Human IL-10 ELISA Set, BD OptEIATM, BD, USA) were
performed according to manufacturer’s protocol. Initially each well of a 96-well flat
bottom plate (Costar®, Corning Life Sciences, USA) was coated with 50 µl capture
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antibody (anti-human TNF-α; anti-human IL-10). The plate was then sealed and 
incubated overnight at room temperature. The following day the wells were aspirated,
and washed twice with addition of 200 µl wash buffer (0.05% Tween 20 in 1 x PBS).
The plate was then blocked by adding 150 µl reagent diluent (TNF-α, 1% bovine serum 
albumin in 1 x PBS; IL-10, 1% fetal calf serum in 1 x PBS), and then incubated at room
temperature for one hour, before two additional washes.
Blister and plasma samples were removed from -80°C, and thawed at room temperature.
Samples were then vortexed and centrifuged (100 g. , 2 min, 20°C) to collect all the
fluid. Samples were diluted 1.5-2 times with reagent buffer. Samples and standards
were added to wells of the plate, and incubated for 2 hours at room temperature. Plates
were washed twice, and 50 µl of detection antibody (biotinylated anti-human TNF-α; 
biotinylated anti-human IL-10 monoclonal antibody) were added to each well. Plates
were incubated for 2 hours at room temperature, before two wash steps. Next 50 µl of
Streptavidin-horseradish peroxidase conjugate (SAv- HRP) were added to each well.
Plates were covered and incubated for 20 minutes at room temperature, before two
additional washes. 50 µl of freshly prepared substrate solution (1:1 mixture of hydrogen
peroxide and tetramethylbenzidine) were added to each well, and incubated for 20
minutes at room temperature. 25 µl of stop solution (2N H2SO4) were then added to
each well, and plates were gently tapped to ensure mixing. Optical density was assessed
using a plate reader and results were exported into an excel spreadsheet.
2.3.5. Adverse events
During this study there was a single adverse event. One subject received a single 24
hour forearm blister on the right arm. 6 days following blister aspiration the subject
reported to the research group a 48 hour history of pain, swelling and redness in several
locations on the arm. He also reported that he had been swimming in an outdoor pond
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within the 48 hours window. On examination there were three sites on infection on the
right arm, with evidence of lymphangitis both distal and proximal to the blister (Figure
2.11). The participant was reviewed as an outpatient in University College Hospital and
prescribed a single course of antibiotics. By 24 hours the lymphangitis was resolving,
and the participant had made a complete recovery after completing the course of
antibiotics. This was the only adverse event in this study (total: 186 blisters), but
previous reports have observed lymphangitis second to cantharidin (184,185).
Figure 2.11 Lymphangitis second to cantharidin exposure. 6 days following blister aspiration the
subject showed evidence of an infective lymphangitis (A). After one week of antibiotic treatment the
participant had made a complete recovery (B).
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2.4. In vivo metabolic assessment during exercise in humans
2.4.1. Background
Recent studies have suggested that IPC can improve aspects of endurance exercise
performance, principally an increased maximal oxygen delivery (ܸ̇O2 max) (126), an
increased maximal power output (WR max) (127), and an improved swimming time
(128). The first two of these studies were using graded exercise tests. Graded or
incremental exercise tests to exhaustion are commonly performed to assess general
aerobic fitness and performance, and to identify the lactate and respiratory thresholds.
These types of exercise test have recently identified improvements in performance
following administration of nitrate supplements (186) and ß-alanine (187). Graded
exercise tests have been routinely used to study the effectiveness of various
interventions as well as to assess endurance capacity and aerobic power in athletes
following training interventions (126,188).
To determine the effect of IPC on aspects of human performance, it was important to
design an experiment that would adequately measure several parameters involved in the
metabolic pathways. As discussed, it remains uncertain whether IPC influences aerobic
or anaerobic metabolism during exercise, and therefore both of these elements should be
considered for investigation. This was achieved by measurements of systemic oxygen
delivery, carbon dioxide elimination, ventilation, skeletal muscle oxygenation, heart rate
response, blood gases, and recovery measurements (see protocol in section 8.2.3).
Below are discussed the methods used to perform this investigation.
2.4.2. Experimental set up
This project was approved by the UCL ethics committee, reference 2907/001, and
conducted within the guidelines of the Declaration of Helsinki. All measurements were
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conducted in the British Olympic Medical Institute in a temperature (21-23ºC)
controlled research laboratory.
Healthy well-trained males (aged 18-45 years) were recruited from local amateur
cycling and triathlon clubs by advertising email. Inclusion criteria were as follows:
participants were training for at least 4 hours per week, were members of a cycling or
triathlon club, and competed in cycling or triathlon events at least once every two
months. All subjects provided written consent, and completed a standard health screen
questionnaire. Participants were excluded if they had any known history of disease or
injury which might pose a contraindication for the testing as defined by the American
College of Sports Medicine guidelines (189), or were taking any regular medication.
Participants taking dietary supplements were not excluded, but were advised to continue
with the same supplement dosing throughout testing. Prior to each study subjects
avoided all competitive events for at least 72 hours, all training for 48 hours, and all
exercise for 36 hours. In additional participants remained free from alcohol and all
medication for 24 hours and caffeine for 12 hours. To standardise for hydration
participants drank a large glass of water upon waking. All testing sessions began
between 6 am and 11 am to account for known variation in circadian rhythm, and
subjects arrived in a fasting state. At least seven days were left between visits to allow
for a period of washout. This study followed a randomised controlled cross-over design.
2.4.3. Baseline measurements
2.4.3.1. Blood pressure and heart rate
Resting blood pressure and heart rate were recorded on the right arm using an automatic
blood pressure cuff (Omron, Japan) after sitting at rest for 10 minutes, and calculated as
the mean of three recordings.
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2.4.3.2. Anthropometric measurements
Subcutaneous fat is proportional to total body fat, and this gives an estimate of training
and nutritional status. In this project mid-thigh skinfold thickness was also necessary to
aid interpretation of the near-infrared spectroscopy results (see section 2.4.5). Calipers
were used to assess the body composition by skinfold thickness measurements. Height
and weight were assessed by a height chart and scales respectively.
Training was given by an International Society for the Advancement of
Kinanthropometry accredited sport scientist. Skinfold thickness measurements were
made in duplets at fixed anatomical locations: biceps, triceps, subscapularis, iliac crest,
supraspinale, abdomen, mid-thigh, and medial calf. If there was greater than a 5%
difference between the two skinfolds at each site, then it was repeated. Percentage body
fat was calculated using a standard 7-site formula (190).
2.4.4. Local ischaemic preconditioning
Preliminary studies demonstrated that receiving a preconditioning stimulus to the lower
limbs is less tolerable that on the upper limbs. The present study was subsequently
designed such that the pressure during the IPC protocol was both tolerable to the
participant, and sufficient to induce a vascular occlusion. Given known heterogeneity in
arterial occlusion pressure, a pre-determined occlusion pressure was established on an
individual basis.
2.4.4.1. Baseline assessment of peripheral flow
Flow was assessed using a pocket Doppler probe (Dopplex MD2, Huntleigh
Diagnostics, UK), and vascular occlusion was confirmed by a loss of both audio and
visual outputs. To determine the occlusion pressure of the femoral artery, a blood
pressure cuff (20x86 cm XXL cuff, Heine, Germany) was gradually inflated on the left
thigh, until the flow was lost over the dorsalis pedis artery. Identification of the dorsalis
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pedis artery was via the pulse on the dorsal aspect of the foot, immediately lateral to the
extensor halluces longus tendon.
2.4.4.2. Application of intervention cuffs
The IPC intervention during this study was induced by inflating two blood pressure
cuffs (20x86 cm XXL cuff, Heine, Germany) at the top of the thighs using an automated
cuff inflator (Hokanson, USA). IPC was induced by cuff inflation to 20-30 mmHg
above the pressure required to induce arterial occlusion. Sham cuff inflations were set to
a pressure of 20 mmHg below resting diastolic blood pressure.
2.4.5. Near infrared spectroscopy
2.4.5.1. Background
Near-infrared spectroscopy (NIRS) has developed through the necessity to non-
invasively monitor cerebral and muscular oxygenation in the clinical and research
settings. In recent years this has developed in the exercise medicine and sport science
field, especially given the availability of small, portable devices, which can be used to
relate muscle oxygenation to oxygen delivery (ܸ̇O2) (191).
NIRS is based upon the principle that when light of the near infrared range (typically
700-1000 nm) is shone on a tissue, it is either reflected or absorbed. These wavelengths
are chosen to enable assessment of haemoglobin, and in particular to quantify the ratio
between concentration of oxygenated haemoglobin ([HbO2]) and total haemoglobin
([HbT]), which absorb light of different wavelengths (peaks at 750 nm for haemoglobin,
and 900 nm for oxyhaemoglobin). The absorption spectra for [HbT] and [HbO2] are
graphed in Figure 2.12. Absorption at these specific wavelengths are proportional to
concentration and described by the Beer-Lambert law (see Equation 2.5).
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A = log10 [I0/I] = a x c x l
Where A = attenuation measured in optical densities
I0 = intensity of incident light
I = intensity of transmitted light
a = specific extinction coefficient
c = concentration of absorbing material
l = length of light path through the material
Equation 2.5 The Beer Lambert Law for assessing level of absorption through a material. This
equation is the basis for calculating the concentration of oxyhaemoglobin by NIRS. From Horecker
1943 (192).
Figure 2.12 Absorption spectra of haemoglobin and oxyhaemoglobin. Graph shows the specific
absorption spectra for haemoglobin (Hb) and oxyhaemoglobin (HbO2), which is used to derive the
concentration using Equation 2.5. Modified from Horecker 1943 (192).
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Several limitations exist with the use of NIRS, including the difficulty distinguishing
the contribution of myoglobin and cytochrome C to the [HbO2] and [HbT] signals.
Whilst NIRS can quantify haem oxidation, is cannot distinguish between this in
haemoglobin or myoglobin. However myoglobin and cytochrome C are believed to
account for less than 15% of the light absorption signal (193), and the current study
employed a crossover design so that small variations are unlikely to pose a confounding
factor.
2.4.5.2. Measurement of muscle oxygenation during exercise
A number of groups have used NIRS to assess muscle oxygenation during exercise
protocols, and in sporting performances tests (194–196). During an incremental exercise
protocol NIRS has shown that muscle oxygenation relates to ܸ̇O2 values (191), and has a
good agreement with respiratory measurements to identify the anaerobic threshold
(197). The protocol in the current study has employed NIRS to assess the changes in
oxygenation in the vastus lateralis muscle during both cuff inflations and exercise, as
our group has recently performed in a group of elite speed skaters (195).
2.4.5.3. InSpectraTM near infrared spectroscopy device
The InSpectraTM 650 device (Hutchinson Technology, USA) is a single-distance
continuous-wave NIRS device. It consists of a main display unit and a disposable probe
attachment, which contains an emitter and a receiver unit. Recordings were made once
every two seconds, producing two values at each time point, the tissue haemoglobin
oxygen saturation (StO2) and the tissue haemoglobin index (THI). Values were
available and recorded in real-time, and analysed following data acquisition. The
distance between the emitter and the receiver was fixed at 15 mm, and it is suggested
that this corresponds to a mean signal depth of 7.5 mm, with the maximum signal depth
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being 15 mm (198). Using a group of well-trained subjects aimed to ensure that this
signal depth corresponded to skeletal muscle and not adipose tissue.
2.4.5.3.1. Tissue haemoglobin oxygen saturation
StO2 is the ratio of oxygenated haemoglobin to deoxygenated haemoglobin, expressed
as a percentage. The algorithm to calculate the StO2 is described in Myers et al. 2005
(198), and is attained from attenuation measurements at 680, 720, 760 and 800 nm,
whereby second derivative spectroscopy is applied to account for light scattering
effects, movement artefacts, baseline drift, and chromophores with constant absorption.
2.4.5.3.2. Tissue haemoglobin index
The THI corresponds to the total haemoglobin within the amount of tissue covered by
the optical path length (199). However this volume of tissue is uncertain, and hence the
index is in arbitrary units. Highly vascular tissues, such as the muscles, exhibit a higher
THI than poorly vascularised tissues, such as adipose tissues. It has also been reported
that during venous occlusion, the rise in blood volume results in an increase in THI,
whereas during arterial occlusion there is no change, or a small decrease (199).
2.4.5.4. Near infrared spectroscopy set up
The InSpectraTM device consists of a skin probe and a main display unit. In the current
study the probe was positioned on the left thigh, two thirds of the distance between the
greater trochanter and the lateral epicondyle, and 2–8 cm medially, such that the probe
rested on the lower third of the belly of the vastus lateralis muscle (Figure 2.13). This
area had been shaven and marked prior to probe application. Preliminary work showed
that during exercise, the probe suffered from extensive movement if not secured. To
account for this, the probe and attached wire were secured using black cloth tape
(Grays, UK), a plastic cap, a crepe bandage, and a support bandage (Tubigrip®,
Mӧlnlycke Heath Care, Sweden). 
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Figure 2.13 Experimental set up of near-infrared spectroscopy recording. Initially the NIRS probe
was positioned at the base of the belly of the vastus lateralis muscle (A), before being secured with
tape and a cap (B). This allowed for sufficient space above the probe for cuff application when
necessary (C). The probe is further secured by a support bandage during exercise testing (D).
2.4.5.5. Data analysis
Values for StO2 and THI were recorded every two seconds throughout all the testing,
and transferred to a spreadsheet for post-test analysis. For each time point, StO2 and
THI were expressed as the mean value of the previous twenty seconds. This was an
optimal window of investigation to account for the noise associated with recording
during exercise, based upon results in the preliminary studies.
2.4.6. Assessment of cardiorespiratory variables
The K4b2 system (Cosmed, Italy) was used to perform respiratory gas analysis during
exercise and recovery. The system consists of a portable unit and a mask, which was
fixed to the participant during testing. The portable unit contains CO2 and O2 analysers,
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the electronics controlling the sampling pump, and barometric sensors. Power is
supplied by a battery pack, which was positioned on the participants back. The portable
unit was connected to a low resistance turbine by a gas sampling line. Inspired and
expired air passing through the mask was directed into the turbine. As the turbine spins
it interrupts infrared light passing through the optoelectronic reader. Gas collected in the
sampling line was rapidly assessed for O2 and CO2 within the portable unit. The K4b2
system has been validated against the Douglas bag method, and was deemed acceptable
over a range of exercise intensities (200). In the current study it was used to measure O2
delivery (ܸ̇O2), CO2 elimination (ܸ̇CO2) and ventilation (ܸ̇E).
2.4.6.1. Gas analyser experimental set up
The K4b2 was prepared for study according to the manufacturers guidelines. In all
studies the main unit was turned on to equilibrate for at least 45 minutes prior to
calibration. Sequential calibration of the unit followed. Firstly the system was calibrated
at room air to adjust the gain of the O2 analyser and to adjust the baseline on the CO2
analyser. Secondly the unit was calibrated by providing known fixed concentrations of
O2 and CO2 (16.00% and 5.00% respectively) from a gas cylinder (Cosmed, Italy), to
update the gain and the baseline of the analysers. A delay calibration was performed to
update the software with the duration required for gas samples to pass from the turbine
to the portable unit. Finally, the turbine was calibrated using a 3 litre gas syringe to
adjust for volume gain and match the predicted value.
Participants were asked to position themselves on a cycle ergometer, and a heart rate
strap (Polar, Finland) was applied to the chest, followed by a secure harness containing
the main unit and battery pack (see Figure 2.14). A mask was then fitted to the face of
each subject, and checked for a tight seal. Having confirmed this, the mask was secured
and the turbine attached to the front of the mask. Participant preparation on the
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ergometer was approximately five minutes in duration. The main unit was connected to
a laptop (Lenova, China) and monitored in real-time using the K4b2 software.
Figure 2.14 Experimental set up for breath by breath gas analyser during exercise testing. A
harness secures the portable unit and battery pack to the subject, whilst inspiratory and expiratory
gases pass through the turbine. This in turn is secured by a mask and head-net.
2.4.6.2. Data analysis
All heart rate and respiratory data were collected breath-by-breath (ܸ̇O2, ܸ̇CO2 and ܸ̇E)
and analysed using specialist software (Cosmed, Italy). Results were calculated from
data acquired at the end of a constant submaximal exercise bout of 150 W (TSUBMAX)
and at peak exercise (TMAX) (see protocol in Figure 2.15). Results at TSUBMAX for all
parameters were calculated as the mean value during the final minute of cycling at a
power of 150W. Maximal heart rate (HR max) was taken as the mean of the final 20
seconds of exercise. In some instances erroneous flattening of respiratory graphs
occurred during the final 1-3 minutes of exercise. Therefore maximum ܸ̇O2, ܸ̇CO2 and ܸ̇E
values were estimated by extrapolation from linear regression above the anaerobic
threshold, but below peak values.
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2.4.7. Exercise protocols and design
To evaluate both the aerobic and anaerobic metabolic pathways during exercise, an
incremental exercise test to volitional exhaustion was employed. Participants began
cycling at a submaximal power output of 150W. This was followed by incremental
increases in resistance (50 W/min), whilst maintaining a constant cadence (80–100
revolutions per minute, rpm). Given the well trained nature of the study population,
increments were set to 50 W.
Exercise testing was carried out on an electronically braked cycle ergometer (SRM,
Germany). The seat and handlebar height and position were adjusted for each subject
during the first visit, and remained constant for subsequent visits. The attached
Powermeter (SRM, Germany), and accompanying software allowed for the application
of an incremental protocol, such that resistance increased to give a specific power
output, given that cadence remained constant throughout the test.
Figure 2.15 Incremental protocol using during exhaustive exercise test. Subjects began by cycling at
150 W at a self-selected cadence for 4 minutes. At this point (TSUBMAX) power output was increased
by 50 W/min until volitional exhaustion (TMAX).
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2.4.8. Rating of perceived exertion
In order to assess the subjects perceived rating of exertion, a modified Borg scale was
used (OMNI Perceived Exertion Scale, 0 – 10) (201). Subjects were asked to rate their
exertion using this scale every minute during exercise.
2.4.9. Blood pressure monitoring
Blood pressures are measured during exercise testing as a rapid, non-invasive method to
monitor systemic cardiovascular function, in combination with heart rate. At maximum
exercise intensity blood pressure increases, often to a systolic pressure of 200 mmHg
and a diastolic pressure of approximately 100 mmHg (20). Blood pressure was assessed
on the right arm during rest, exercise, and recovery using an automated blood pressure
cuff (Omron, Japan). Manual blood pressures were impractical due to the number of
other outcomes that were measured during and following the exercise test.
2.4.10. Assessment of blood lactate
Exercise above the anaerobic threshold increases circulating lactate (La) and hydrogen
ion (H+) concentration, causing a metabolic acidosis, which contributes to a muscular
fatigue and physical exhaustion. Lactate measurements from capillary blood samples
are commonly used during exercise testing to allow athletes to calculate their anaerobic
threshold, to modify training strategies, and to test subject responses to a single exercise
regime. Following an exhaustive period of exercise, circulating [La] is often greater
than 10 mmol/L.
In the current study a Lactate ProTM (Arkway, Japan) device was used to offer a rapid,
method for assessing blood [La] during rest, exercise and recovery (Figure 2.16).
Following blood drawing with a sterile lancet, a disposable test strip was held to the
finger tip, which used capillary action to take up the sample, such that only 5 µl of
blood were required per sample. In the device, blood lactate combined with lactate
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oxidase and potassium ferricyanide to form potassium ferrocyanide and pyruvate (202).
When a voltage was applied, ferrocyanide was oxidised, creating a current proportional
to the concentration of lactate, and measured amperometrically. The Lactate ProTM
device is accurate and repeatable, having been validated against gold-standard blood gas
machines (203).
Figure 2.16 Capillary sampling during exercise testing. Following blood drawing, lactate
concentration was measured from a drop of capillary blood (A). A capillary tube was then used to
acquire a sufficient blood sample (B), which was transferred by pipette into the well of an iSTAT
cartridge for blood gas and electrolyte measurement (C).
2.4.11. Assessment of blood gases and electrolytes
An exhaustive cycling test induces profound changes to blood gases and biochemistry
(20). To account for exercise-induced metabolic acidosis, circulating bicarbonate
(HCO3-) buffers the acid, and the resulting CO2 is then expired. Blood gases at the end
of an exhaustive test are associated with a high [La] and a low [HCO3-]. As the acidosis
progresses, the [H+] stimulate the carotid bodies, such that ܸ̇E increases more rapidly
than ܸ̇CO2, and decreases arterial partial pressure of CO2 (PaCO2) (20).
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Plasma electrolytes increase above the anaerobic threshold. This is most likely due to
the increased intracellular osmolality due to accumulation of lactate and other
metabolites during exercise (20). The increase in intracellular osmolality causes water to
move into the cell along the osmotic gradient, and thus causing an increase in
concentration in plasma electrolytes.
Blood gases are typically measured using a standard blood gases machine, such as the
Radiometer ABL 700 (Radiometer, Denmark). However with the growing necessity for
point-of-care testing, novel devices have been developed which allow for rapid
detection of gases, whilst maintaining a high sensitivity to aid clinical diagnostics. One
such device is the i-STAT® system (Abbott Laboratories, USA). The iSTAT® allows for
different analyses to be made on the same sample. The current study has used CG8+
cartridges, which provide plasma concentrations for pH, partial pressure of carbon
dioxide (PCO2), partial pressure of oxygen (PO2), oxygen saturation (sO2), total carbon
dioxide (TCO2), bicarbonate (HCO3-), base excess (BE), sodium (Na+), potassium (K+),
ionised calcium (iCa2+), glucose, haematocrit (Hct) and haemoglobin (Hb). The
methods used to perform each analysis are summarised in Table 2.3.
The cartridges were filled and processed according to manufacturer guidelines. Briefly
capillary samples were taken from the finger tips during the exercise testing studies
(Figure 2.16). A disposable lancet was held over the fingertip, and pressed onto the
skin. Capillary blood was collected using two heparinised capillary tubes per sample
(Na heparinised microhaematocrit capillary tubes, Hawksley, UK), and then
immediately transferred to the cartridge by sterile pipette. The cartridge was transferred
to the handheld unit and results were acquired within two minutes of sample
acquisition.
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Table 2.3 Analysis methods performed by iSTAT® CG8+ cartridges. Details obtained from
manufacturer website (204).
Factor Method of analysis Range of values
pH Direct potentiometry 6.50 – 8.20
pCO2 Direct potentiometry 5 – 130 mmHg
pO2 Amperometrically (similar to a conventional Clark electrode) 5 – 800 mmHg
TCO2 Based upon Henderson-Hasselbalch equation 5-50 mmol/L
HCO3 Calculated from pH and PCO2 N/A
BE Calculated from pH and PCO2 N/A
sO2 Function of PO2 N/A
Na+ Ion-selective electrode potentiometry 100-180 mmol/L
K+ Ion-selective electrode potentiometry 2-9 mmol/L
iCa2+ Ion-selective electrode potentiometry 0.25– 2.50 mmol/L
Glucose Amperometrically 1.1-38.9 mmol/L
Haematocrit Conductometrically 10-75%
Haemoglobin Function of Hct N/A
2.4.12. Assessment of blood haemoglobin and haematocrit
Haemoglobin is often assessed during exercise testing; it increases during an intense
exercise bout to improve the delivery of oxygen during exercise (205). This study
utilised the HemoCue® Hb 201+ haemoglobin system (HemoCue® AB, Sweden), which
provides a rapid point of care assessment of haemoglobin using a modified
azidemethemoglobin reaction (206). Within each microcuvette a reagent containing
sodium deoxycholate, sodium nitrite and sodium azide nitrite induces blood lysis, and
converts haemoglobin to azide methamoglobin. Haemoglobin concentration is then
assessed by a photometer, where the absorbance is measured at 570 and 880 nm, to
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compensate for turbidity. The HemoCue® offers good agreement with a gold standard
measure of haemoglobin, even at low concentrations (207).
Venous blood was collected using a 21-G butterfly needle (Becton Dickinson, USA)
from the left antecubital vein, into 6 ml EDTA tubes which were kept at room
temperature. All haemoglobin measurements were taken in duplets. Haematocrit was
assessed by filling sodium heparinised micro-haematocrit capillary tubes with EDTA
venous blood samples. Tubes were then spun (14000 g. , 5 min, room temperature)
using a desktop microcentrifuge (HaematoSpin 1400, Hawksley, UK), and the
haematocrit was measured in duplicate using a tube reader.
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3. THE EFFECT OF ISCHAEMIC
PRECONDITIONING ON CEREBRAL
ISCHAEMIA-REPERFUSION IN RATS
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3.1. Introduction
Human stroke currently accounts for 53,000 deaths per year in the UK (208).
Thrombolysis, induced by infusion of tissue plasminogen activator, is the only widely
used specific therapy for the treatment of acute stroke, but it is limited by a small
treatment effect and risk of intracranial haemorrhage (209).
To reduce the burden of stroke, in vivo animal models are needed both to develop our
understanding of stroke pathophysiology, and to identify novel treatments. Acute stroke
in humans is characterised by an arterial or arteriolar occlusion that causes cerebral
ischaemia, and is often followed by endogenous or exogenous thrombolysis and
subsequent reperfusion. Modelling this in animals requires a method to cause a transient
occlusion, allowing for reperfusion of the cerebral circulation, and therefore more
representative of human stroke than permanent occlusion models. However in vivo
stroke models are often limited by large between-animal variability, and as such stroke
studies designed for testing novel therapies are often underpowered.
Recently groups have suggested that remote ischaemic preconditioning (RIPC) protects
the brain from permanent cerebral arterial occlusion and ischaemia occurring after total
circulatory arrest (88,210). This chapter describes the methodology for the development
of a rat IR stroke model that uses a transient middle cerebral artery (MCA) occlusion.
The initial experiments characterised the stroke model. Following this I sought to
investigate whether MK-801, a known neuroprotective agent, reduces infarct size in this
model. Finally studies investigated several RIPC protocols as potential neuroprotective
strategies.
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3.2. Methods
3.2.1. Experimental set up
Animal preparation and surgical procedures are described in section 2.1.2.
3.2.2. Experimental protocols
Seventy-one male, Sprague Dawley rats (aged 10-12 weeks, weight 180-200 g) were
used to perform the experimental protocols detailed below.
3.2.2.1. Characterising the rat cerebral ischaemia-reperfusion model
The protocols used to characterise the model investigated two factors (see Figure 3.1).
Firstly, whether a contralateral common carotid artery (CCA) occlusion applied during
MCA occlusion influenced infarct size and between-animal variability. In protocol A
the contralateral CCA was patent throughout the study; in protocol B the contralateral
CCA was occluded for the first 30 minutes of the MCA occlusion; in protocol C the
contralateral CCA was occluded for the full 60 minutes of the MCA occlusion.
Secondly whether the duration of recovery influenced the infarct size and variability. In
protocol D the duration of recovery was extended from 24 to 72 hours.
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Figure 3.1 Experimental protocols to characterise the rat stroke model. This consisted of 60
minutes of MCA occlusion followed by 24 hours recovery (A), 60 minutes of MCA occlusion with 30
minutes contralateral CCA occlusion followed by 24 hours recovery (B), 60 minutes of MCA
occlusion with 60 minutes contralateral CCA occlusion followed by 24 hours recovery (C), and 60
minutes of transient MCA occlusion with 30 minutes contralateral CCA occlusion followed by 72
hours recovery (D). +cont, contralateral CCA occlusion; MCA, middle cerebral artery; TTC,
triphenyltetrazolium chloride staining analysis.
3.2.2.2. Effect of MK-801 and remote ischaemic preconditioning on
cerebral ischaemia-reperfusion injury
MK-801 was used as a positive control (see section 2.1.2.6); it was administered 15
minutes prior to filament insertion (dose = 3 mg/kg i.p.) (Figure 3.2E). To determine the
effect of RIPC, rats received 4 cycles of 5 minutes ischaemia followed by 5 minutes
reperfusion on the right lower limb, immediately prior to filament insertion. This was
performed with protocols consisting of a contralateral CCA occlusion of both 30
(Figure 3.2F) and 60 minutes duration (Figure 3.2G).
.
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Figure 3.2 Experimental protocols to investigate the effect of MK-801 and RIPC on rodent stroke.
MK-801 was administered 15 minutes prior to filament insertion (E). RIPC consisted of 4 cycles of
5 minutes occlusion followed by 5 minutes reperfusion, with both 30 (F) and 60 (G) minutes
contralateral occlusion. +cont. denotes contralateral CCA occlusion. MCA, middle cerebral artery;
TTC, triphenyltrazolium staining analysis.
RIPC was investigated further using additional protocols. Firstly the total duration of
limb occlusion and reperfusion was extended to 90 minutes (3 RIPC cycles of 15
minutes occlusion and 15 minutes reperfusion, Figure 3.3H). Secondly the effects of
anaesthesia on RIPC were investigated, by replacing injectable anaesthetics with
inhaled anaesthesia (5% isoflurane for induction, 2% isoflurane for maintenance)
(Figure 3.3J). Due to the extended duration of anaesthesia during these RIPC protocols,
sham controls were used to mimic the revised schedule of the experiments (Figure
3.3I&K).
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Figure 3.3 Experimental protocols to investigate the effects of duration and anaesthesia on RIPC-
induced neuroprotection. The cycles of RIPC were extended to 3 cycles of 15 minutes occlusion and
reperfusion (H). A sham control had matched anaesthetic dosing but without limb occlusions (I).
Both of these protocols were repeated with inhaled isoflurane replacing injected anaesthesia (J &
K). +cont. denotes contralateral CCA occlusion. MCA, middle cerebral artery; TTC,
triphenyltrazolium staining analysis.
3.2.3. Image analysis
All images were analysed as described in section 2.1.3.
3.2.4. Calculations and statistics
Results are presented as the modified lesion area, as the percentage of the total
hemispheric volume, and as the percentage of the area of the single MCA slice (see
section 2.1.4). Group data are given as the mean ± SD. Results from RIPC protocols
were matched with respective controls from the characterisation protocols, and were
compared by unpaired t test or one-way ANOVA with a post-hoc Bonferroni multiple
comparison test where appropriate. Within-group variation was expressed using the
coefficient of variation (CV). Sample sizes were calculated using statistical software
(Power and Sample Size Calculations, Dupont & Plummer, v3.0, (144)). p < 0.05 was
deemed statistically significant.
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3.3. Results
3.3.1. Contralateral occlusion increases infarct size and reduces between
animal variability
MCA occlusion for 60 minutes caused a cerebral infarct (lesion volume, 45.9 ± 11.2%,
n = 5). Contralateral CCA occlusion during MCA occlusion resulted in an increase in
hemispheric lesion volume (30 min contralateral, 58.3 ± 8.9%, n = 6; 60 min
contralateral, 71.7 ± 8.6%, n = 9; one-way ANOVA: 0 vs 60 min p < 0.001, 30 vs 60
min p < 0.05, Figure 3.4A). The increase in infarct size was associated with a reduction
in within-protocol variability (no contralateral, CV = 24.5%; 30 min contralateral
occlusion, CV = 15.2%; 60 min contralateral occlusion, CV = 12.0%).
Similar conclusions were drawn when data were analysed by single slice; lesion size
increased after contralateral occlusion (no contralateral, 63.5 ± 8.2%, n = 5; 30 min
contralateral, 73.0 ± 7.5%, n = 6; 60 min contralateral, 85.0 ± 4.8%, n = 9; one-way
ANOVA: 0 vs 60 min p < 0.001, 30 vs 60 min p < 0.05; Figure 3.4B) and variability
was reduced (no contralateral occlusion, CV = 12.9%; 30 min contralateral occlusion,
CV = 10.3%; 60 min contralateral occlusion, CV = 5.7%).
In the group that received 60 minutes of contralateral CCA occlusion, 4 out of 9 (44%)
showed evidence of a mild subcortical contralateral infarction, with none observed in
the two remaining groups. Contralateral infarctions might confound the oedema
correction in the lesion size calculation, so the majority of the intervention studies used
30 minutes of contralateral occlusion, at the expense of a greater within-protocol
variability, but without confounding contralateral infarctions. A power calculation
showed that 5 rats were needed to detect a 30% reduction in lesion size, and hence all
intervention protocols had no fewer than 5 rats.
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Figure 3.4 Effect of contralateral common carotid artery occlusion on lesion size. Increasing the
duration of contralateral CCA occlusion in the rat stroke model resulted in an increase in lesion
volume and a decrease in variability (A). These observations were consistent when the single slice
analysis approach was used (B). Each point represents one animal, lines are group means.
Triangles, 0 minutes of contralateral occlusion (n = 5); squares, 30 minutes of contralateral
occlusion (n = 6); diamonds, 60 minutes of contralateral occlusion (n = 9); ** , p < 0.01; * , p <
0.05.
3.3.2. Extending the duration of recovery has no effect on infarct size, but
increases between-animal variability
Further characterisation included extending the duration of reperfusion from 24 to 72
hours. This had no effect on hemispheric lesion volume (24 hours, 58.3 ± 8.9%, n = 6;
72 hours, 56.9 ± 15.1%, n = 7; unpaired t test, p = 0.83; Figure 3.5A). There was,
however, an increase in variability (24 hours, CV = 15.2%; 72 hours, CV = 26.6%). The
single slice analysis gave a similar result for both lesion size (24 hours, 73.0 ± 7.5%, n =
6; 72 hours, 72.3 ± 9.2%, n = 7; unpaired t test, p = 0.89; Figure 3.5B), and variability
(24 hours, CV = 10.3%; 72 hours, CV = 12.8%).
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Results show that the stroke model with 30 minutes of contralateral CCA occlusion and
24 hours of recovery has a low between-animal variability, irrespective of whether the
whole brain or the single slice analysis method is used. Subsequent protocols used only
the hemispheric lesion volume analysis method.
Figure 3.5 Effect of increasing the duration of recovery on lesion size. Increasing the duration of
reperfusion had no effect on hemispheric lesion volume, but increased the variability (A). This
observation was matched when the single slice analysis approach was used (B). Each point
represents one animal, lines are group mean. White squares, 24 hours recovery (n = 6); black
squares, 72 hours recovery (n = 7).
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3.3.3. MK-801 reduces rat cerebral ischaemia-reperfusion injury
MK-801 conferred neuroprotection against cerebral infarction resulting in a
significantly reduced hemispheric lesion volume when compared to control (control
58.3 ± 8.9%, n = 6; MK-801 48.0 ± 6.6%, n = 6; unpaired t test, p < 0.05; Figure 3.6).
Figure 3.6 Effect of MK-801 on lesion size. MK801 was administered as a 3 mg/kg i.p. dose 15
minutes prior to filament insertion, and this significantly reduced the infarct size of the whole
hemisphere. Each point represents one animal, lines are group mean. Squares, control with 30
minutes contralateral occlusion (n = 6); circles, MK801 with 30 minutes contralateral occlusion (n =
6). * , p < 0.05.
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3.3.4. Remote ischaemic preconditioning using four 5-minute cycles does
not protect against rat cerebral ischaemia-reperfusion injury
RIPC was initially studied using protocols consisting of 4 cycles of 5 minutes lower
limb occlusion and 5 minutes of reperfusion. There was no difference between control
and RIPC with 30 minutes (control, 58.3 ± 8.9%, n = 6; RIPC, 66.3 ± 12.1% n = 7;
unpaired t test, p = 0.21; Figure 3.7) or 60 minutes of contralateral occlusion (control,
71.7 ± 8.6%, n = 9; RIPC, 76.1 ± 6.1%, n = 7; unpaired t test, p = 0.27; Figure 3.7).
Figure 3.7 Effect of 4 cycles remote ischaemic preconditioning of 5 minutes on lesion size. RIPC had
no effect on hemispheric infarct volume with either 30 or 60 minutes of contralateral CCA
occlusion. Each point represents one animal, lines are group mean. White squares, control with 30
minutes contralateral occlusion (n = 6); black squares, RIPC with 30 minutes contralateral
occlusion (n = 7); white diamonds, control with 60 minutes contralateral occlusion (n = 9); black
diamonds, RIPC with 60 minutes contralateral occlusion (n = 7).
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3.3.5. Remote ischaemic preconditioning protects against cerebral IR
injury with inhaled, but not injectable anaesthesia
A final set of protocols examined whether a stronger stimulus of RIPC was required to
induce protection against cerebral infarction, and whether the type of anaesthesia
influenced the protective effect. Three RIPC cycles of an increased duration of 15
minutes occlusion, followed by 15 minutes of reperfusion, caused a non-significant
reduction in infarct size when compared to the sham control (sham, 47.2 ± 6.0%, n = 5;
RIPC, 41.8 ± 13.3%, n = 7; unpaired t test, p = 0.42; Figure 3.8). When repeated using
inhaled anaesthesia, there was significant protection by RIPC to reduce stroke volume
(sham, 38.3 ± 9.3%, n = 6; RIPC, 18.3 ± 5.3%, n = 6; unpaired t test, p = 0.001; Figure
3.8).
Figure 3.8 Effect of injected and inhaled anaesthesia on remote ischaemic preconditioning-induced
neuroprotection. Increasing RIPC to 3 cycles of 15 minutes ischaemia and 15 minutes of
reperfusion caused a non-significant reduction in infarct volume. Significant protection was
observed when the anaesthetic was switched from injected to inhaled anaesthesia. RIPC studies
were compared with time matched controls, and data analysed in a blinded fashion. Each point
represents one animal, lines are group mean. White diamonds, sham control with injectable
anaesthetic (n = 5); black diamonds, RIPC with injectable anaesthetic (n = 7); white squares, sham
control with inhaled anaesthesia (n = 6); black squares, RIPC with inhaled anaesthesia (n = 6). ** ,
p < 0.01.
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3.4. Discussion
The initial characterisation experiments presented in this chapter showed that the
between-animal variability within the transient MCA occlusion model can be reduced
using a contralateral CCA occlusion. Intervention studies initially supported previous
observations that MK-801, a non-competitive antagonist of NMDA, reduces infarct
volume, and thereby acted as a positive control for the model. Investigations of RIPC
observed that it reduced infract size, but only to a significant extent when using inhaled,
rather than injected anaesthesia.
3.4.1. Contralateral occlusion reduces variability in the middle cerebral
artery occlusion model
To achieve a repeatable stroke model several factors were controlled in the
methodology that might otherwise have increased variability (see section 2.1.2). These
included the strain of the animal, age, sex and weight. Technical factors included the
anesthetic regime, animal temperature during surgery and the size of the filament.
However several factors were difficult to account for, such as the between-animal
variability in collateral flow, which may differ considerably even within animal strain
(211).
One way to reduce the effects of collateral flow was to reduce the flow throughout the
cerebral circulation during MCA occlusion. This was achieved by occluding the
contralateral CCA, whilst the patent vertebral arteries ensured the some cerebral blood
flow was maintained. This resulted in a small increase in lesion size, and a decrease in
the between-animal variability. However 60 minutes of contralateral CCA occlusion
reduced cerebral flow to the extent that a small contralateral subcortical infarct
developed in some animals. The presence of a contralateral infarct will induce
contralateral oedema, and might confound the correction employed for ipsilateral
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oedema. Therefore 30 minutes of contralateral CCA occlusion was chosen as the control
for subsequent protocols.
Extending the duration of reperfusion had no effect on the mean infarct volume, but was
associated with an increase in variability. Cell death in the infarcted territory is believed
to occur during the arterial occlusion and initial 24 hours following reperfusion, and
thus 24 hours of recovery were suitable for this study, matching protocols in the
published literature (212,213).
3.4.2. Injectable anaesthesia inhibits the protective effect of remote
ischaemic preconditioning
In the initial experiments using 4 cycles of 5 minutes RIPC did not reduce cerebral
infarction, whereas the NMDA-receptor antagonist MK-801 showed significant
protection. This was surprising, given that 3 or 4 cycles of 5 minutes occlusion and
reperfusion is the gold standard RIPC protocol most commonly used in animal and
human IR injury studies (5). The RIPC protocol was modified to match that performed
in a recent rat stoke study; Ren et al. showed that 15 minute cycles of ischaemia and
reperfusion were sufficient to induce a substantial protective effect (210). Using this
protocol, there was a trend towards a reduced infarct size, but this was not significant.
One major experimental difference between my protocol and that by Ren et al., was the
use of isoflurane to achieve anaesthesia, compared to the regime used in the present
studies (a mixture of midazolam, fentanyl and fluanisone). When RIPC was induced
using three 15-minute cycles, in the presence of isoflurane-based anaesthesia, a
substantial protective effect of RIPC was identified. This suggests that the injected
anaesthetic mixture inhibited RIPC. Of the three agents, only the opiate fentanyl is
known to modulate preconditioning pathways, with most studies demonstrating that
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opiates induce ischaemic protection (214). Further work is required to investigate the
inhibitory action of these agents.
3.4.3. Remote ischaemic preconditioning as a treatment for human stroke
Since the start of this project several papers have been published, reporting the
protective effects of RIPC using MCA models (212,213,215). Hahn et al. showed that
RIPC reduces infarct size in a transient model of cerebral IR injury using a 4 cycles of 5
minutes occlusion protocol (212). Others have shown that RIPC may be abolished by
inhibiting the adenosine A1 receptor (213), and by sensory nerve inhibition (215). All of
these studies used an inhaled anaesthetic, further supporting the hypothesis that the lack
of protective effect observed in my initial protocols was due to inhibition by the injected
anaesthetic regime.
The onset of human stroke is unpredictable, and thus preconditioning is not plausible in
this setting. However, future studies might aim to investigate whether intermittent cuff
inflation applied during (RIPerC), or immediately following (RIPostC), a cerebral
vessel occlusion, can afford protection. Whilst it has been suggested that both RIPerC
(212), and RIPostC induce effective experimental neuroprotection (216), the
mechanistic pathways are less well documented than RIPC. If RIPerC and RIPostC
demonstrate sufficient efficacy and safety profile, it justifies a clinical trial. Indeed,
Hougaard et al. have recently reported the study design for a phase III trial to validate
the benefit of RIPerC in thrombolysed stroke patients, whereby intermittent limb
ischaemia is started in the ambulance prior to hospital admission (217), using a similar
study design to another trial that demonstrated efficacy of RIPerC in myocardial
infarction (218).
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3.5. Conclusion
My results describe the characterisation of an in vivo rat model of transient MCA
occlusion, and identified an optimal schedule of vascular occlusion and reperfusion to
generate the most consistent data. There are neuroprotective effects of RIPC, though
stronger stimuli may be needed than appear effective in other organs. The effect of
RIPC is masked by certain anaesthetic schedules. Further work aims to investigate the
efficacy of RIPC in humans using an in vivo IR injury model.
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4. CHARACTERISING A HUMAN IN VIVO
VASCULAR MODEL OF ISCHAEMIA-
REPERFUSION INJURY
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4.1. Introduction
Flow mediated dilatation (FMD) has been used for nearly 20 years as a measure of
endothelial function in humans in vivo. It is believed to be primarily nitric oxide
mediated, and patients with endothelial dysfunction exhibit a reduced FMD.
Importantly FMD exhibits a low within-subject variability when assessed by trained
ultrasonographers, which has been documented by several research groups
(154,161,219). Our research group has pioneered a human in vivo model of endothelial
ischaemia-reperfusion (IR) injury over the past 10 years, using FMD as a marker of
endothelial function. This model has been used to investigate therapeutic interventions
for safety and efficacy against IR injury (15), prior to clinical trials in patients (118).
Despite the years of research, some uncertainty still exists regarding the physiological
mechanisms regulating vascular diameter during basal, low, and high flow states. Most
recently interest has developed in the arterial constriction that occurs during cuff
occlusion, with Gori et al. demonstrating that this constriction (low-flow mediated
constriction, L-FMC) is repeatable, is reduced in patients with atherosclerosis, and is
correlated with FMD (154), consistent with it being a flow mediated phenomenon
similar to FMD.
Our group has previously shown that upper limb IR injury induced by 20 minutes of
proximal cuff inflation followed by reperfusion and subsequent recovery, reduces
brachial artery FMD by 44–65% with no effect on baseline arterial diameter, blood
pressure and heart rate, baseline arterial flow, or the hyperaemic flow stimulus
(79,110,111). The IR-induced FMD reduction in the radial artery appears more
profound, ranging from 55-87%, despite shorter durations of ischaemia and reperfusion
(15,113,114,220).
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The aim of this chapter was to explore the effect of IR injury on L-FMC, to validate L-
FMC as a flow-dependent phenomenon. Here I report a characterisation of a human IR
injury model in the brachial and the radial arteries. Initially within-subject variability
was quantified for a number of vascular parameters including FMD and L-FMC.
Secondly, the relationships between diameter and flow were investigated, during both
low flow and transient high flow. Finally the response of these factors to IR injury is
reported.
4.2. Methods
One hundred and sixty-seven studies were performed on 54 healthy male subjects aged
24 ± 6 (mean ± SD).
4.2.1. Subject preparation
Subjects were recruited and prepared for the study as outlined in section 2.2.2. All study
participants were healthy males (aged 18-45 years).
4.2.2. Experimental set up
The FMD technique and IR experiments were set up according to section 2.2.2.
Acquired images were analysed according to section 2.2.3.
4.2.3. Experimental protocols
4.2.3.1. Variability of the endothelial function test
To assess the within-subject variability of the ultrasound technique, subjects underwent
imaging on two occasions of the brachial artery (n = 13) and the radial artery (n = 9). To
assess between-analyser variability subjects were scanned by myself and an experienced
sonographer (n = 6). Ultrasound images were analysed for baseline diameter, FMD, L-
FMC, baseline velocity time integral (VTI), high flow VTI, and low flow VTI. At least
24 hours elapsed between scans on the same subjects.
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4.2.3.2. Relationship between diameter and flow
To analyse the relationships between vessel diameter and flow, single ultrasound scans
were performed on subjects in the brachial (n = 48) and radial (n = 24) artery. All scans
were analysed for baseline diameter, FMD, L-FMC, baseline VTI, high flow VTI and
low flow VTI.
4.2.3.3. Effect of limb ischaemia-reperfusion injury on endothelial
function
The effect of IR on endothelial function was assessed using the protocols described in
Figure 4.1. Brachial artery protocols were initially based upon previous results by our
group which used 20 minutes of ischaemia, followed by reperfusion and 20 minutes of
recovery (n = 20) (79,110–112). Results observed in section 4.3.3.1 led to additional
brachial artery studies with the duration of post-reperfusion recovery extended by 5
minutes (n = 21). Radial artery protocols were carried out with 15 minutes of ischaemia
and recovery, consistent with studies in the published literature, which have reported
that this significantly reduces FMD (113,114).
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Figure 4.1 Experimental protocols for characterising a human vascular ischaemia-reperfusion
injury model. Brachial artery studies were initially based upon 20 minutes ischaemia and 20
minutes of reperfusion (A) before being extended to 25 minutes of reperfusion (B). Radial artery
studies consisted of durations of 15 minutes ischaemia and 15 minutes reperfusion (C). FMD-B,
brachial artery flow mediated dilatation; FMD-R, radial artery flow mediated dilatation; I,
ischaemia; R, recovery following reperfusion.
4.2.4. Calculations and statistics
FMD and L-FMC are expressed as absolute delta change (mm) or as a percentage of
baseline (%). VTI at baseline, low-flow and high-flow are expressed as absolute values
(m) or as absolute delta change (m) (see 2.2.4). FMD and L-FMC were corrected for
baseline diameter, and VTI was corrected for heart rate. Results were excluded if there
was a difference in baseline diameter of greater than 0.2 mm between scans performed
before and after IR injury. Variability results are presented using the coefficient of
variation (CV) and the intraclass correlation coefficient (ICC). Results are displayed
using Bland-Altman plots, which include the mean difference, the standard deviation of
the differences, and the 95% limits of agreement. Sample sizes were calculated using
statistical software (see 3.2.4). Relationships between diameter changes and flow are
presented using scatter plots including a linear regression with Pearson’s r and a
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correlation to assess whether the slope differs from 0. Pre and post-IR data were
analysed for baseline diameter, FMD, L-FMC and VTI. Results are given as mean ±
SD, and within group results were compared using paired t tests, given that baseline
values fulfill normality criteria. p < 0.05 was deemed statistically significant.
4.3. Results
Consistent with experimental protocols, results are described firstly for testing
variability, secondly to investigate relationships between variables, and finally to
investigate the effect of IR injury on the responses to low and high flow stimuli. All
studies were carried out with no adverse events.
4.3.1. Variability of endothelial function testing
The variability of changes in diameter and flow was assessed in the brachial and the
radial arteries, and are described below.
4.3.1.1. Within-subject variability
In the brachial artery L-FMC (CV = 80.3%) was considerably more variable than FMD
(CV = 12.1%) with no evidence of systematic bias in any outcome measure (Figure
4.2). This is primarily due to L-FMC having a lower mean value compared to FMD
with a similar within subject SD (FMD, 8.50 ± 1.03%; L-FMC 1.74 ± 1.40%).
Compared to the brachial artery, the radial artery had a higher CV for FMD (brachial,
12.1%; radial, 22.8%), but a lower ICC (brachial, 0.76; radial, 0.84) (Figure 4.3). For L-
FMC the radial artery had a lower CV (brachial, 80.3%; radial, 28.9%), and a lower
ICC (brachial, 0.66; radial, 0.71). VTI variability was similar in both arteries.
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BL diameter
(mm)
FMD
(%)
L-FMC
(%)
BL VTI
(m)
LF VTI
(m)
HF VTI
(m)
Mean 3.64 8.50 1.74 0.062 0.017 0.306
between subject SD 0.34 1.81 1.96 0.022 0.006 0.044
within subject SD 0.08 1.03 1.40 0.008 0.002 0.016
Mean CV (%) 2.1 12.1 80.3 12.7 12.8 5.20
ICC 0.95 0.76 0.66 0.88 0.88 0.88
mean difference 0.03 -0.97 0.41 -0.002 -0.001 -0.020
difference SD 0.13 1.47 2.46 0.022 0.005 0.037
n 13 13 13 13 13 13
Figure 4.2 Within-subject variability of brachial artery outcome variables. Brachial artery flow
mediated dilatation (FMD) scans were performed on 13 subjects on two occasions. Table
summarises statistical results. Bland-Altman plots are shown for baseline diameter (A), FMD (B),
low-flow mediated constriction (L-FMC) (C), baseline velocity time integral (VTI) (D), high flow
VTI (E) and low flow VTI (F). Dotted lines represent 95% limits of agreement. Each point
represents one subject.
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BL diameter
(mm)
FMD
(%)
L-FMC
(%)
BL VTI
(m)
LF VTI
(m)
HF VTI
(m)
Mean 2.12 8.37 6.55 0.076 0.011 0.290
between subject SD 0.22 4.40 2.97 0.051 0.003 0.075
within subject SD 0.10 1.90 1.89 0.009 0.002 0.023
Mean CV (%) 4.6 22.8 28.9 12.1 15.5 7.8
ICC 0.83 0.84 0.71 0.97 0.80 0.92
mean difference -0.02 0.87 -1.28 0.007 0.000 -0.040
difference SD 0.18 3.18 3.50 0.027 0.004 0.052
n 9 9 9 8 8 8
Figure 4.3 Within-subject variability of radial artery outcome variables. Radial artery flow
mediated dilatation (FMD) scans were performed on 9 subjects on two occasions. Table summarises
statistical results. Bland-Altman plots are shown for baseline diameter (A), FMD (B), low-flow
mediated constriction (L-FMC) (C), baseline velocity-time integral (VTI) (D), high flow VTI (E)
and low flow VTI (F). Dotted lines represent 95% limits of agreement. Each point represents one
subject.
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4.3.1.2. Between-sonographer variability
There was some evidence of systematic bias for L-FMC, but not diameter of FMD for
between-sonographer studies (Figure 4.4). Brachial artery between-sonographer
variability was similar to within-sonographer variability for baseline diameter (BL
diameter, 1.8 vs 2.1; FMD, 18.1 vs 12.1; L-FMC, 52.9 vs 80.3).
BL diameter
(mm)
FMD
(%)
L-FMC
(%)
Mean 3.57 7.81 2.41
between subject SD 0.36 1.80 2.06
within subject SD 0.06 1.42 1.27
Mean CV (%) 1.8 18.1 52.9
ICC 0.97 0.62 0.72
mean difference 0.05 0.19 -1.80
difference SD 0.09 2.69 2.65
n 6 6 6
Figure 4.4 Between-sonographer variability of brachial artery flow mediated dilatation outcome
variables. Brachial artery flow mediated dilatation scans were performed on 6 subjects on two
occasions by two investigators. Table summarises statistical results. Bland-Altman plots are shown
for baseline diameter (A), flow mediated dilatation (FMD) (B) and low-flow mediated constriction
(L-FMC) (C). Dotted lines represent 95% limits of agreement. Each point represents one subject.
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4.3.2. Relationships between changes in diameter and flow
4.3.2.1. Flow mediated dilatation and low-flow mediated constriction
are correlated with baseline diameter.
The relationships between resting baseline diameter, FMD and L-FMC are shown in
Figure 4.5. FMD had a negative correlation with baseline diameter in both the brachial
and radial arteries (brachial, r = -0.391, p = 0.006, n = 48; radial, r = -0.408, p = 0.048,
n = 24; linear regression). L-FMC was positively correlated with baseline diameter in
the brachial and radial arteries (brachial, r = 0.260, p = 0.075, n = 48; radial, r = 0.603,
p = 0.002, n = 24; linear regression). There was a trend of negative correlation between
L-FMC and FMD in both arteries, but this did not reach statistical significance
(brachial, r = -0.092, p = 0.534, n = 48; radial, r = -0.376, p = 0.070, n = 24; linear
regression).
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Figure 4.5 Relationships between flow mediated dilatation, low-flow mediated constriction and
baseline diameter. Resting ultrasound recordings were made on healthy male subjects in the
brachial (n = 48) and radial (n = 24) artery. Calculations were made of flow mediated dilatation
(FMD), low-flow mediated constriction (L-FMC), and baseline diameter. FMD was negatively
correlated with baseline diameter in both arteries. L-FMC was positively correlated with baseline
diameter in both arteries, though this did not reach statistical significance in the brachial artery.
FMD and L-FMC tended towards a negative correlation in both arteries, but this did not reach
statistical significance in either artery. Each point represents one subject. Lines show linear
regression.
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4.3.2.2. Diameter changes are weakly associated with flow
The relationship between FMD and the change in VTI during the transient high flow
(ΔVTI high-flow), and L-FMC and the change in VTI during the low flow (ΔVTI low-flow),
are shown in Figure 4.6. FMD had a weak positive correlation with ΔVTI high-flow in both
arteries (brachial, r = 0.155, p = 0.293, n = 48; radial, r = 0.285, p = 0.177, n = 24;
linear regression). L-FMC was positively correlated with ΔVTI low-flow in both arteries
(brachial, r = 0.309, p = 0.033, n = 48; radial, r = 0.466, p = 0.022, n = 24; linear
regression).
Figure 4.6 Relationship between arterial diameter and velocity time integral. Resting ultrasound
recordings were made on healthy male subjects in the brachial (n = 48) and radial (n = 24) artery.
Calculations were made of flow mediated dilatation (FMD), low-flow mediated constriction (L-
FMC), and the change in velocity-time integral (ΔVTI). ΔVTIhigh-flow and FMD were weakly
correlated in both arteries, but this did not reach statistical significance in either artery. ΔVTIlow-flow
was correlated with L-FMC in both arteries. Each point represents one subject. Lines show linear
regression.
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4.3.3. Effect of ischaemia-reperfusion injury on endothelial function
Results are summarised in table Table 4.1 and described below.
4.3.3.1. Twenty minutes of recovery is insufficient duration for arterial
diameter to return to baseline
Following 20 minutes of recovery following reperfusion, resting arterial diameter
remained dilated when compared to baseline (BL, 3.62 ± 0.32; post IR 3.69 ± 0.38; p =
0.001, paired t test; n = 20; Figure 4.7A). By extending the duration of recovery to 25
minutes, the vessel was no longer significantly dilated (BL, 3.60 ± 0.37; post IR 3.63 ±
0.36; p = 0.105, paired t test; n = 21; Figure 4.7B). After 15 minutes of recovery in the
radial artery, the vessel was dilated, but did not reach statistical significance (BL, 2.34 ±
0.15; post IR, 2.38 ± 0.17; p = 0.083, paired t test; n = 10; Figure 4.7C).
Figure 4.7 Effect of ischaemia-reperfusion injury on baseline diameter. Flow mediated dilatation
recordings were made on healthy male subjects. This was followed by IR, and a second recording.
Brachial artery baseline diameter was significantly increased 20 minutes following reperfusion (n =
20, A). Brachial artery baseline diameter was increased at 25 minutes of reperfusion, but this was
not significant (n = 21, B). Radial artery baseline diameter was increased at 15 minutes
reperfusion, but this was not significant (n = 10, C). Bars show mean ± standard error. ** , p < 0.01
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4.3.3.2. Ischaemia-reperfusion injury reduces flow mediated dilatation
and increases low-flow mediated constriction
FMD and L-FMC values were corrected for differences in baseline diameter, using
baseline correlations (Figure 4.5). IR reduced brachial artery FMD at 20 minutes (BL,
7.64 ± 2.06%; post IR, 5.09 ± 1.90%; p < 0.0001, n = 20) and 25 minutes of reperfusion
(BL, 8.05 ± 2.49%; post IR 6.53 ± 3.08%, p = 0.004, n = 21), and in the radial artery
(BL, 9.36 ± 2.91%; post IR, 5.96 ± 4.93%, p = 0.017, n = 10; paired t test) (Figure 4.8).
IR increased brachial artery L-FMC at 20 minutes (BL, 2.50 ± 2.54%; post IR 3.49 ±
2.10%, p = 0.025, n = 20) and at 25 minutes of reperfusion (BL, 1.85 ± 2.17%; post IR
2.80 ± 1.85%, p = 0.041, n = 21), and in the radial artery (BL, 5.46 ± 4.60%; post IR
8.71 ± 4.64%, p = 0.055, n = 10; paired t test) (Figure 4.8).
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Figure 4.8 Effect of ischaemia-reperfusion injury on flow mediated dilatation and low-flow
mediated constriction. FMD recordings were made on healthy male subjects. This was followed by
IR, and a second recording. IR caused a reduction in FMD in the brachial artery 20 minutes
following reperfusion (n = 20, A), 25 minutes following reperfusion (n = 21, B), and in the radial
artery at 15 minutes following reperfusion (n = 10, C). IR caused an increase in L-FMC in the
brachial artery 20 minutes following reperfusion (n = 20, D), 25 minutes following reperfusion (n =
21, E), and in the radial artery at 15 minutes following reperfusion (n = 10, F). Bars show mean ±
standard error. ***, p < 0.001; ** , p < 0.01; * , p < 0.05
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4.3.3.3. Ischaemia-reperfusion injury results in a complex alteration to
arterial flow
There was a slight decrease in heart rate (HR) during IR injury studies (see Table 4.1),
and hence velocity-time integral (VTI) was HR-adjusted according to baseline
correlations. IR resulted in a decrease in the baseline VTI, however this was only
significant in the brachial artery with 25 minutes of reperfusion (brachial 20 min, BL
0.071 ± 0.020 m, post IR 0.066 ± 0.029 m, p = 0.377, n = 20; brachial 25 min, BL 0.075
± 0.025 m, post IR 0.063 ± 0.018 m, p = 0.042, n = 21; radial 15 min, BL 0.090 ± 0.065
m, post IR 0.077 ± 0.047 m, p = 0.368, n = 10; paired t test; Figure 4.9A-C). IR resulted
in an increase in high flow VTI (brachial 20 min, BL 0.321 ± 0.046 m, post IR 0.361 ±
0.056 m, p < 0.001, n = 20; brachial 25 min, BL 0.300 ± 0.052 m, post IR 0.326 ± 0.052
m, p = 0.001, n = 21; radial 15 min, BL 0.299 ± 0.090 m, post IR 0.318 ± 0.092 m, p =
0.191, n = 10; paired t test; Figure 4.9D-F). IR had no effect on low flow VTI (brachial
20 min, BL 0.019 ± 0.006 m, post IR 0.020 ± 0.006 m, p = 0.566, n = 20; brachial 25
min, BL 0.025 ± 0.010 m, post IR 0.025 ± 0.010 m, p = 0.544, n = 21; radial 15 min, BL
0.013 ± 0.005 m, post IR 0.014 ± 0.004 m, p = 0.856, n = 10; paired t test; Figure 4.9G-
I).
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Figure 4.9 Effect of ischaemia-reperfusion injury on arterial flow. FMD recordings were made on
healthy male subjects. This was followed by IR, and a second recording. IR caused a small decrease
in baseline velocity time integral (VTI), which reached statistical significance in the brachial artery
with 25 minutes of reperfusion (n = 21, B) but not with 20 minutes of reperfusion (n = 20, A) or in
the radial artery with 15 minutes (n = 10, C). IR increased arterial high flow VTI, but this did not
reach significance in the radial artery (F). IR had no effect on low flow VTI in any artery. Bars
show mean ± standard error. ***, p < 0.001; ** , p < 0.01; * , p < 0.05
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Table 4.1 Summarised results of the effect of ischaemia-reperfusion injury on endothelial function
in humans.
Brachial IR(20) Brachial IR(25) Radial IR(15)
n = 20 n = 21 n = 10
BL post IR p BL post IR p BL post IR p
BL Diam
(mm) 3.62 ± 0.32 3.69 ± 0.38 0.001 3.60 ± 0.37 3.63 ± 0.36 0.105 2.34 ± 0.15 2.38 ± 0.17 0.083
FMD
(%) 7.64 ± 2.06 5.09 ± 1.90 <0.001 8.05 ± 2.49 6.53 ± 3.08 0.004 9.36 ± 2.91 5.96 ± 4.93 0.017
L-FMC
(%) 2.50 ± 2.54 3.49 ± 2.10 0.025 1.85 ± 2.17 2.80 ± 1.85 0.041 5.46 ± 4.60 8.71 ± 4.64 0.055
SBP
(mmHg) 115 ± 8 114 ± 8 0.416 114 ± 7 116 ± 9 0.115 114 ± 8 112 ± 9 0.285
DBP
(mmHg) 62 ± 6 61 ± 5 0.658 60 ± 5 63 ± 7 0.009 58 ± 5 60 ± 6 0.052
HR
(bpm) 62 ± 11 57 ± 9 0.019 64 ± 9 59 ± 7 0.033 59 ± 7 57 ± 6 0.141
baseline
VTI (m) 0.071 ± 0.020 0.066 ± 0.029 0.377 0.075 ± 0.025 0.063 ± 0.018 0.042 0.090 ± 0.065 0.077 ± 0.047 0.368
high flow
VTI (m) 0.321 ± 0.046 0.361 ± 0.056 <0.001 0.300 ± 0.052 0.326 ± 0.052 0.001 0.299 ± 0.090 0.318 ± 0.092 0.191
low flow
VTI (m) 0.019 ± 0.006 0.020 ± 0.006 0.566 0.025 ± 0.010 0.025 ± 0.010 0.544 0.013 ± 0.005 0.014 ± 0.004 0.856
4.4. Discussion
The results in this chapter have characterised the FMD and L-FMC phenomena, their
relationship to resting arterial diameter and VTI, and their response to IR injury. The
within-subject variability and agreement for repeated tests for this technique has been
reported by several groups (154,161,221,222). In the current study brachial artery
coefficient of variation (FMD, 12.1%; BL diameter, 2.1%) was comparable to that of
Donald et al. (FMD, 10.6%; BL diameter, 2.6%) (161), and Hijmering et al., (FMD,
13.9%) (222). In the radial artery intraclass correlation coefficient (FMD 0.84; L-FMC
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0.71) was similar to that of Gori et al. (FMD 0.68; L-FMC 0.80) (154). This reassures
that the current ultrasound technique is comparable with the published literature.
Furthermore, given that analysis itself (see 2.2.3.3) is attributable to some of this
variability (FMD 3.4%; BL diameter 0.2%), this shows that my ultrasound methodology
provides a repeatable measure of FMD and L-FMC. The between-sonographer
variability was similar to a single analyser, verifying this technique with previous
experienced sonographers in our research group.
4.4.1. Assessment of endothelial function by flow mediated dilatation and
low-flow mediated constriction
Using the ultrasound technique, baseline studies were performed on subjects at the
brachial and radial artery. Results show similar relationships between FMD, L-FMC
and resting arterial diameter for both arteries. The brachial artery has a smaller mean L-
FMC than the radial artery, for reasons which remain uncertain.
Since its initial description FMD is known to be dependent on baseline diameter (150),
however it has been unknown whether this is also the case for L-FMC. Results in this
chapter identified a positive correlation between baseline diameter and L-FMC in both
arteries. In contradiction, two previous papers reported that no relationship exists
between brachial artery L-FMC and baseline diameter (166,223). Their findings may be
due to a weak correlation in the brachial artery, attributable to a low mean L-FMC, and
subsequently a higher within-subject variability (current study, CV = 80.3%). Lower
variability in the radial artery (current study, CV = 28.9%), allows the relationship
between L-FMC and baseline diameter to be more apparent. Results in this chapter also
show a weak negative correlation between FMD and L-FMC in both arteries. In the
literature to date, this relationship has been uncertain, with studies reporting a negative
(168), positive (224), and no correlation (223). My data contribute to this uncertainty,
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and additional studies of greater sample sizes are required to finalise associations
between these variables.
There was a stronger relationship between blood flow (using VTI as a proxy) and L-
FMC that there was between VTI and FMD. One explanation for this is that blood flow
is in a steady state during L-FMC, whereas the flow stimulus changes rapidly during
reactive hyperaemia.
4.4.2. Ischaemia-reperfusion injury reduces dilator endothelial function
Prolonged upper limb cuff inflation inducing ischaemia, followed by reperfusion has
been used as a model to induce a transient endothelial dysfunction in our research group
for over 10 years. Kharbanda et al. were the first to show that 20 minutes of ischaemia
resulted in a reduction in radial artery FMD at 15 minutes following reperfusion, but
that the vessel had recovered by 60 minutes (15). The reduction in FMD was
independent of changes in baseline diameter or flow. More recent brachial studies have
an extended duration of reperfusion of 20 minutes (110–112).
In the current study subjects received durations of IR that was identical to previous
studies; 20 minutes of ischaemia followed by 20 minutes of recovery. However in my
studies 20 minutes of reperfusion were insufficient to allow the brachial artery to return
to baseline following the post-ischaemic vasodilatation (BL, 3.62 mm; post IR, 3.69
mm). An additional protocol extended reperfusion to 25 minutes, such that vessels were
no longer significantly dilated at the start of the second recording (BL, 3.60 mm; post
IR, 3.63 mm). In addition, a protocol was carried out in the radial artery using 15
minutes of ischaemia and 15 minutes of reperfusion, based upon studies of other groups
(113,114,220).
Results in this chapter showed that IR reduces FMD, and increases L-FMC. IR is
known to reduce endothelium-dependent vasodilatation in response to acetyl choline in
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animals and humans (40,41). Furthermore, IR reduces bioavailability of vasodilators
such as NO, and increases vasoconstrictors such as endothelin-1 and pro-inflammatory
mediators (16). The mechanism of IR-induced endothelial dysfunction may include an
increase in reactive oxygen species and a reduced bioavailability of NO. Were L-FMC
merely the flip-side of FMD, then one would expect that it too would diminish after IR
injury. That it increased suggests that it has a different mechanism from FMD, and this
could include a role for local accumulation of vasoconstrictors including endothelin-1
(167) and thromboxane (154).
4.5. Conclusion
This chapter used an in vivo vascular function test to describe the variability
characteristics, correlations and response to IR injury, for FMD, L-FMC, resting
diameter and VTI. Correlations exist between FMD, L-FMC and baseline diameter in
both the radial and brachial artery. Given the negative correlation between FMD and L-
FMC, and that IR injury reduces FMD but increases L-FMC, it is suggested that the two
are mechanistically different. Using this model I plan to investigate ischaemic
preconditioning as a protective phenomenon against in vivo IR injury in humans.
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5. THE EFFECT OF ISCHAEMIC AND EXERCISE
PRECONDITIONING ON ISCHAEMIA-
REPERFUSION INJURY IN HUMANS
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5.1. Introduction
Arterial occlusion results in tissue ischaemia, cellular hypoxia, and an accumulation of
waste metabolites, contributing to irreversible injury secondary to necrotic cell death.
Reperfusion, whilst necessary for recovery, contributes to injury. Preventing ischaemia-
reperfusion (IR) injury has been the focus of extensive research, but few therapies have
successfully developed from “bench to bedside”. Human in vivo models can act as a
bridge between animal studies and clinical trials in patients; a convenient proxy to
facilitate the identification of novel interventions that are safe and have a therapeutic
potential in humans.
In chapter 4 a human in vivo model of endothelial IR injury was characterised. IR
induced endothelial dysfunction, defined as a decrease in flow mediated dilatation
(FMD). This was consistent with previous observations by our group and others
(15,113), and complemented animal studies investigating the effect of IR on endothelial
biology (39). IR also resulted in an increase in low-flow mediated constriction (L-
FMC), a phenomenon only recently described, but may offer additional information of
the behaviour of the arterial endothelium.
In chapter 3 a rat stroke model was described, which demonstrated that remote
ischaemic preconditioning (RIPC) protects the brain from a subsequent IR injury.
Previous studies by our group have observed that non-lethal, intermittent bouts of local
(IPC) or remote (RIPC) ischaemic preconditioning applied prior to a prolonged limb IR
protect against a reduction in FMD (15,41,79,111). IPC and RIPC have also afforded
protection against IR in early phase clinical trials (see section 1.3). However, to date no
studies have investigated the effect of IPC and RIPC on L-FMC following IR injury. I
have speculated that, like FMD, L-FMC is an endothelium dependent phenomenon, and
hypothesise that IPC and RIPC prevent the IR-induced increase in L-FMC.
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Animal experiments suggest that exercise too might confer protection against IR injury
(exercise preconditioning, ExPC) (section 1.3.3). Brief, intense exercise reduces
experimental cerebral infarct size (108), and stimulate cellular pathways that are
comparable to components of the IPC mechanism (100,101). This has not been
demonstrated in a human IR injury model to date.
This chapter initially investigates the effect of RIPC on brachial artery IR injury.
Secondly it describes IPC as a therapeutic intervention against IR injury in both the
brachial and the radial artery. Finally ExPC is investigated as a novel therapeutic
intervention against IR injury.
5.2. Methods
Fifty-nine studies were performed on 20 subjects aged 22 ± 3 years (mean ± SD).
5.2.1. Subject preparation
Subjects were recruited and prepared for study as outlined in section 2.2.2. All study
participants were healthy males (aged 18-45 years).
5.2.2. Experimental set up
FMD and IR injury experiments were set up according to section 2.2.2. Acquired
images were analysed according to section 2.2.3.
5.2.3. Experimental protocols
Experimental protocols designed to identify the effects of RIPC, IPC and ExPC on IR
injury are detailed below.
5.2.3.1. Effect of remote ischaemic preconditioning on ischaemia-
reperfusion injury
Initially studies investigated RIPC using a standard protocol, identical to that described
in previous publications by our group (Figure 5.1) (79,111). After an initial brachial
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artery FMD measurement on the right arm, RIPC was induced by 3 cycles of 5 minutes
of left upper arm ischaemia and reperfusion. This was followed by 20 minutes of right
upper limb ischaemia, reperfusion, and 20 minutes of recovery (Figure 5.1A).
Results in section 4.3.3.1 observed that 20 minutes of recovery were insufficient to
allow the brachial artery to return to its resting baseline diameter following reperfusion.
Therefore studies were carried out using an identical RIPC protocol, but with an
extended recovery of 25 minutes (Figure 5.1B). Furthermore, to investigate whether an
increased “dose” of RIPC could induce a more robust protective effect, the RIPC
protocol was extended to 4 cycles (Figure 5.1C).
Figure 5.1 Experimental protocols to investigate the effect of remote ischaemic preconditioning on
ischaemia-reperfusion injury. The initial protocol consisted of a brachial artery FMD recording on
the right arm, three RIPC cycles of 5 minutes ischaemia and 5 minutes reperfusion on the left arm,
20 minutes of right arm ischaemia, reperfusion, and recovery of 20 minutes, and a second FMD
recording (A). The second protocol was identical bar an extended recovery duration of 25 minutes
(B). The third protocol was identical to B, with an additional cycle of RIPC (C). FMD-B , brachial
artery FMD recording; I , ischaemia; R , recovery.
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5.2.3.2. Effect of local ischaemic preconditioning on ischaemia-
reperfusion injury
Studies then investigated the effect of IPC on IR injury using a standard protocol
(Figure 5.2). After an initial brachial artery FMD recording, the right upper arm was
submitted to an IPC protocol identical to those of previous studies, with three cycles of
5 minutes ischaemia and 5 minutes of reperfusion (15). This was followed by 20
minutes of ischaemia, reperfusion, and 25 minutes of recovery, and a final recording
(Figure 5.2D).
Further studies investigated the effect on IPC on radial artery IR injury. Following a
radial FMD recording, the same IPC protocol was used as in the brachial artery. IR
injury consisted of 15 minutes of ischaemia, reperfusion, and 15 minutes of recovery,
before a final recording (Figure 5.2E).
Figure 5.2 Experimental protocols to investigate the effect of local ischaemic preconditioning on
ischaemia-reperfusion injury. All procedures took place on the right upper limb. The initial
protocol consisted of an FMD recording, followed by three IPC cycles of 5 minutes ischaemia and 5
minutes reperfusion, 20 minutes of limb ischaemia, recovery of 20 minutes, and a second recording
(D). The second protocol was in the radial artery, consisting of a recording, an identical IPC
protocol, followed by 15 minutes of ischaemia and 15 minutes of reperfusion, and a final recording
(E). FMD-B, brachial artery FMD; FMD-R, radial artery FMD; I , ischaemia; R , recovery.
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5.2.3.3. Effect of exercise preconditioning on ischaemia-reperfusion
injury
To determine whether acute exercise induced a preconditioning effect (ExPC) against
upper limb IR injury, subjects underwent exercise testing prior to IR injury (Figure 5.3).
After an initial brachial artery FMD recording, subjects were moved onto a stationary
cycle ergometer and performed an exhaustive incremental exercise test (see section
2.2.2.5). This was followed by 35 minutes of rest to allow for heart rate recovery, and
then by 20 minutes of ischaemia, 20 minutes of reperfusion, and a final recording
(Figure 5.3F).
Figure 5.3 Experimental protocols to investigate the effect of exercise preconditioning on ischaemia-
reperfusion injury. An FMD recording was followed by an incremental exercise test until physical
exhaustion. Subjects then rested in a supine position for 35 minutes, before 20 minutes of
ischaemia. After 20 minutes of reperfusion a final FMD was assessed.
5.2.4. Calculations and statistics
FMD, baseline diameter, and L-FMC were analysed from all recordings. Post IR values
were corrected for differences in baseline diameter. Within protocol data were analysed
using paired t tests. Comparisons were performed between preconditioning and control
studies, firstly by using analysis of covariance (ANCOVA) to adjust for baseline FMD,
providing a correlation existed between post IR values. Post IR values were matched
with IR control results from section 4.3.3, and compared using a paired t test. A
minimum sample size of 5-6 subjects was used based upon calculations from statistical
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software (Power and Sample Size Calculations, Dupont & Plummer, v3.0, (144)) using
an α of 0.05 and a power of 0.8. Within-subject SD for brachial artery FMD was from 
Figure 4.2, and complete prevention of the IR-induced reduction in FMD was assumed,
based upon previous results (79). Values are expressed as mean ± SD, and correlations
by Pearson r. p < 0.05 was deemed statistically significant.
5.3. Results
Protocols were tolerated well by all subjects, with no adverse events.
5.3.1. Remote ischaemic preconditioning has no effect on flow mediated
dilatation following ischaemia-reperfusion injury
Results are displayed in Figure 5.4 and Table 5.1. Three cycles of RIPC applied
immediately prior to IR did not preserve FMD at 20 minutes or 25 minutes of recovery.
Increasing the stimulus to four RIPC cycles did not preserve FMD. A significant
correlation existed between baseline FMD and post IR FMD for three cycles of RIPC at
20 minutes (r = 0.75, p < 0.001), 25 minutes of reperfusion (r = 0.81, p < 0.0001), and
for 4 cycles of RIPC (r = 0.87, p = 0.001). These correlations justified an adjustment to
post IR values using baseline FMD as the covariate. No difference existed between post
IR and post RIPC+IR for all protocols.
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Figure 5.4 Effect of remote ischaemic preconditioning on flow mediated dilatation following
ischaemia-reperfusion injury. Subjects underwent brachial artery FMD recording, followed by
cycles of RIPC, prolonged limb IR, and a final recording. Results were adjusted for baseline
diameter. RIPC did not prevent the IR-induced decrease in FMD, irrespective of whether the
duration of recovery from reperfusion was 20 minutes (n = 11), 25 minutes (n = 14), or whether the
RIPC stimulus was increased to 4 cycles (n = 5). Post IR and post RIPC+IR results were matched
and adjusted for baseline FMD. There were no significant difference in post IR values between IR
alone and RIPC+IR in all protocols. Groups were compared by paired t tests, and adjustments
were made according to linear regressions. Bars and error bars are mean and standard error.
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5.3.1. Remote ischaemic preconditioning has no effect on low-flow
mediated constriction following ischaemia-reperfusion injury
Results are displayed in Figure 5.5 and Table 5.1. RIPC applied immediately prior to IR
injury did not prevent the increase in L-FMC with 20 minutes of recovery. RIPC with
25 minutes of recovery prevented this increase; however this trend was not reproduced
when increasing the number of RIPC cycles. A significant correlation existed between
baseline L-FMC and post IR L-FMC for three cycles of RIPC at 20 minutes (r = 0.64, p
= 0.001), for 4 cycles of RIPC (r = 0.85, p = 0.001), and almost reached significance for
3 cycles at 25 minutes of reperfusion (r = 0.35, p = 0.065). These correlations justified
an adjustment to post IR values using baseline L-FMC as the covariate. No significant
difference existed between post IR and post RIPC+IR for all protocols. There was a
trend towards a difference for 3 cycles RIPC and 25 minutes reperfusion, but this
observation was not maintained when the stimulus was increased to 4 cycles.
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Figure 5.5 Effect of remote ischaemic preconditioning on low-flow mediated constriction following
ischaemia-reperfusion injury. Subjects underwent baseline brachial FMD recording, followed by
cycles of RIPC, prolonged limb IR, and a final recording. Results were adjusted for baseline
diameter. RIPC did not prevent the IR-induced increase in L-FMC when the duration of recovery
was 20 minutes (n = 11). When reperfusion was extended to 25 minutes, there was no increase in L-
FMC (n = 14), however these results were not replicated when the RIPC stimulus was increased
from 3 to 4 cycles (n = 5). Post IR and post RIPC+IR results were matched and adjusted for
baseline FMD. There were no significant differences in post IR values between IR alone and
RIPC+IR in all protocols. Groups were compared by paired t tests, and adjustments were made
according to linear regressions. Bars and error bars are mean and standard error.
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Table 5.1 Summarised results of the effect of remote ischaemic preconditioning on ischaemia-
reperfusion injury in humans.
3 cycles RIPC IR(20) 3 cycles RIPC IR(25) 4 cycles RIPC IR(25)
n = 11 n = 14 n = 5
BL postRIPC+IR p BL
post
RIPC+IR p BL
post
RIPC+IR p
BL Diam
(mm) 3.62 ± 0.36 3.70 ± 0.35 0.003 3.64 ± 0.33 3.69 ± 0.37 0.137 3.64 ± 0.26 3.67 ± 0.31 0.485
FMD
(%) 8.37 ± 2.37 6.20 ± 2.24 0.006 7.87 ± 3.07 6.76 ± 2.54 0.010 7.52 ± 1.54 5.42 ± 0.53 0.030
L-FMC
(%) 2.18 ± 1.42 3.71 ± 1.22 0.015 1.18 ± 1.71 1.19 ± 1.26 0.985 0.69 ± 1.15 1.82 ± 0.73 0.006
SBP
(mmHg) 108 ± 9 112 ± 11 0.073 116 ± 9 117 ± 9 0.199 118 ± 7 120 ± 5 0.554
DBP
(mmHg) 57 ± 4 61 ± 7 0.009 58 ± 6 62 ± 7 0.004 60 ± 2 63 ± 4 0.012
HR
(bpm) 61 ± 7 58 ± 8 0.161 56 ± 7 58 ± 7 0.276 58 ± 8 59 ± 8 0.683
5.3.2. Local ischaemic preconditioning protects against the ischaemia-
reperfusion induced reduction in flow mediated dilatation in the
brachial artery
Results are displayed in Figure 5.6 and Table 5.2. IPC applied immediately prior to IR
injury preserved FMD in the brachial artery but not in the radial artery. A significant
correlation existed between FMD at baseline and post IR values in the brachial (r =
0.75, p < 0.001) and in the radial (r = 0.80, p < 0.001). These correlations justified an
adjustment to post IR values using baseline FMD as the covariate. A significant
difference existed between IPC+IR and IR alone in the brachial but not in the radial
artery.
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Figure 5.6 Effect of local ischaemic preconditioning on flow mediated dilatation following
ischaemia-reperfusion injury. Subjects underwent baseline brachial or radial FMD recording. This
was followed by cycles of IPC, prolonged limb IR, and a final recording. Results were adjusted for
baseline diameter. IPC preserved FMD following IR injury in the brachial (n = 14), but not the
radial artery (n = 8). Post IR and post IPC+IR results were matched and adjusted for baseline
FMD. Brachial FMD following IPC+IR was significantly increased compared to IR alone. There
were no significant differences between radial FMD for IPC+IR and IR alone. Groups were
compared by paired t tests, and adjustments were made according to linear regressions. Bars and
error bars are mean and standard error.
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5.3.3. Local ischaemic preconditioning has no effect on low-flow mediated
constriction following ischaemia-reperfusion injury
Results are displayed in Figure 5.7 and Table 5.2. IPC applied immediately prior to IR
injury prevented a significant increase in L-FMC in both the brachial and radial artery.
A significant correlation existed between L-FMC at baseline and post IR for values in
the brachial (r = 0.55, p = 0.002) and in the radial (r = 0.65, p = 0.006). These
correlations justified an adjustment to post IR values using baseline L-FMC as the
covariate. There was no significant difference between IPC+IR and IR alone for the
brachial or radial artery.
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Figure 5.7 Effect of ischaemic preconditioning on low-flow mediated constriction following
ischaemia-reperfusion injury. Subjects underwent baseline FMD recording in the brachial and
radial artery. This was followed by cycles of IPC, a prolonged limb IR, and a final recording.
Results were adjusted for baseline diameter. L-FMC was increased following IPC+IR in the
brachial (n = 14) and the radial artery (n = 8), but this did not reach significance. Post IR and post
IPC+IR results were matched and adjusted for baseline L-FMC. L-FMC during IPC+IR was not
significantly different to IR alone in either artery. Groups were compared by paired t tests, and
adjustments were made according to linear regressions. Bars and error bars are mean and
standard error.
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Table 5.2 Summarised results of the effect of local ischaemic preconditioning on ischaemia-
reperfusion injury in humans.
Brachial IPC IR Radial IPC IR
n = 14 n = 8
BL post IPC+IR p BL post IPC+IR p
BL Diam (mm) 3.53 ± 0.31 3.47 ± 0.30 0.017 2..42 ± 0.22 2.43 ± 0.23 0.807
FMD (%) 7.09 ± 2.44 6.99 ± 3.77 0.889 9.41 ± 3.66 5.08 ± 4.95 0.001
L-FMC (%) 1.76 ± 2.07 2.17 ± 1.77 0.412 7.22 ± 3.97 8.72 ± 5.49 0.193
SBP (mmHg) 114 ± 9 117 ± 10 0.079 113 ± 10 116 ± 10 0.196
DBP (mmHg) 59 ± 3 64 ± 7 0.010 59 ± 4 64 ± 6 0.028
HR (bpm) 59 ± 7 57 ± 7 0.141 61 ± 11 61 ± 9 0.927
5.3.4. Exercise preconditioning has no effect on flow mediated dilatation,
but prevents the increase in low-flow mediated constriction following
ischaemia-reperfusion injury
Results are displayed in Figure 5.8 and Table 5.3. ExPC prior to IR did not prevent the
IR-induced reduction in FMD. ExPC did prevent the IR-induced increase in L-FMC. A
correlation existed between baseline and post IR values, which tended towards
significance for FMD (r = 0.38, p = 0.185), and was significant for L-FMC (r = 0.66, p
= 0.021). These correlations justified an adjustment to post IR values using baseline
FMD as the covariate. ExPC+IR was not significantly different to IR alone for FMD,
but was for L-FMC.
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Figure 5.8 Effect of exercise preconditioning on flow mediated dilatation and low-flow mediated
constriction following ischaemia-reperfusion injury. Subjects underwent baseline FMD recording
in the brachial artery. This was followed by a cycling test whereby subjects cycled against an
increasing resistance (20-40 W/min) for 8-12 minutes until exhaustion. After 35 minutes rest
subjects received limb IR, and a final recording. Results were adjusted for baseline diameter. FMD
was reduced and L-FMC was increased following ExPC+IR in the brachial artery (n = 7), but
neither reached statistical significance. Post IR and post ExPC+IR results were matched and
adjusted for baseline FMD / L-FMC. FMD was not different between ExPC+IR and IR alone. L-
FMC was preserved by ExPC+IR compared to IR alone. Groups were compared by paired t tests,
and adjustments were made according to linear regressions. Bars and error bars are mean and
standard error.
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Table 5.3 Summarised results for the effect of exercise preconditioning on ischaemia-reperfusion
injury in humans
ExPC IR
n = 7
BL post ExPC+IR p
BL Diam (mm) 3.85 ± 0.27 3.99 ± 0.24 <0.001
FMD (%) 7.99 ± 3.19 5.44 ± 2.71 0.108
L-FMC (%) 2.35 ± 1.74 2.76 ± 1.72 0.263
SBP (mmHg) 115 ± 7 113 ± 8 0.601
DBP (mmHg) 58 ± 4 59 ± 4 0.722
HR (bpm) 60 ± 8 67 ± 8 < 0.001
5.4. Discussion
Results demonstrate that RIPC does not protect against the IR induced decrease in
FMD. In contrast, IPC exerts a degree of protection against IR injury in the brachial but
not the radial. ExPC protected against the increase in L-FMC but had no effect on FMD.
5.4.1. Lack of protection by remote ischaemic preconditioning
In contradiction to previous studies, my results show that RIPC has no effect on post IR
endothelial dysfunction defined as FMD. Observations by our group have shown that
limb RIPC exhibits a robust protective phenotype against experimental IR in healthy
subjects. Loukogeorgakis et al. demonstrated that 20 minutes of ischaemia and
reperfusion induced a 44% reduction in FMD, but preceding IR with RIPC limited this
reduction to just 15% (41). Further studies observed that when correcting for baseline
FMD, this difference became highly significant (p < 0.0001) with 9 subjects in the
RIPC group (111).
161
In the current studies an identical protocol observed a 33% reduction in FMD by IR
alone in 20 subjects, and a 26% reduction with IR was preceded by RIPC in 11 subjects.
The reason for the lack of a protective effect is unclear. Given that 20 minutes of
recovery were of insufficient duration to return arterial diameter to baseline, both IR and
RIPC+IR studies were conducted with an extended recovery of 25 minutes. The
extended duration had no effect on RIPC, which remained when the “dose” was
increased to 4 RIPC cycles. The difference in observations is potentially attributable to
1.) subject population, 2.) image analysis, 3.) experimental set up or 4.) experimental
technique, which are discussed in more detail below.
The subject population in the current study was similar to previous experiments,
consisting of healthy young males (aged 18 – 24 years) who were requested to adhere to
dietary restrictions as previously. The subject age previously was 28.9 ± 7.7 (mean ±
SD) (79) and 24.9 ± 5.4 (111), slightly older than subjects in my study (22 ± 3).
However this small age difference seems unlikely to account for the inconsistencies
between my data and previous studies. The sample sizes in the current study (n = 11 &
n = 14) were comparable with the previous RIPC studies (n = 13, (79); n = 9, (111)).
Image analysis technique was verified by the strong agreement between analysers for
baseline FMD data (section 2.2.3.3). To account for potential analyser bias, RIPC and
control ultrasound scans were reanalysed in a blinded fashion by a senior researcher,
and almost identical values were observed, with no effect by RIPC (data not shown).
Furthermore individual recorded traces were thoroughly scrutinised by members of the
research group, but were confident that the results were not attributable to movement
artefacts, or to vascular spasm.
Thirdly experiment set up was investigated. In the months prior to starting experiments,
the research laboratory had moved, and during this time the ultrasound recording
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equipment was upgraded to a newer machine with a higher frequency probe than
previously used by our group (10.0 vs 7.0 MHz respectively). This resulted in an
improvement in image resolution. In addition a fully adjustable ultrasound probe holder
was used in the current studies to reduce the likelihood of movement artefacts during
the study. These equipment upgrades are unlikely to account for the null effect observed
in my studies. Environmental conditions (24-26°C) were matched to previous studies.
Finally, differences in experimental technique could explain a null finding. No major
systematic error was evident when directly observed. My ultrasound technique was
heavily scrutinised and. Senior researchers within our group expressed a high level of
confidence in my sonography, and that the images acquired were suitably representative
of arterial diameter. In addition a fellow PhD student performed an identical set of RIPC
studies with appropriate controls, and obtained similar results to my own (personal
communication).
To date no satisfactory explanation has emerged to explain why the current study has
failed to demonstrate a protective effect of RIPC on endothelial injury. Further studies
are required using RIPC and IR with a greater sample size, and with multiple blinded
analysers to verify the observations.
5.4.2. Protection with local ischaemic preconditioning
Results in this study identified a significant protective phenotype of IPC in the brachial
artery against the IR-induced reduction in FMD. However this effect was not present in
the radial artery, and had no effect on L-FMC. The difference between the arterial
responses is uncertain, but unlikely to be attributable to experimental technique, image
analysis, or study population, as these were almost identical for brachial and radial
studies.
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Differences between brachial and radial arteries may be explained by the study
protocols. The radial protocol used 15 minutes ischaemia and reperfusion, which other
groups have shown is sufficient to induce a reduction in FMD (113). In the brachial
studies, ischaemia lasted 20 minutes with 25 minutes reperfusion. Chapter 4 observed
that these IR in these protocols exerted similar reductions in FMD (radial, 36%;
brachial, 19%), suggesting that it is unlikely that a timing difference can account for the
altered response to IPC.
Alternatively the factors which control resting and stimulated endothelial function could
differ between vessels. Chapter 4 made direct comparisons between responses in both
the brachial and radial artery. The most obvious difference is that mean L-FMC is
greater in the radial that the brachial artery, which suggests a different balance of
endogenous vasodilators and vasoconstrictors (such as NO, EDHF, prostacyclin and
endothelin-1) may govern control of the two vessels. Differences in the release of
vasoactive mediators controlling tone could reasonably influence the lack of response to
IPC in the radial artery.
5.4.3. Exercise as a preconditioning stimulus
Results in this chapter showed that unlike IPC, exercise was unable to prevent the IR-
induced reduction in FMD. Whilst evidence supporting acute exercise as a
preconditioning stimulus exists (section 1.3.3), there are several reasons why exercise
might not have complemented these findings in the current model. Firstly there are
fundamental differences between IPC and exercise. Whilst cellular hypoxia occurs in
exercise above the anaerobic threshold, the maintenance of blood flow ensures that
glycolytic metabolites are unlikely to accumulate. This continual washout may prevent
the accumulation of endogenous autacoids to a sufficient concentration to activate G-
protein coupled receptors, and the subsequent intracellular protective kinases.
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IPC is stimulated by intermittent ischaemia and reperfusion, whereas the ischaemia
during the current exercise protocol was brief and continuous. It is possible that the
exercise stimulus differs from IPC because it did not have the same intermittent nature
as IPC. Evidence suggests that repeated reperfusion may be a prerequisite for IPC, most
likely so that cells can adapt to repeated non-lethal concentrations of reperfusion injury
mediators. One study observed vascular protection using an exercise protocol that
involved subjects exercising intermittently above and below the anaerobic threshold
(109).
Alternatively the reason for a lack of protection could be that exercise does not exert
systemic protection. As has been described in this chapter, RIPC is unable to exert a
systemic protective effect against IR injury. Given that the aim was to observe a remote
ExPC effect (lower limb exercise, upper limb IR) this may explain the results. Further
studies would aims to use intermittent arm exercise to protect against IR injury in the
same limb.
5.4.4. Low-flow mediated constriction following ischaemic and exercise
preconditioning
The IR-induced increase in L-FMC was unaffected by IPC and RIPC, but attenuated by
ExPC. Data in chapter 4 indicated that there were similarities between FMD and L-
FMC in their relationship to baseline diameter, but also differences in their response to
IR. Results in this chapter have identified that FMD and L-FMC have differing
responses to preconditioning stimuli in that IPC prevented the IR-induced reduction in
FMD, but did not attenuate the increase in L-FMC. The opposite effect was seen with
ExPC. The biological significance of these observations is uncertain.
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5.5. Conclusion
This chapter has suggested that local ischaemic preconditioning induces protection
against the IR-induced reduction in endothelial function, as assessed by IPC. The
protective effect of IPC in humans is supported by evidence in early phase clinical trials
(7). Further studies in this thesis aim to investigate IPC in other models of IR injury.
This will include a model of the IR injury induced sterile inflammatory response, and
the muscle deoxygenation and resaturation which occurs during intense exercise.
This chapter has observed that IPC, but not RIPC or ExPC can protect against human
endothelial IR injury using an in vivo model. The reason for the discrepancy between
the results for RIPC and previous experiments remain uncertain. Further studies in this
thesis aim to investigate the mechanistic properties of IPC in humans.
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6. CHARACTERISING A HUMAN IN VIVO SKIN
BLISTER MODEL OF ACUTE INFLAMMATION
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6.1. Introduction
Growing evidence suggests that ischaemic preconditioning (IPC) might protect against
IR injury by dampening the acute inflammatory response, in particular by reducing
leukocyte trafficking (66). Assessing acute inflammation in healthy humans however is
challenging. In vitro experiments are often performed to investigate individual elements
of the immune system. However given the complex overlapping of innate immune
pathways, such as leukocyte trafficking and complement, in vitro studies are often
unrepresentative. The cantharidin skin blister is a non-invasive in vivo model, which
allows for assessment of the inflammatory response by quantifying leukocyte
trafficking, and has previously been used to document the anti-inflammatory effects of
low and high dose aspirin (181). Thus, in collaboration with Professor Derek Gilroy’s
research group, the blister model was characterised, to enable its use in a crossover trial
for investigating the effect of IPC on leukocyte trafficking.
To assess whether IPC reduces the human inflammatory response, a randomised
crossover study was designed using a forearm skin blister model to quantify leukocyte
trafficking. The protocol and results from this study are reported in chapter 7. In the
current chapter the characterisation of the cantharidin skin blister model is reported.
Initially a preliminary study was performed to assess the within-subject variability of
the 24 hour skin blister, for a sample size calculation in the subsequent intervention
study. A novel strategy to identify cell populations by flow cytometry is then described,
both for circulating venous and blister leukocytes. This is followed by a report on the
changes in individual cell populations, and HLA-DR and CD19 receptor expression that
occur in the blister between 24 and 72 hours. By investigating two time points, this
provides a picture of the cell kinetics that govern the human innate immune response,
both during the onset of inflammation, and during inflammatory resolution.
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6.2. Methods
6.2.1. Study participants
Participants were prepared as outlined in section 2.3.2.
6.2.2. Experimental protocol
6.2.2.1. Variability of cantharidin skin blister
A preliminary study was designed to calculate the within-subject variability of the
cantharidin skin blister at 24 hours, and thus perform a sample size calculation. 10
healthy male participants (age 22 ± 2 years, mean ± SD) received two cantharidin skin
blisters over two weeks. Subjects received a blister on one forearm, which was aspirated
after 24 hours. At least 6 days following aspiration, a second blister was applied to the
contralateral forearm, which was again aspirated after 24 hours. Blisters were induced
and aspirated as described in section 2.3.2. Blisters were analysed for volume and total
leukocyte count.
6.2.2.2. Leukocyte analysis in the 24 and 72 hour blisters
To characterise the cell composition in the 24 and 72 hour skin blisters, a retrospective
analysis was performed on the results from the control protocol of the crossover study
described in chapter 7 (see section 7.2.2). Briefly, 17 healthy male participants (age 22
± 4 years, mean ± SD) received two blisters to the same forearm at the same time. Skin
blisters were induced and aspirated at 24 hours and 72 hours (section 2.3.2). Circulating
leukocytes were isolated from venous blood by a flash lysis (section 2.3.2.4). Both
blister and circulating leukocytes were analysed by flow cytometry for the expression of
CD3, CD14, CD16, CD19, CD56 and HLA-DR (section 2.3.3). 3 additional participants
were investigated for expression of CD11b, CD15 and CD33 in the 72 hour blister.
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6.2.3. Calculations and statistics
Cantharidin skin blister variability was assessed using coefficient of variation (CV) and
intraclass correlation coefficient (ICC). Results are presented as total cell count (n) and
cell concentration (n/ml). Total cell count and cell concentration were non-parametric,
and hence presented on a logarithmic scale, with results reported as the median ±
interquartile range. Given the large number of data points and the skewed distributions,
results are presented as box and whisker plots, showing the median, interquartile range,
and the minimum and maximum values. Sample sizes were calculated by performing a
log transformation and using statistical software (Power and Sample Size Calculations,
Dupont & Plummer, v3.0, (144)).
Populations identified by flow cytometry are expressed as the percentage of the total
cells (linear scale, mean ± SD) and as the absolute number of cells (logarithmic scale,
median ± interquartile range). Between time-point differences were assessed by paired t
test for the percentage of the total cells, or by Wilcoxon matched pairs test for absolute
cell number.
Mean fluorescence intensity (MFI) varies between cytometers and settings, and is hence
expressed in arbitrary units (logarithmic scale, median ± interquartile range). Between
time-point differences for blood and blister leukocyte MFI was assessed by a repeated
measures Friedman test and a Dunn’s post-test.
6.3. Results
6.3.1. The cantharidin skin blister has a low within-person variability
Results from the preliminary study show that the total cell count was a repeatable
measure of the leukocyte trafficking (CV = 5.3%, ICC = 0.82) (Figure 6.1). The within-
subject variability was reduced when expressed as cell concentration (CV = 3.2%, ICC
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= 0.92). There was no difference between week 1 and week 2 in the total cell count
(week 1, 328,000 ± 897,000 cells; week 2, 314,000 ± 1,161,000 cells; p = 0.389, paired
t test; n = 10; Figure 6.1A) or the cell concentration (week 1, 2,827,000 ± 4,624,000
cells/ml; week 2, 1,740,000 ± 6,761,000 cells/ml; p = 0.333, paired t test; n = 10; Figure
6.1B). Sample size calculations determined the number of subjects required to show a
30, 50 and 70% reduction in the total leukocyte count.
cell count reduction sample size (total cells) sample size (cell conc.)
30% 93 49
50% 25 13
70% 8 4
Figure 6.1 Results from preliminary 24 hour blister study. 10 healthy males received two skin
blisters on two weeks, with both aspirated at 24 hours. Cells were isolated by centrifugation and
enumerated by haemocytometer. Charts show results from repeated blisters, with each line
representing one subject. Infiltration of leukocytes into the blister was repeatable, whether
expressed as total cells (A) or as total cells per oedema volume (B). Table shows sample size results
for given reductions in cell count (total cells) and cell concentration (cell conc.), using an α = 0.05 
and a power of 0.8.
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6.3.2. Gating strategy to differentiate individual cell populations
Using the panel of antibodies (section 2.3.3) a gating strategy was designed that could
identify the populations of leukocytes present in circulating venous blood, and in the
skin blister. Receptor expression, in combination with size (forward scatter, FSC) and
granularity (side scatter, SSC) allowed for the identification of specific cell types. The
strategy was based upon published literature for differentiating human circulating
leukocytes (225,226), and following advice from experienced cytometry researchers
within our research group. Flow chart in Figure 6.2 explains the gating strategy, and
representative dot plots for venous and blister leukocytes are shown in subsequent
figures (Figure 6.3 - Figure 6.5). FMO controls are provided in the appendix (Figure
10.1 - Figure 10.4).
Briefly, leukocytes were isolated from erythrocytes and cell debris by size and
granularity. Cell doubles were removed using a FSC-height versus FSC-area plot.
Lymphocytes were then identified as CD3hi (T lymphocytes), CD19hi (B lymphocytes)
or CD56hi (natural killer cells) (see Figure 6.3). Remaining cells were split according to
their expression of HLA-DR and CD16, into a.) HLA-DRlo/dim CD16dim/hi cells and b.)
HLA-DRhi cells (Figure 6.4 and Figure 6.5 respectively). This considerably reduced the
contamination by neutrophils of the monocyte and macrophage population, and is based
upon a gating strategy described recently (227).
Within the HLA-DRlo/dim CD16dim/hi gate; granulocytes and a myeloid derived
suppressor-like cell (MDSC) population were differentiated by CD14 and CD16
expression (Figure 6.4). CD16hi CD14lo cells were identified as granulocytes, with the
remainder being a mixed cell population, believed to be primarily MDSCs. CD16hi
CD14lo cells were separated into neutrophils (FSCmid SSCmid) and eosinophils (FSChi
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SSChi). MDSCs were differentiated into FSClo CD14hi cells and FSClo/mid/hi CD14dim/lo
cells.
In the HLA-DRhi population, monocytes were identified as FSClo/mid SSClo, with
macrophages the remaining cells. Both the monocyte and macrophage subpopulations
were determined by CD14 and CD16 expression. Monocytes were separated into
classical (CD14hi CD16dim), intermediate (CD14dim CD16dim), and non-classical
(CD14dim CD16hi) monocytes, and a myeloid precursor population (CD14dim CD16dim).
Circulating macrophages were similarly differentiated by CD14 and CD16 expression.
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Figure 6.2 Flow chart describing the gating strategy employed to identify inflammatory and venous
leukocyte populations by flow cytometry. Boxes show the different cell types separated in this
manner, with arrows showing the direction in which the gating was applied. Firstly single cells were
identified, and were separated into different types of lymphocyte (red box, see Figure 6.3). The
remaining cells were separated by HLA-DR and CD16 expression, with HLA-DRlo CD16hi/dim cells
identified as granulocytes (green box, see Figure 6.4) and myeloid derived suppressor-like cells
(MDSC) (orange box, see Figure 6.4). HLA-DRhi cells were identified as monocytes (blue box, see
Figure 6.5) or macrophages (purple box, see Figure 6.5). Coloured boxes match boxes in subsequent
figures.
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Figure 6.3 Lymphocyte gating strategy for venous and inflammatory leukocytes. Above are representative dot plots for the flow cytometry gating strategy to isolate
CD3hi T lymphocytes, CD19hi B lymphocytes, and CD56hi natural killer cells. Circulating leukocytes were obtained from venous blood and following a flash lysis to
remove erythrocytes. Inflammatory leukocytes were obtained from cantharidin skin blisters in healthy males. Single cells were isolated using a forward (FSC) vs
side scatter (SSC) plot, and an area vs height plot. T, B and NK cells were then isolated (red boxes), with the remaining non-lymphocytes separated into HLA-DR hi
cells and HLA-DRlo/dim CD16hi/dim cells. The strategy was almost identical for venous (top row), 24 hour blister (middle row) and the 72 hour blister (bottom row)
leukocytes. Arrows indicate gating strategy.
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Figure 6.4 Granulocyte and myeloid derived suppressor cell gating strategy for venous and inflammatory leukocytes. Above are representative dot plots for the
flow cytometry gating strategy. Circulating leukocytes were obtained from venous blood and following a flash lysis to remove erythrocytes. Inflammatory
leukocytes were obtained from cantharidin skin blisters in healthy males. Following removal of lymphocytes, HLA-DR lo/dim CD16hi/dim cells were differentiated into
CD16hi granulocytes (green box) and CD16dim MDSCs (orange box). MDSCs were differentiated into CD14hi and CD14lo cells. CD16hi cells were differentiated into
neutrophils (FSCmid SSCmid) and eosinophils (FSChi SSChi). The strategy was almost identical for venous (top row), 24 hour blister (middle row) and the 72 hour
blister (bottom row) leukocytes. Arrows indicate gating strategy.
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Figure 6.5 Monocyte and macrophage gating strategy for venous and inflammatory leukocytes. Above are representative dot plots for the flow cytometry gating
strategy. Circulating leukocytes were obtained from venous blood and following a flash lysis to remove erythrocytes. Inflammatory leukocytes were obtained from
cantharidin skin blisters in healthy males. Following removal of lymphocytes, HLA-DR hi cells were differentiated into SSClo monocytes (blue box) and SSCmid/hi
macrophages (purple box). Monocytes and macrophages were further differentiated by CD14 and CD16 expression. The strategy was almost identical for venous
(top row), 24 hour blister (middle row) and the 72 hour blister (bottom row) leukocytes. Arrows indicate gating strategy.
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6.3.3. Characterising the timecourse of the innate immune response
A comparison was made of leukocyte populations in the 24 and 72 hour blister.
6.3.3.1. Blister resolution is associated with an increase in fluid volume,
but no change in absolute cell count
There was no change in the absolute cell count from 24 to 72 hours (24 hours 270,000 ±
271,000; 72 hours 179,000 ± 274,000; n = 17, Wilcoxon paired test, p = 0.822). Cell
concentration was non-significantly decreased (24 hours 1,746,000 ± 1,520,000; 72
hours 796,000 ± 1,168,000; n = 17, Wilcoxon paired test, p = 0.139). This was most
likely due to a significant increase in oedema volume from 24 to 72 hours (24 hours
0.178 ± 0.073; 72 hours 0.263 ± 0.178; n = 17, paired t test, p = 0.028). Results are
shown in Figure 6.6.
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Figure 6.6 Leukocyte count and oedema volume in the 24 and 72 hour blisters. 17 healthy males
received two skin blisters, with the first aspirated at 24 hours, and the second at 72 hours. Aspirates
were measured for volume, and cells were isolated by centrifugation and enumerated. Results are
expressed as the total cells, cell concentration, and oedema volume. There was no change in cell
count from 24 to 72 hours, but oedema was increased. * denotes p < 0.05
6.3.3.2. Blister resolution is associated with granulocyte clearance and
accumulation of MDSC-like cells
Despite a lack of change in total cell count, considerable changes occurred in the
proportions of individual blister cell populations. No difference was observed in venous
leukocyte populations analysed at 24 and 72 hours (no difference - data not shown).
In the blister there was an increase in the proportion of CD3+ T cells, (24 hours 3.37 ±
1.83%; 72 hours 4.25 ± 2.24%; n = 17, paired t test, p = 0.06), CD16hi NK cells (24
hours 0.04 ± 0.04%; 72 hours 0.07 ± 0.10%; n = 17, paired t test, p = 0.161) and
CD16lo NK cells (24 hours 0.09 ± 0.10%; 72 hours 0.16 ± 0.14%; n = 17, paired t test, p
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= 0.030), with a decrease in the proportion of CD19+ B cells (24 hours 0.04 ± 0.03%; 72
hours 0.01 ± 0.01%; n = 17, paired t test, p = 0.002) (Figure 6.7A).
There was a substantial decrease in both the proportion and absolute number of
granulocytes in the blister from 24 to 72 hours consistent with resolution (Figure 6.7B);
this was true for neutrophils (24 hours 38.9 ± 21.8%; 72 hours 13.7 ± 8.4%; n = 17,
paired t test, p < 0.001) and eosinophils (24 hours 8.8 ± 3.7%; 72 hours 2.9 ± 1.4%; n =
17, paired t test, p < 0.0001). The reduction in the granulocyte population coincided
with a substantial increase in the MDSCs (Figure 6.7C), whether they were CD14hi
FSClo (24 hours 0.3 ± 0.2%; 72 hours 25.3 ± 11.1%; n = 17, paired t test, p < 0.0001), or
CD14dim/lo (24 hours 4.0 ± 2.3%; 72 hours 12.7 ± 7.4%; n = 17, paired t test, p <
0.0001).
Changes in the HLA-DRhi monocytes and macrophages populations, are more complex
(Figure 6.8). There was a reduction in the classical monocyte population (24 hours 19.1
± 9.5%; 72 hours 14.0 ± 5.9%; n = 17, paired t test, p = 0.056), and an increase in the
HLA-DRhi CD14dim/lo population (24 hours 5.6 ± 3.6%; 72 hours 14.2 ± 6.8%; n = 17,
paired t test, p < 0.001). This coincided with an increase in the absolute CD14hi CD16dim
macrophage population (24 hours 1.3 ± 2.0%; 72 hours 2.2 ± 1.3%; n = 17, paired t test,
p = 0.160), no change in the CD14hi CD16hi macrophage population (24 hours 0.9 ±
1.3%; 72 hours 0.7 ± 0.5%; n = 17, paired t test, p = 0.403), and a decrease in the
CD14dim CD16hi macrophage population (24 hours 1.3 ± 1.9%; 72 hours 0.6 ± 0.6%; n =
17, paired t test, p = 0.157).
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Figure 6.7 Lymphocyte, granulocyte and myeloid derived suppressor-like cell numbers in the 24
and 72 hour blister. 17 healthy males received two skin blisters, with the first aspirated at 24 hours,
and the second at 72 hours. Isolated leukocytes were differentiated by flow cytometry into
lymphocytes (A), granulocytes (B) and myeloid derived suppressor-like cells (MDSC) (C) according
to gating in Figure 6.3 and Figure 6.4. From 24 to 72 hours there was an increase in T lymphocytes
and natural killer (NK) cells, and a reduction in B lymphocytes. This coincided with a decrease in
neutrophils and eosinophils and an increase in the CD14hi and CD14lo/dim MDSCs. * denotes p <
0.05; ** denotes p < 0.01; *** denotes p < 0.001.
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Figure 6.8 Monocyte and macrophage numbers in the 24 and 72 hour blister. 17 healthy males
received two skin blisters, with the first aspirated at 24 hours, and the second at 72 hours. Isolated
leukocytes were differentiated by flow cytometry into HLA-DRhi cells and then SSClo cells (A) and
SSCmid/hi macrophages (B) according to gating in Figure 6.5. Classical monocytes were significantly
decreased from 24 to 72 hours, and HLA-DRhi myeloid derived suppressor-like cells (MDSC) were
significantly increased (A). There was an increase in CD14hi CD16dim macrophages, with decreases
in the CD14hi CD16hi and CD14dim CD16hi macrophages (B). * denotes p < 0.05; ** denotes p < 0.01;
*** denotes p < 0.001.
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6.3.3.3. Increased HLA-DR expression during resolution
Human leukocyte antigen and its cluster (HLA-DR) form part of the major
histocompatibility receptor complex (MHC) class II. MHC class II present intracellular
polypeptide chains acquired from foreign antigens, to CD4+ T lymphocytes that inspect
and respond appropriately (228). HLA-DR is thus highly expressed on antigen
presenting cells, which include monocytes, macrophages, dendritic cells, and B
lymphocytes. HLA-DR expression is used as an indication of cell activation status. In
the current study an increase in HLA-DR expression verified that the antigen
presentation was increased in most cell populations in the blister when compared to
circulating leukocytes (Figure 6.9). Furthermore HLA-DR expression was further
enhanced between 24 and 72 hours within the blister. There was no change from 24 to
72 hours in HLA-DR expression in venous leukocytes (data not shown).
HLA-DR was increased in T lymphocytes (venous 155 ± 192; 24 hours 6652 ± 4468; 72
hours 25350 ± 13050; n = 16, Friedman test, p < 0.0001), neutrophils (venous 60 ± 135;
24 hours 149 ± 183; 72 hours 571 ± 418; n = 16, Friedman test, p < 0.0001), eosinophils
(venous 125 ± 346; 24 hours 333 ± 657; 72 hours 1150 ± 1385; n = 16, Friedman test, p
< 0.0001), HLA-DRlo CD14lo MDSCs (venous 59 ± 88; 24 hours 127 ± 119; 72 hours
312 ± 343; n = 16, Friedman test, p < 0.0001), CD14hi CD16dim monocytes (venous
1997 ± 1576; 24 hours 15500 ± 11250; 72 hours 23650 ± 16400; n = 16, Friedman test,
p < 0.0001), and CD14hi CD16 hi macrophages (venous 2803 ± 7427; 24 hours 24300 ±
17200; 72 hours 44600 ± 32000; n = 16, Friedman test, p < 0.0001).
183
Figure 6.9 HLA-DR expression of circulating venous and blister leukocytes. 17 healthy males
received two skin blisters, with the first aspirated at 24 hours, and the second at 72 hours.
Circulating leukocytes were obtained from venous blood. Inflammatory leukocytes were obtained
from blisters. Cells were differentiated according to gating strategy in Figure 6.3, Figure 6.4 and
Figure 6.5. Individual populations were investigated for HLA-DR expression, reported in arbitrary
units. Compared to venous blood, there was an increase in HLA-DR expression at 24 and 72 hours
in the following blister cell types: T lymphocytes, neutrophils, eosinophils, CD14lo/dim MDSCs,
CD14hi CD16dim monocytes, and CD14hi CD16hi macrophages. * denotes p < 0.05; ** denotes p <
0.01; *** denotes p < 0.001.
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6.3.3.4. CD19 expression on non-lymphocytes during resolution
Unpublished work within our lab has shown that tissue-resident macrophages in the
murine peritoneum can be derived from B lymphocytes, both in the steady state and
during inflammation. By investigating CD19, a marker of mature B lymphocytes, I have
investigated whether this phenomenon might exist in humans.
Hardly any CD19+ B cells are present in the blisters at either 24 or 72 hours (see Figure
6.10). However an increasing CD19 expression was observed in the non-lymphocyte
blister population from 24 to 72 hours. Further investigation of CD19 expression on
individual populations, identified an increase in CD19 expression in HLA-DRdim/lo
CD14dim/lo MDSCs (venous 19 ± 8; 24 hours 40 ± 41; 72 hours 73 ± 58; n = 16,
Friedman test, p < 0.0001), CD14hi CD16dim monocytes (venous 84 ± 34; 24 hours 124
± 75; 72 hours 177 ± 143; n = 16, Friedman test, p < 0.0001), and CD14hi CD16hi
macrophages (venous 203 ± 198; 24 hours 211 ± 111; 72 hours 299 ± 167; n = 16,
Friedman test, p = 0.012).
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Figure 6.10 CD19 expression of circulating venous and blister leukocytes. 17 healthy males received
two skin blisters, with the first aspirated at 24 hours, and the second at 72 hours. Circulating
leukocytes were obtained from venous blood. Inflammatory leukocytes were obtained from blisters.
Cells were differentiated according to gating strategy in Figure 6.3, Figure 6.4 and Figure 6.5.
There were negligeable B lymphocytes in the blisters. However there was an increase in CD19
expression in non-lymphocyte populations at 72 hours (72 hour dot plot). Individual populations
were investigated for CD19 expression, reported in arbitary units. Compared to venous blood,
there was an increase in CD19 expression at 24 and 72 hours in the following blister cell types:
HLA-DRlo/dim CD14lo/dim MDSCs, CD14hi CD16dim monocytes, and CD14hi CD16hi macrophages. *
denotes p < 0.05; ** denote p < 0.01; *** denotes p < 0.001.
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6.3.3.5. 72 hour blister is infiltrated by myeloid derived suppressor- like
cells
Myeloid derived suppressor cells (MDSCs) are immature myeloid cells that inhibit T
cell activity and are myeloid in origin. In the majority of reports, MDSCs are described
as being CD33hi HLA-DRlo and CD11bhi, but without common lineage markers (229).
Section 6.3.3.2 indicates an increase in three populations from 24 to 72 hours, which
might be candidates for MDSCs, due to their receptor expression. The increase at 72
hours suggests these cells may have a role in the resolution of inflammation. MDSCs
have been coded to aid additional analyses: HLA-DRlo/dim CD16dim CD14hi cells
[MDSC-α], HLA-DRlo/dim CD16dim CD14lo cells [MDSC-β], and HLA-DRhi CD14lo
cells [MDSC-δ].  
MDSCs were investigated further for their size, granularity, morphology, and
expression of three typical “MDSC markers”, CD33, CD11b and CD15 (see Figure
6.11). This was achieved by inducing 72 hour blisters in 3 additional subjects, and using
flow assisted cell sorting (FACS) to assess morphology. Results show that MDSC-α 
cells are small, granular, and express CD11bhi CD33hi and CD15hi (CD11bhi CD33hi
cells 98.7 ± 1.7%; CD11bhi CD33hi CD15hi cells 97.6 ± 1.6%; mean ± SD, n = 3). The
MDSC-β cells were more heterogeneous, comprising primarily of CD11bhi CD33hi cells
that were a mixture of CD15hi and CD15lo cells (CD11bhi CD33hi cells 68.0 ± 24.7%;
CD11bhi CD33hi CD15hi cells 43.5 ± 24.8%; mean ± SD, n = 3). Finally, the MDSC-δ 
cells were fairly homogeneous, small, agranular, primarily CD11bhi CD33hi CD15lo
cells (CD11bhi CD33hi cells 66.7 ± 2.4%; CD11bhi CD33hi CD15lo 57.1 ± 2.3%; mean ±
SD, n = 3).
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Figure 6.11 Identification of myeloid derived suppressor-like cells in the 72 hour blister. Representative plots are shown for three MDSC populations.
Inflammatory leukocytes were obtained from 72 hour skin blisters in 3 subjects. MDSCs were identified by flow cytometry as described in Figure 6.4 and Figure
6.5. HLA-DRlo/dim CD16dim CD14hi (MDSC-α) cells were homogenous, small, granular, and CD33hi, CD11bhi and CD15hi. HLA-DRlo/dim CD16dim CD14dim/lo (MDSC-
β) cells were heterogeneous, CD11bhi, CD33hi and with a split expression of CD15. HLA-DRhi CD14dim/lo (MDSC-δ) cells were homogeneous, CD11bhi, CD33hi and
CD15lo. Red histograms show fully stained sample, blue histograms show corresponding FMO control.
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6.4. Discussion
These results have described a thorough characterisation of the cantharidin skin blister.
Preliminary results showed that that the blister model is repeatable, and sample size
calculations showed that fewer than 10 subjects would be required to identify a 70%
reduction in total cell count, and fewer than 25 for a 50% reduction. These calculations
were used to design the crossover study described in chapter 7.
6.4.1. A novel gating strategy for identifying inflammatory and circulating
leukocytes
The gating strategy was used to identify leukocytes both within the circulation and the
blister at two time points. Using this, results showed that the granulocytes were cleared
from 24 to 72 hours, as our group has previously described (181). This was not
associated with a substantial increase in macrophages, but rather an increase in three
other myeloid populations: 1.) HLA-DRlo CD16dim CD14hi, 2.) HLA-DRlo CD16dim
CD14dim/lo, and 3.) HLA-DRhi SSClo CD14lo. An increase in HLA-DR expression was
also observed across all major cells types, from venous to 24 hour to 72 hour blister,
verifying leukocyte activation during the resolving blister.
Blisters contained few CD19hi B cells, however resolution coincided with an increase in
CD19 expression in non-lymphocytes. Closer examination revealed that this property
was primarily observed on the HLA-DRhi CD16dim CD14dim/lo cells, CD14hi CD16dim
classical monocytes, and CD14hi CD16hi macrophages. This increase in CD19
expression is corroborative with murine data from our group, which implicates that
myeloid cells develop B cell receptor expression and phenotype. However, this data is
only preliminary, and additional B lymphocyte markers and functional assessments are
required before this phenomenon can be confirmed in humans.
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6.4.2. Myeloid derived suppressor cells
In healthy participants, myeloid progenitor cells released from the bone marrow mature
rapidly, and are subsequently a sparse population in circulating leukocytes. These cells
are more commonly described in the blood of cancer patients, whereby malignancy
invokes rapid myeloid progenitor cell production. Such myeloid progenitors are known
to be immunosuppressive by inhibiting antigen-specific CD8+ and CD4+ T cell
activation, through release of IL-10, increasing arginase and iNOS expression, ROS
production, and down-regulation of IL-12 release (229–231). They are hence known as
myeloid derived suppressor cells (MDSCs). MDSCs are believed to contribute to
tumour progression and a reduced efficacy of cancer immunotherapy (229). MDSCs
have also been described in experimental sepsis and trauma (230), suggesting that they
may also complement the innate immunity.
No strict criteria exist for identifying human MDSCs, most likely due to their
heterogeneous nature, malignancy-specific populations, and the sparsity in the healthy
circulation. In most cases, MDSCs are CD11bhi HLA-DRlo CD33hi and have a low
expression of lineage markers (229). Recently CD14hi MDSCs have been described,
which secrete TGF-ß and IL-10, and are T cell suppressive in nature (231,232). Several
reviews have now characterised MDSCs into two populations: “monocytic” MDSCs
(CD14hi), and “granulocytic” MDSCs (CD14lo) (229,233).
Results in this chapter are the first to describe the presence of MDSCs in the
inflammatory skin blister. Three populations were identified that increase in number
from 24 to 72 hours. Firstly, a small, granular, HLA-DRlo, CD16dim, CD14hi, CD33hi,
CD11bhi and CD15hi population (MDSC-α). These cells had approximately a 100-fold 
increase from 24 to 72 hours, suggesting a function in the resolution phenotype.
Secondly a granular, HLA-DRlo, CD16dim, CD14lo/dim, CD33hi, CD11bhi and CD15hi
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population (MDSC-β), which increased to a lesser extent, and was a composite of 
multiple cell types. Finally an agranular HLA-DRhi, SSClo, CD16lo/dim, CD14lo/dim,
CD33hi, CD11bhi and CD15lo population, which resembled immature monocytes
(MDSC-δ). Again, an increase in the 72 hour blister suggests a function during 
resolution.
These populations do not match exactly with known described populations. Firstly
MDSC-α cells were granular, but unlike “granulocytic MDSCs” were also CD14hi.
Secondly MDSC-β cells were heterogeneous, including some CD15hi and CD15lo cells.
Finally MDSCs are usually expressed as HLA-DRlo, however MDSC-δ were HLA-DRhi
CD14lo and CD16lo, despite resembling immature monocytes. Studies by our group and
others have observed similar MHC class IIhi MDSCs in murine inflammatory models
(234).
Further work is required to investigate receptor expression and function of these cells,
but this is beyond the scope of this thesis. Additional experiments would aim to assess
the role of the cells, whether it be in mediating the innate response, or as described in
cancer, mediating the adaptive response, in particular by T cell suppression.
Alternatively these cells could have a more specific role in the repair and remodeling of
the basement membrane between the dermis and epidermis, facilitating recovery of
keratinocytes, melanocytes, and other cells present in the skin.
6.5. Conclusion
To summarise, these results describe a model for investigating the innate immune
response in humans. They show for the first time in humans that resolution is
characterised by an infiltration of MDSC-like cells. The model is repeatable, and can be
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used to for investigate the effects of anti-inflammatory interventions on the human
innate immune response.
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7. THE EFFECT OF ISCHAEMIC
PRECONDITIONING ON THE INNATE
INFLAMMATORY RESPONSE IN HUMANS
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7.1. Introduction
Preliminary evidence suggests that IPC might alter the acute, sterile inflammatory
reaction that occurs during IR injury. As described in section 1.3.1.4, animal studies
have demonstrated that IPC reduces leukocyte rolling, adhesion and migration
following IR injury in vivo (66,67). These findings are consistent with human in vitro
studies: IPC modifies circulating leukocytes by reducing neutrophil adhesion and
apoptosis (72), decreasing expression of neutrophil kinin receptors (70), and reducing
platelet-monocyte aggregates (71). Whilst these studies suggest that IPC modifies
circulating leukocytes, this provides only limited information into how preconditioned
leukocytes will respond to human IR injury. One would assume that a decrease in
leukocyte adhesion is reflected in a decrease in leukocyte trafficking but this requires
validation in in vivo.
In chapter 6 I categorised a cantharidin skin blister model, which quantified human
leukocyte trafficking in response to a sterile inflammatory stimulus (cantharidin), and is
thus comparable to the inflammatory response that is observed during IR injury, albeit
to a different stimulus. Results show that the model is repeatable, and can be used to
characterise the initiation (24 hours) and resolution (72 hours) of the innate immune
response. This model has been previously been used to demonstrate the anti-
inflammatory effects of TNF inhibitors (235), corticosteroids (235), trypsin inhibitors
(236), and aspirin (181).
Results in chapter 5 indicate that local IPC, induced by three cycles of upper limb cuff
inflations, conferred a protective effect against human endothelial IR injury. We have
previously observed that ischaemic conditioning in humans is dependent on both
humoral and neural pathways (79,112). To progress our understanding of the
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components which govern IPC in humans, a study was performed to assess whether IPC
modifies the innate immune response in vivo, using the skin blister model.
This chapter reports on a randomised crossover trial, designed to investigate whether
IPC reduces leukocyte trafficking, with aspirin as a positive control. Cell migration into
the cantharidin blister was quantified, individual cell types were identified, and the
cytokine concentrations was calculated. Finally two inflammatory phenotypes are
described, the early and the delayed resolvers, and how they individually respond to
aspirin and IPC.
7.2. Methods
7.2.1. Study participants
Twenty healthy male subjects (age, 21 ± 4.1, mean ± SD) were recruited for this study.
Participants were prepared as outlined in section 2.3.2. The sample size was based on
the results in Figure 6.1.
7.2.2. Experimental protocol
The study was performed in a randomised crossover design (see Figure 7.1).
Methodology for blister application and aspiration was described in section 2.3. Each
subject attended the laboratory for nine visits over three weeks, to receive a total of 6
blisters. Each week represented a different arm of the study: control, IPC, or high dose
aspirin. Blister application and processing protocol were consistent. At the start of each
week (visit 1), a pair of blister patches were applied. After 24 hours (visit 2) subjects
returned to the laboratory, a venous blood sample was taken, and one blister (24 hour
blister) was aspirated with the other blister being secured and covered. After a further
48 hours (visit 3) subjects returned to the laboratory, a venous blood sample was taken,
and the remaining blister (72 hour blister) was aspirated. The order of weeks was
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randomised, with a washout period of at least 72 hours between the aspiration of the
second blister, and the application of the next pair. Forearms were switched after each
week.
Venous blood was acquired prior to blister aspiration from the antecubital vein on the
contralateral arm to that with the skin blister. Plasma and leukocytes were isolated from
venous blood (see section 2.3.2.4). Blister aspirates were volume assessed, and samples
were centrifuged to isolate leukocytes. Cells were enumerated by haemocytometer,
before being processed for antibody labeling and measurement by flow cytometry (see
2.3.2 and 2.3.3). Plasma and blister oedema were frozen at -80°C for subsequent
cytokine analysis. The concentrations of tumour necrosis factor-α (TNF-α) and 
interleukin-10 (IL-10) were analysed using an ELISA (see section 2.3.4).
7.2.2.1. Control protocol
In the control protocol there was no intervention, with subjects performing the blister
protocol as described above.
7.2.2.2. Ischaemic preconditioning protocol
On visit 1 of the IPC protocol, subjects received three IPC cycles of 5 minutes upper
limb cuff inflation to 200 mmHg, followed by 5 minutes of reperfusion. Immediately
after IPC skin blisters were applied to the same forearm that received the IPC stimulus.
Blister aspiration at 24 and 72 hours was as above.
7.2.2.3. High dose aspirin protocol
On the aspirin protocol week, subjects were administered 3 doses of aspirin (3 x 300 mg
p.o., Boots Pharmaceuticals, UK) at 8-hour intervals prior to visit 1. Immediately
following blister application, a fourth dose of aspirin (300 mg p.o.) was administered.
The dosing was matched to a previous study that demonstrated a reduction in leukocyte
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trafficking by approximately 70% following high dose aspirin (181). Blister aspiration
at 24 and 72 hours were as above.
Figure 7.1 Experimental protocol for blister crossover study. 20 subjects received six blisters, two
each for control, aspirin and IPC. On each week subjects received two skin blister patches (visit 1).
One blister was aspirated at 24 hours (visit 2) and the other at 72 hours (visit 3). Venous samples
were taken at visit 2 and visit 3 from the contralateral arm to that with the blister. In the aspirin
week subjects received 4 doses of 300 mg aspirin, 3 doses at 8 hour intervals prior to blister
application, and one dose immediately following application. In the IPC week subjects received 3
cycles of 5 minutes ischaemia with 5 minutes reperfusion immediately prior to blister application.
Control, aspirin and IPC were performed in a random order.
7.2.3. Early and delayed resolvers of inflammation
Validation of the early and delayed resolution phenotype was made by repeating studies
on six subjects at a later time point with a 24 and 72 hour blister in the control protocol
conditions.
7.2.4. Statistical analysis
Data are presented as in chapter 6, using total cell count (n) and cell concentration
(n/ml). Total cell count and cell concentration were non-parametric data, and hence
presented on a logarithmic scale, and reported as median ± interquartile range. Oedema
volume was parametric, and reported as mean ± standard deviation (SD). Given the
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large number of data points and skewed distributions, results are presented as box and
whisker plots, showing the median, interquartile range, and the minimum and maximum
values.
Individual cell populations are given as the absolute cell count (logarithmic scale,
median ± interquartile range). Between protocol differences were assessed using a
repeated measures one-way ANOVA with a Bonferroni post-hoc test (parametric), or by
a repeated measures Friedman test and a Dunn’s post-test (non-parametric). Cytokines
were non-parametric, and are reported as median ± interquartile range and displayed
using a box and whisker plot. Changes from 24 to 72 hour results for cells and cytokines
were assessed using Wilcoxon paired rank test.
The definition of the resolution phenotype was based upon previous work by our group
(174). Subjects were retrospectively categorised using this definition from the results in
their control protocol week. Missing subjects were removed by listwise deletion. Early
and delayed resolver blisters are expressed as the delta change in cell count from 24 to
72 hours (mean ± SD), and comparisons between groups are made using unpaired t
tests.
7.3. Results
There were technical issues (either blister popped or clotted) in one subject in the 24
hour blister set, and in three subjects in the 72 hour blister set. Results from remaining
blisters are given below.
7.3.1. Ischaemic preconditioning has no effect on the acute and resolving
inflammatory response
Results for cell number and oedema are summarised in Figure 7.2. There were no
differences between groups at 24 hours whether measured as total cell count (control,
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270,000 ± 278,000 cells; aspirin, 276,000 ± 178,000 cells; IPC, 285,000 ± 374,000
cells; n = 19, Friedman test, p = 0.196), cell concentration (control, 1,746,000 ±
1,707,000 cells/ml; aspirin, 1,680,000 ± 1,518,000 cells/ml; IPC, 1,651,000 ± 2,852,000
cells/ml; n = 19, Friedman test, p = 0.949) or oedema volume (control, 0.177 ± 0.068
ml; aspirin, 0.166 ± 0.075 ml; IPC, 0.181 ± 0.080 ml; n = 20, one-way ANOVA, p =
0.638).
There were no differences between groups at 72 hours whether measured as total cell
count (control, 191,000 ± 261,000 cells; aspirin, 230,000 ± 268,000 cells; IPC, 336,000
± 343,000 cells; n = 16, Friedman test, p = 0.646), cell concentration (control, 1,094,000
± 1,168,000 cells/ml; aspirin, 814,000 ± 1,597,000 cells/ml; IPC, 1,741,000 ± 1,369,000
cells/ml; n = 16, Friedman test, p = 0.472) or oedema volume (control, 0.279 ± 0.183
ml; aspirin, 0.290 ± 0.194 ml; IPC, 0.363 ± 0.295 ml; n = 17, one-way ANOVA, p =
0.295).
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Figure 7.2 Effect of ischaemic preconditioning and aspirin and on total blister leukocyte trafficking.
20 subjects received six blisters, two each for control, aspirin, and IPC. Following aspiration, fluid
volumes were measured, and cells enumerated by haemocytometer. Results are displayed for total
blister cell count, cell concentration, and oedema volume alone, at 24 and 72 hours. Box and
whisker plots show median, interquartile range, minimum and maximum values for control (blue),
aspirin (yellow) and IPC (red). Groups were compared by Friedman test (cells) or one-way
ANOVA (oedema). p < 0.05 was deemed statistically significant. There were no differences between
the groups at either 24 or 72 hours.
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There were no differences between control, aspirin or IPC in individual cell populations
at either the 24 or 72 hours (Figure 7.3). Results are shown for CD3hi T lymphocytes
(24 hours, p = 0.854, n = 19; 72 hours, p = 0.607, n = 14), neutrophils (24 hours, p =
0.331, n = 19; 72 hours, p = 0.135, n = 14), eosinophils (24 hours, p = 0.505, n = 19; 72
hours, p = 0.607, n = 14), CD14hi CD16dim classical monocytes (24 hours, p = 0.076, n
= 19; 72 hours, p = 0.395, n = 14), and HLA-DRlo CD16dim CD14dim/lo MDSCs (24
hours, p = 0.949, n = 19; 72 hours, p = 0.931, n = 14).
201
Figure 7.3 Effect of ischaemic preconditioning and aspirin on individual population blister
leukocyte trafficking. 20 subjects received six blisters, two each for control, aspirin, and IPC.
Following aspiration, fluid volumes were measured, cells enumerated by haemocytometer, and
remaining cells stained with fluorescent antibodies and analysed by flow cytometry. Results are
displayed for five major leukocytes populations present in the blister (see Figure 6.2). Box and
whisker plots show median, interquartile range, minimum and maximum values for control (blue),
aspirin (yellow) and IPC (red). Groups were compared by Friedman test. p < 0.05 was deemed
statistically significant. There were no differences between the groups at either 24 or 72 hours.
202
From 24 to 72 hours there was no difference in the concentration of TNF-α (24 hours, 
189 ± 173 pg/ml; 72 hours, 175 ± 185 pg/ml; n = 8, Wilcoxon rank test, p = 0.641) but
there was an increase in the concentration of IL-10 (24 hours, 30 ± 13 pg/ml; 72 hours,
50 ± 33 pg/ml; n = 7, Wilcoxon rank test, p = 0.031). There was no difference between
control, aspirin and IPC for either TNF-α (24 hours, p = 0.814, n = 9; 72 hours, p =
0.398, n = 9; Friedman test) or IL-10 (24 hours, p = 0.654, n = 8; 72 hours, p = 0.430, n
= 6, Friedman test).
Figure 7.4 Effect of ischaemic preconditioning and aspirin on blister cytokine concentration. 20
subjects received six blisters, two each for control, aspirin, and IPC. Following aspiration, cells and
fluid were separated, and fluids stored at -80°C. At a later date, samples from 9 subjects were
analysed for TNF-α, and 8 subjects for IL-10, by ELISA. Results show the change in the control 
blisters from 24 to 72 hours, and the difference between control, aspirin and IPC at 24 and 72
hours. Box and whisker plots show median, interquartile range, minimum and maximum values.
Groups were compared by non-parametric tests. p < 0.05 was deemed statistically significant. IL-10
but not TNF-α was increased from 24 to 72 hours. No difference existed between control, aspirin 
and IPC at any time point. *, p < 0.05
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7.3.2. Early and delayed resolving inflammatory phenotype
Subjects were retrospectively divided into early (n = 8) and delayed (n = 10) resolvers
of inflammation, based upon whether they increased or decreased their total cell count
from 24 to 72 hours, as has been previously described (174). To confirm that this
phenotype is consistent, six subjects (early, n = 4; delayed n = 2) repeated the control
week, and results are shown in Table 7.1. All subjects who were early resolvers in the
control week were early resolvers in the repeat week. One of the two delayed resolvers
in the control week, switched to an early resolver phenotype in the repeat week (see E*
in Table 7.1). However a consistent delayed resolver phenotype was obtained when
results were expressed as cell concentration.
Table 7.1 Results for repeated early and delayed resolver phenotype. Six subjects (A to F) who had
completed the main study, repeated the control week to confirm their resolution phenotype at a
later date. A decrease from 24 to 72 hours is an early resolver (▼), an increase from 24 to 72 hours
is a delayed resolver (▲). Results are given as total cell count (cells) and cell concentration (cells /
ml).
control week repeat control week
subject 24 hours 72 hours delta 24 hours 72 hours delta
A
cells 446,000 165,000 ▼ 1,020,000 403,000 ▼ 
cells / ml 4,018,000 1,542,000 ▼ 3,505,000 2,305,000 ▼ 
B
cells 270,000 52,000 ▼ 1,483,000 146,000 ▼ 
cells / ml 1,849,000 494,000 ▼ 7,975,000 1,759,000 ▼ 
C
cells 217,000 120,000 ▼ 923,000 483,000 ▼ 
cells / ml 1,167,000 756,000 ▼ 4,295,000 1,236,000 ▼ 
D
cells 434,000 715,000 ▲ 203,000 1,010,000 ▲ 
cells / ml 2,874,000 3,505,000 ▲ 604,000 3,196,000 ▲ 
E*
cells 152,000 178,000 ▲ 366,000 108,000 ▼*
cells / ml 1,523,000 1,633,000 ▲ 2,377,000 2,626,000 ▲ 
F
cells 427,000 397,000 ▼ 2,255,000 317,000 ▼ 
cells / ml 2,481,000 1,632,000 ▼ 7,091,000 693,000 ▼ 
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Summarised results from the control week of blisters from 24 to 72 hours are shown in
Figure 7.5. Early resolvers had a decreased total cell count from 24 to 72 hours (24
hours, 364,000 ± 197,000 cells; 72 hours, 165,000 ± 196,000 cells; n = 8, Wilcoxon
rank test, p = 0.008). Delayed resolvers had an increased total cell count from 24 to 72
hours (24 hours, 160,000 ± 254,000 cells; 72 hours, 354,000 ± 421,000 cells; n = 10,
Wilcoxon rank test, p = 0.002). There was a significant difference between groups in the
change from 24 to 72 hours for total cell count, and the cell concentration (cells,
unpaired t test, p < 0.0001; cells / ml, unpaired t text, p < 0.001). Early resolvers had an
increased clearance of neutrophils from 24 to 72 hours compared to delayed resolvers
(early 24 to 72 hours, -38.2 ± 25.5%; delayed 24 to 72 hours, -11.8 ± 18.7%; unpaired t
test, p = 0.027).
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Figure 7.5 Early and delayed resolver phenotype in the 24 to 72 hour blister. 20 subjects received
six blisters, two each for control, aspirin, and IPC. Following aspiration, fluid volumes were
measured, and cells enumerated by haemocytometer. Control arm results allowed subjects to be
subdivided into early (n = 8) or delayed (n = 10) resolvers of inflammation, according to whether
they decreased (early) or increased (delayed) their total blister cell count from 24 to 72 hours. The
early and delayed resolution phenotype was reflected in the change in the proportion of neutrophils
from 24 to 72 hours. Results for total cell count, cell concentration, and neutrophil proportion are
shown as box and whisker plots, with the median, interquartile range, minimum, and maximum
values. *, p < 0.05; **, p < 0.01; ***, p < 0.001
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7.3.3. Aspirin, but not IPC, reduces leukocyte trafficking in the early
resolvers of inflammation
Early and delayed resolvers were assessed for their response to aspirin and IPC (Figure
7.6). Early resolvers had a significantly lower total cell count at 24 hours following
administration of aspirin compared to control (control, 364,000 ± 197,000 cells; aspirin,
286,000 ± 161,000 cells; n = 8, Wilcoxon pairs, p = 0.016). There was no difference
between control and aspirin in the delayed resolvers (control, 160,000 ± 254,000 cells;
aspirin, 167,000 ± 198,000 cells; n = 10, Wilcoxon pairs, p = 0.922).
There was no difference in leukocyte trafficking between control and IPC in either the
early (control, 364,000 ± 197,000 cells; IPC, 318,000 ± 456,000 cells; n = 8, Wilcoxon
pairs, p = 0.547) or delayed resolvers (control, 160,000 ± 254,000 cells; IPC, 276,500 ±
290,000 cells; n = 10, Wilcoxon pairs, p = 0.846).
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Figure 7.6 Effect of ischaemic preconditioning and aspirin on total cell trafficking in early and
delayed resolvers. 20 subjects received six blisters, two each for control, aspirin, and IPC.
Following aspiration, fluid volumes were measured, and cells enumerated by haemocytometer.
Subjects were subdivided into early (n = 8) and delayed (n = 10) resolvers of inflammation, and
then assessed for their response to aspirin and IPC. Results for total cell count are shown as box
and whisker plots, with the median, interquartile range, minimum, and maximum values. p < 0.05
was deemed statistically significant. Early resolvers had a reduced leukocyte trafficking with
aspirin compared to control at 24 hours. There was no difference in delayed resolvers, or with IPC
in either group. * , p < 0.05
The reduction in leukocyte trafficking by aspirin in the early resolvers was attributable
to the granulocyte population. In early resolvers aspirin administration was associated
with a reduction in neutrophils (control, 145,000 ± 120,000 cells; aspirin, 91,000 ±
120,000 cells; n = 8, Wilcoxon rank test, p = 0.109) and eosinophils (control, 40,000 ±
32,000 cells; aspirin, 18,000 ± 29,000 cells; n = 8, Wilcoxon rank test, p = 0.008). There
was no difference in delayed resolvers for neutrophils (control, 71,000 ± 99,000 cells;
aspirin, 75,000 ± 107,000 cells; n = 10, Wilcoxon rank test, p = 0.557) or eosinophils
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(control, 9,000 ± 27,000 cells; aspirin, 13,000 ± 29,000 cells; n = 10, Wilcoxon rank
test, p = 1.000).
Figure 7.7 Effect of ischaemic preconditioning and aspirin on granulocyte trafficking in early and
delayed resolvers. 20 subjects received six blisters, two each for control, aspirin, and IPC.
Following aspiration, cells were enumerated, stained with fluorescent antibodies, and analysed by
flow cytometry. Subjects were subdivided into early (n = 8) and delayed (n = 10) resolvers of
inflammation, and then assessed for their response to aspirin and IPC. Granulocyte results in
response to aspirin for the early and delayed resolvers are shown as box and whisker plots, with the
median, interquartile range, minimum, and maximum values. p < 0.05 was deemed statistically
significant. Granulocyte populations in the early resolvers were lower following aspirin and control
at 24 hours. There was no difference in the delayed resolvers. ** , p < 0.01.
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7.4. Discussion
7.4.1. Ischaemic preconditioning does not reduce leukocyte trafficking in
an in vivo skin blister model
Results from the study observed no difference in leukocyte trafficking between IPC and
control, irrespective of whether total cells or individual populations were investigated.
Two plausible reasons might explain this null effect: 1.) IPC does not reduce the IR-
induced innate immune response, 2.) model limitations prevented the detection of an
immune modifying effect. There are several arguments in support of each.
Firstly, as described, the evidence supporting a role for a reduced leukocyte trafficking
in IPC is primarily based upon evidence from animal in vivo studies (66,67) and human
in vitro experiments (15,70,72). Animal experiments have demonstrated that IPC
reduces leukocyte rolling, migration, expression of CD11b, selectins, and ICAM-1
expression (66–68). However, there are numerous examples of therapeutic interventions
that have shown protection against experimental IR in animals, but have failed to
transfer into clinically useful effects, including antioxidants (237), and erythropoietin
(238).
Shimizu et al. observed that following IPC stimulation, circulating neutrophils have a
decreased adhesion and an increased cytokine secretion in vitro (72). However these are
only two elements of the inflammatory pathway, and no differences were seen for
phagocytic activity, NADPH oxidase production, and apoptosis in neutrophils at 24
hours. Our group has previously observed that IPC abolishes the increase in neutrophil
CD11b expression following IR (15).
Unfortunately, it is not uncommon for in vitro observations to fail to materialise in
effects in vivo, and recently two studies did not observe an IPC-induced alteration in the
systemic inflammatory response to IR. Karuppasamy et al. randomised 54 patients to
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RIPC or sham prior to coronary artery bypass graft surgery (239). They observed no
difference in the post-surgical increase in circulating cytokines (including IL-6, IL-8,
monocyte chemotactic protein-1) between the groups. Furthermore Memtsoudis et al.
measured the increase in circulating inflammatory markers post-operatively following a
total knee arthroplasty (240). They observed no difference in IL-6, C-reactive protein,
TNF-α and white blood cell count between patients who received preconditioning prior 
to surgery, and matched controls.
If IPC does not dampen acute inflammation, this might be attributed to the role of
immunity in reperfusion injury itself. Section 1.2.2.2 described a substantial leukocyte
migration into reperfused tissue, and how leukocyte activity contributes to the
pathogenesis of reperfusion injury by enzymatic and ROS release within the interstitial
tissue. However, this theory is controversial, and the arguments for and against a role of
inflammation in the pathogenesis of reperfusion injury have been summarised by
Vinten-Johansen (36).
The argument against a role for inflammation is supported by a number of observations.
Firstly a substantial infarction can be obtained from isolated heart preparations
submitted to IR injury, despite reperfusion with a neutrophil-free buffer (241). In
addition the superoxide anion burst during reperfusion has been largely attributed to
NADPH oxidase activity by neutrophils in the tissue. However Kevin et al. observed
that this superoxide anion burst can still occur in isolated hearts supplied by a
neutrophil-free buffer (241).
Secondly a number of clinical trials have investigated whether anti-inflammatory
therapies can protect against IR injury. Baran et al. randomised 394 patients who
presented with ST-segment elevation consistent with acute myocardial infarction, to
either a monoclonal antibody for CD18 (part of the CD11b/CD18 glycoprotein complex
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on neutrophils) or placebo (242). No differences were observed between groups for any
clinically relevant outcome. If IR injury itself is not dependent on the innate immunity,
it is unlikely that IPC activates an anti-inflammatory pathway. However, as has been
described, the pathogenesis of IR is complex, and the exact role of inflammation in IR
may depend on the site and type of injury, and may vary between species.
Despite these arguments, section 1.3.1.4 described strong evidence supporting an anti-
inflammatory role for IPC. An alternative hypothesis for the null effect is that inherent
limitations of the experimental technique prevented the detection of an anti-
inflammatory effect, such as 1.) powering of the study, 2.) differences in inflammatory
phenotype, 3.) windows of preconditioning activity.
The sample size in this study was powered to detect at least a 50% reduction in
leukocyte trafficking at 24 hours. It was anticipated that this would be sufficient to
detect a clinically relevant anti-inflammatory effect. However, the mechanism of IPC is
multifactorial, believed to include a reduction in necrotic and apoptotic cell death, an
improved glucose uptake, and a reduced Ca2+ overload (see Figure 1.3). Given this, the
mechanistic component of modulating the inflammatory response could be small, and as
such the study might be underpowered to detect an effect.
Another factor is the fundamental differences in the vascular beds between this study
and experiments to date. In vivo experiments by Szabo et al. and Erling et al. reported a
reduction in leukocyte migration in periosteal and mesenteric post-capillary venules
respectively (66,67). Leukocyte trafficking into the blister primarily occurs from the
vasculature supplying the dermis of the skin, and it is plausible that differences exist
between endothelial cells in the dermis, and the periosteum or mesentery. In particular,
the blood flow to these tissues is likely to be significantly greater than the skin.
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In addition this study has assumed that the innate immune response in the blister is
similar to that occurring during IR. It is likely that the balance of cytokines,
chemokines, complement, lipid mediators and ROS which are known to activate the
immune response, may vary between IR and in response to cantharidin. This may also
be attributable to differences in local tissue metabolic requirements, given that cells in
the dermis and epidermis, including keratinocytes, melanocytes, fibroblasts and
adipocytes, have a low metabolic requirement when compared to cardiomyocytes and
neurons.
IPC exerts its protective effects in an initial window lasting 1-2 hours, and a second
window, present from 12 hours and lasting to 72 hours (55). This study has
characterised skin blisters which were aspirated at 24 and 72 hours, consistent with the
second window of protection. These time points were chosen because they match with
previous studies in this field (181), and aspirating prior to 24 hours is limited by the
requirement of several hours for the blister itself to form. The timing of blister
aspiration is in contrast with the in vitro human leukocyte studies, whereby circulating
neutrophils were isolated within an hour of IPC application, therefore in the first
window of protection (15,72). It is plausible that the anti-inflammatory property of IPC
occurs in the early, but not the second window of protection.
Several reasons have been speculated that might account for the null effect of this study.
Further research aims to investigate whether RIPC reduces circulating inflammatory
mediators in a clinical trial of live-donor kidney transplant, which is currently being
carried out by our research group.
7.4.1. Aspirin, and the resolution phenotype in humans
In contrast to previous studies, my results did not show a substantial reduction in
leukocyte trafficking following administration of high-dose aspirin. This result was
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surprising; Morris et al. noted a 70% reduction in total leukocyte trafficking with aspirin
at a similar dose (181). One reason for this could be methodological differences in the
assessment of leukocyte trafficking. Morris et al. observed a substantially larger
leukocyte infiltration at 24 hour control blisters in comparison to my study (W Jenner,
total cell count = 270,000 ± 271,000 cells [median ± interquartile range]; T Morris, total
cell count ≈ 700,000 ± 150,000 [mean ± standard error]). This difference could be
attributable to aspects of the experimental set up, including size of paper, film and
dressing. A more substantial inflammatory response may be is required to observe a
robust anti-inflammatory effect of aspirin.
Our group has previously shown that those with a heightened early immune activity
(early resolvers), exhibit a robust response to administration of aspirin (174). Those
with a more tempered profile (delayed resolvers) are refractory to aspirin. This response
is reflected in differences in blister IL-1β and 15-epi-lipoxin concentration, and by 
neutrophil clearance. Subjects in my study were also subdivided according to early and
delayed resolver phenotype. Early resolvers had a greater reduction in total leukocyte
trafficking from 24 to 72 hours, and this was reflected in an increase in neutrophil
clearance. Furthermore the early resolvers were responsive to aspirin administration at
24 hours, unlike the delayed resolvers, consistent with previous observations (174).
Neither the early nor delayed resolvers exhibited an anti-inflammatory response to IPC.
7.4.2. Study limitations
The study population was a homogenous group of young males, and results may not be
reflected in female or older subjects. This study has investigated TNF-α and IL-10 
concentration, but further experiments are required to assess whether other mediators,
such as IL-6, IL-8 and interferon-γ are altered between the groups, and whether the 
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differences in early and delayed resolvers are matched by a modulation of their cytokine
profile.
7.5. Conclusion
To summarise, this study has, for the first time in humans, observed that IPC does not
influence the human innate immune response to an in vivo skin blister model. As
previously described, aspirin reduces leukocyte trafficking in subjects with the early,
but not delayed resolver phenotype. Further experiments aim to investigate alternative
mechanistic properties of IPC.
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8. THE EFFECT OF ISCHAEMIC
PRECONDITIONING ON INCREMENTAL
EXERCISE IN HUMANS
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8.1. Introduction
Improving exercise performance is of vital importance to elite athletes, coaches and
sponsors across the world. Months, even years of training are required to improve
competitive performance, often by a small margin. In the 21st century sport scientists
regularly investigate novel interventions which can aid training and performance in
competition. Recent studies have included nitrate (186), bicarbonate (187), polyphenols,
(243) and ischaemic preconditioning (IPC) (126), to the list of methods able to acutely
influence exercise performance.
Several studies have shown that IPC improves sporting performance (see section 1.3.5.).
Groot et al. observed that 3 IPC cycles of 5 minutes ischaemia and 5 minutes
reperfusion cycles applied to each leg, improves intense exercise tolerance, resulting in
an increased maximal power output of 1.6% and an increased maximal oxygen delivery
(ܸ̇O2 max) of 3% (126). IPC may also increase the time to exhaustion and maximal heart
rate during a standardised cycling test (127). Another study has suggested that IPC can
improve swimming performance over 100 m by 1% (128).
High-flow ischaemia and the subsequent resaturation known to occur during high-
intensity exercise have been suggested as a model for low-flow ischaemia-reperfusion
(IR) following arterial occlusion (see section 1.2.1.2). The mechanisms attributable to
the improvement in exercise performance by IPC have been hypothesised, but this area
of research remains in its infancy. Establishing the mechanisms by which IPC
influences exercise could implicate the pathways conferred by IPC against IR injury in
humans.
Based upon the evidence in chapter 5 that IPC protects the endothelium from IR injury,
and published data showing that IPC can alter skeletal muscle function (244), the
current study was designed to investigate whether IPC alters a number of physiological
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parameters associated with incremental exercise. These principally included
measurements of cardiorespiratory fitness, metabolic function and blood gases during
exercise and recovery. In addition to the above skeletal muscle oxygenation was
measured by near-infrared spectroscopy (NIRS) throughout. This study aimed to
provide a mechanistic insight into the effects of IPC on incremental exercise, in addition
to complementing results from other studies (126,127).
In summary, a randomised crossover study was designed to investigate the effects of
local IPC on exercise physiology using an incremental cycling test.
8.2. Methods
8.2.1. Study participants
Twenty-one healthy male amateur club cyclists and triathletes were recruited for this
study. The sample size was calculated using the expected change in ܸ̇O2 max (126), and
the standard deviation of ܸ̇O2 max from preliminary data in our laboratory. Well-trained
subjects were recruited due to their low thigh skinfold thicknesses to improve accuracy
of NIRS measurement (see 2.4.5.3), and aid the applicability to elite athletes. Subject
characteristics are described in Table 8.1.
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Table 8.1 Exercise testing subject characteristics. Results are reported for 21 healthy male subject
characteristics during the familiarisation study. Results are given as mean ± SD.
subject characteristics mean ± SD
age (years) 35.0 ± 6.1
height (cm) 180.0 ± 6.5
weight (kg) 75.4 ± 7.7
body mass index (kg/m2) 23.3 ± 2.3
resting systolic blood pressure (mmHg) 134 ± 12
resting diastolic blood pressure (mmHg) 80 ± 8
resting heart rate (bpm) 60 ± 7
sum of 7 skinfolds (mm) 75.4 ± 32.7
front thigh skinfold (mm) 13.7 ± 6.3
body fat (%) 13.3 ± 7.6
ܸ̇O2 max (ml/min/kg) 64.0 ± 9.0
8.2.2. Experimental set up and subject preparation
All experimental procedures were performed as described in detail in section 2.4.
Subjects were prepared as outlined in section 2.4.2.
8.2.3. Experimental protocol
A schematic of the testing protocol is given in Figure 8.1. Subjects attended the
laboratory in the British Olympic Medical Institute on three occasions. The first visit
was a familiarisation study. The remaining two visits were experimental studies, either
“preconditioning” or “sham” and performed in a random order. Subjects were not
informed of the rationale behind the differences between the preconditioning and sham
visits until the end of all testing.
8.2.3.1. Familiarisation study
Subjects were briefed and consented for the study. This was followed by baseline
measurements of height, weight and blood pressure, and followed by baseline venous
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and capillary blood samples. Blood samples were assessed for blood gases (pO2, pCO2,
HCO3-), pH, lactate, electrolytes (Na+, K+, Ca2+) and haemoglobin.
Subjects then rested in a supine position, the NIRS probe was applied to the thigh and
the pressure required to occlude the femoral artery was obtained. Participants then
performed an incremental exercise test on a cycle ergometer until physical exhaustion
(see protocol in Figure 2.15). The exercise test started with 4 minutes of submaximal
cycling at a power output of 150W at a constant, self-selected cadence (80-100 rpm).
This was followed by cycling against an increasing resistance of 50 W/min increments
until volitional exhaustion (TMAX), as judged by an inability to maintain a cadence
within 5 rpm of selected cadence despite encouragement. Oxygen delivery (ܸ̇O2), carbon
dioxide elimination (ܸ̇CO2), ventilation (VE), heart rate (HR), perceived exertion (RPE),
power output (WR) and skeletal muscle oxygenation (StO2) were measured
continuously throughout the test.
Following TMAX subjects stopped pedalling but remained stationary on the bike. A
capillary sample was immediately taken to measure gases, lactate, and electrolytes.
After 2 minutes subjects moved to lie supine on a couch. During recovery sequential
measurements were made of blood pressure (at 1, 4, 10, 15, 20, 25 and 30 minutes post-
TMAX) and lactate (at 3, 4.5, 15 and 30 minutes post-TMAX). In addition a venous blood
sample was taken at 5 minutes of recovery to assess haemoglobin and haematocrit.
Heart rate and respiratory measurements were continually measured for 30 minutes of
recovery.
8.2.3.2. Experimental study
Subjects underwent baseline measurements and blood sampling. The NIRS probe was
attached over the vastus lateralis, and cuffs were applied to the upper thigh of both legs.
Cuffs were inflated 3 cycles of 5 minutes occlusion and recovery, with inflations
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alternating between legs. Inflation pressures were suprasystolic for IPC (20 mmHg
above occlusion pressure in the familiarisation study) and subdiastolic for sham study
(20 mmHg below resting diastolic pressure) (see 2.4.4.2). Capillary and venous blood
samples were taken immediately following cuff inflations and measured for lactate and
haemoglobin. Subjects then performed the exercise test and subsequent recovery as
described in the familiarisation study.
Figure 8.1 Schematic for experimental study. After one hour of laboratory set up, subjects attended
the laboratory and underwent baseline measurements. This was followed by cuff inflation on the
thigh: 3 cycles of 5 minutes occlusion followed by five minutes reperfusion, alternating legs. Cuff
inflation was to a suprasystolic pressure for IPC, or a subdiastolic pressure for sham. This was
followed by an incremental exercise protocol (see Figure 2.15), and subsequent recovery.
8.2.4. Statistical analysis
Submaximal results were calculated as the mean value attained over the final minute of
pedalling at 150W (TSUBMAX). HR max was calculated as the mean HR in the final 20
seconds prior to TMAX. ܸ̇O2 max, ܸ̇CO2 max and ܸ̇E max were estimated by extrapolation from
submaximal values. StO2 and THI are expressed as percentage change from baseline,
and were measured prior to and at the end of each cuff inflation, immediately before
221
starting exercise, at 10% increments (deciles) between TSUBMAX and TMAX, and at 0.5, 1
and 5 minutes of recovery. Differences between the IPC and sham trials at specific time
points were assessed using paired t tests. Differences in StO2, blood pressure and lactate
during cuff inflations, exercise testing and recovery were assessed using 2-way
ANOVA, accounting for time and treatment.
Complete data sets were achieved in all subjects for time to exhaustion (TTE), WR max
and StO2/THI. A high percentage of data points were complete for the other variables:
heart rate (60/63, 95.2%), iSTAT (109/126, 86.5%), lactates (454/483, 94.0%), blood
pressures (488/504, 96.8%), and haemoglobin (161/168, 95.8%). In cases of missing
data, multiple imputations were applied as others have used (245), according to the
multiple imputation function in SPSS (IBM SPSS® statistics version 20, IBM, USA).
Data were assumed missing at random, and 5 imputations were applied to all data, with
pooled results used for subsequent statistics. p < 0.05 was deemed statistically
significant.
8.3. Results
Participants completed all exercise protocols with no adverse events. First are described
the changes in StO2 during IPC and sham cuff inflations, and during exercise. Secondly
full physiological results are reported for TSUBMAX and TMAX, and finally for
measurements observed during recovery.
8.3.1. Skeletal muscle oxygenation is decreased during the ischaemic
preconditioning protocol
Cuff inflations caused a reduction in StO2, and reductions were more profound during
IPC than sham cuff inflations (IPC, 55 ± 10%; sham, 79 ± 5%; n = 21, two-way
ANOVA, p < 0.0001; Figure 8.2A). IPC reduced THI, whereas THI was increased by
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sham cuff inflations (IPC, 93 ± 29%; sham, 122 ± 15%, two-way ANOVA, p = 0.002;
Figure 8.2B). Lactate assessed at the end of the three cuff inflation cycles was increased
following IPC compared to sham (IPC, 1.4 ± 0.6 mmol/l; sham 1.0 ± 0.4 mmol/l; n =
21, paired t test, p = 0.014, Figure 8.2C).
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Figure 8.2 Effect of ischaemic preconditioning on skeletal muscle oxygenation and circulating
lactate during cuff inflations. 21 healthy male subjects attended the laboratory on three occasions.
On the IPC and sham visits, subjects received intermittent cuff inflations to either suprasystolic or
subdiastolic pressures respectively. IPC caused a greater reduction in oxygenation than sham (A).
IPC caused a small reduction in THI, whereas sham inflations caused an increase in THI (B). IPC
increased circulating lactate concentration (C). Red lines/bar show IPC, blue lines/bar show sham
results. StO2 and THI were calculated as the percentage change from baseline (%). Results are
presented as mean ± SD. * , p < 0.05.
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8.3.2. Ischaemic preconditioning improves skeletal muscle oxygenation
during exercise
IPC had no overall effect on StO2 (n = 21, two way ANOVA, p = 0.44, Figure 8.3A).
However, closer examination of specific time points observed that IPC improved
exercise during the submaximal, aerobic phase of exercise and during the immediate
recovery. At the 1st decile (10%) between TSUBMAX and TMAX, StO2 was greater in the
IPC group than the sham group (IPC, 89 ± 8%; sham 84 ± 9%; n = 21, paired t test, p =
0.034, Figure 8.3B). There was no difference at TMAX (IPC, 51 ± 15%; sham, 51 ± 13%;
n = 21, paired t test, p = 0.923, Figure 8.3C). IPC improved reoxygenation during the
initial 30 seconds of recovery with subjects at rest (IPC, 90 ± 14%; sham, 84 ± 12%; n =
21, paired t test, p = 0.013, Figure 8.3D).
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Figure 8.3 Effect of ischaemic preconditioning on skeletal muscle oxygenation during exercise. 21
healthy male subjects attended the laboratory on three occasions. On the IPC and sham visits,
subjects received intermittent cuff inflations to a suprasystolic or subdiastolic pressure respectively.
Following cuff inflations subjects performed an incremental exercise test to physical exhaustion,
with StO2 recorded throughout. IPC tended towards preserving StO2 during exercise and recovery
(A). A difference was evident during the early aerobic phase of exercise (B), but no difference
existed at maximal exercise (C). IPC improved reoxygenation during recovery (D). Graphs show
mean and SD. * , p < 0.05.
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8.3.3. Ischaemic preconditioning has no effect on cardiorespiratory factors
and perceived exertion during submaximal exercise
There were no differences in cardiorespiratory parameters between IPC and sham for at
TSUBMAX (n = 21, paired t test, p > 0.05, Figure 8.4).
Figure 8.4 Effect of ischaemic preconditioning on respiratory parameters during submaximal
exercise. 21 healthy male subjects attended the laboratory on three occasions. Following cuff
inflations subjects performed an incremental exercise test to physical exhaustion, with respiratory
parameters measured throughout. Table summarises results calculated at Tsubmax. Bars show the
mean and SD from the familiarisation (white), IPC (red) and sham (blue) studies. There was no
difference between IPC and sham for ࢂ̇O2 (A), ࢂ̇CO2 (B), ࢂ̇E (C), HR (D), lactate, and RPE (E).
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8.3.4. Ischaemic preconditioning has no effect on cardiorespiratory
factors, perceived exertion or blood gases during maximal exercise
There were no differences in cardiorespiratory parameters or blood gases between IPC
and sham at TMAX (n = 21, paired t test, p > 0.05, Figure 8.5, Table 8.2).
Figure 8.5 Effect of ischaemic preconditioning on physiological parameters at maximal exercise. 21
healthy male subjects attended the laboratory on three occasions. Following cuff inflations, subjects
performed an incremental exercise test to physical exhaustion, with respiratory parameters
measured throughout. Table summarises results calculated at TMAX. Bars show the mean and SD
from the familiarisation (white), IPC (red) and sham (blue) studies. There were no differences
between IPC and sham for ࢂ̇O2 (A), ࢂ̇CO2 (B), ࢂ̇E (C), HR (D), lactate, StO2, RPE (E) and TTE (F).
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Table 8.2 Effect of ischaemic preconditioning on blood gas and electrolytes during incremental exercise. 21 healthy male subjects attended the laboratory on three
occasions. Following cuff inflations subjects performed an incremental exercise test to physical exhaustion, with respiratory parameters measured throughout.
Table summarises results from capillary and venous blood samples taken at baseline and immediately following peak exercise. Exercise alone caused a decrease in
pH, HCO3-, BE, TCO2, SO2, and an increase in pO2, Na+, K+, Ca2+, haemoglobin, haematocrit and lactate. There were no observed differences between IPC and
sham. p > 0.05, n = 21.
229
8.3.5. Ischaemic preconditioning has no effect on lactate and blood
pressure recovery following an incremental exercise test
Lactate and blood pressure were transiently increased during exercise and recovery, but
there were no differences between IPC and sham (lactate, n = 21, two-way ANOVA, p
= 0.924; systolic blood pressure, n = 21, two-way ANOVA, p = 0.504; diastolic blood
pressure, n = 21, two-way ANOVA, p = 0.658; Figure 8.6).
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Figure 8.6 Lactate and blood pressure during recovery. 21 healthy male subjects attended the
laboratory on three occasions. Following cuff inflations subjects performed an incremental exercise
test to physical exhaustion, followed by recovery. Graphs summarise results for 30 minutes of
recovery. Exercise caused an increase in lactate (A) systolic blood pressure (B) and diastolic blood
pressure (C). There were no differences between IPC (red) and sham (blue). Lines represent group
mean ± SD.
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8.4. Discussion
8.4.1. Ischaemic preconditioning improves skeletal muscle oxygenation
during aerobic exercise and resaturation
A substantial deoxygenation occurred during IPC (45%) as observed by NIRS,
consistent with results made during arterial occlusion by others (198). Subdiastolic cuff
inflation caused a small reduction in StO2 (21%) and an increase in haemoglobin (22%),
attributed to blood pooling within the interstitium, second to venous but not arterial
occlusion (199). IPC improved skeletal muscle oxygenation by 6% during early aerobic
exercise, but there was no difference at maximal exercise. This is a post hoc
observation and requires demonstration in a validation cohort.
The reason for improved oxygenation during aerobic exercise is uncertain. In one of the
seminal IPC papers, Murry et al. observed that IPC reduced cardiomyocyte ATP
utilisation during early ischaemia, but differences were lost as ischaemia was prolonged,
suggesting that IPC lowers ATP demand during early ischaemia (54). A similar effect
has been identified in humans: an in vitro study suggested that aerobic metabolism of
human skeletal muscle was improved by simulated IPC (246). These results suggest that
IPC alters myocyte function at a molecular level to improve efficiency, and hence
reduces requirement for oxygen extraction from capillaries. It is unlikely that IPC has
any effect on anaerobic metabolism during exercise given that no difference in lactate
production was observed in the current study, and others have reported that IPC has no
effect on performance in an anaerobic exercise test (127).
IPC is now believed to be more closely associated with treating reperfusion over
ischaemic injury (section 1.3.1). Indeed the current study showed an improved post-
exercise tissue resaturation of 7% by IPC, consistent with results observed in animal
studies (122). Saito et al. observed that IR injury induced by clamping of the abdominal
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aorta and iliac artery in rats, impaired subsequent oxygen uptake within the
musculature, assessed by an increase in half-resaturation time following stimulation
gastrocnemius (122). IPC applied prior to IR injury prevented this impairment,
suggesting that IPC improves the oxygen delivery pathway during reperfusion. Another
study has shown by functional MRI that post-ischaemic phosphocreatine is increased by
IPC in humans (124).
The mechanism of improved oxygenation resaturation can be attributed to either a
reduced cellular oxygen uptake, or an improved oxygen delivery. Firstly, IPC is known
to reduce the reperfusion-induced cellular reactive oxygen species (56), and if this is
due to limiting oxidative phosphorylation, it is possible this may feedback to a reduced
oxygen uptake, and subsequent increase in interstitial oxygen saturation. Further work is
required on isolated human skeletal myocytes to investigate their response to
reperfusion following IPC.
Alternatively the improved resaturation may be attributable to an increase in delivery.
My results did not identify an increase in systemic oxygen delivery during submaximal
or maximal exercise, however if IPC induced vasodilatation within the muscle
vasculature this could increase blood flow. Increased flow will improve muscle oxygen
saturation, given that resaturation time is positively correlated with the severity of
arterial occlusion in patients with peripheral arterial disease (247). However the results
in chapter 5, in conjunction with previous work (15), have shown that IPC improves
endothelial response to IR in a manner that is independent of changes in vessel
diameter. Further work is required to confirm this is the case during exercise.
The increase in reoxygenation due to IPC might be reflected in an improved post-
ischaemic muscular function. Mattei et al. took groups of rats and either exposed them
to 2.5 hours of hindlimb ischaemia, or ischaemia that was preceded by IPC (244). IPC
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improved post-ischaemic function of both fast and slow-twitch muscle fibres. To
investigate this in humans, specific testing can be performed to investigate changes in
muscular force following limb IPC and IR.
8.4.2. Ischaemic preconditioning does not alter systemic physiological
measures of performance
In the current study IPC had no effect on systemic cardiorespiratory outcomes, power
output, or time to exhaustion. There were no differences between IPC and sham for ܸ̇O2,
ܸ̇CO2, ܸ̇E, RPE and HR during submaximal exercise, consistent with two previous studies
(126,129). This suggests that despite an increased oxygenation, this did not reflect in a
systemic improvement in metabolic efficiency. There were also no differences between
IPC and sham at maximal exercise, in contrast with two previous studies (126,127).
Groot et al. observed an increase in ܸ̇O2 max and WR max (126), and Crisafulli et al.
observed an increase in WR max, HR max and TTE (≈ 6%) (127). However in a similar 
study, Clevidence et al. recently did not observe an improvement in any physiological
outcomes following IPC, other than a small change in submaximal heart rate (129).
There are several reasons which may account for differences. Firstly, whilst the current
study was matched closely with Groot et al., some methodological difference did exist.
The ramp protocol of my study was steeper (50 W/min) than the three other studies (20-
30 W/min). Varying durations at which subjects were metabolising aerobically or
anaerobically might alter the potential benefit from IPC, and as such it is possible that
these differences did exist but were hidden by protocol design. Secondly, population
differences may explain response to IPC. The current experiment consisted of well-
trained, male subjects, unlike the mixed-sex population studied by Groot et al, and the
physically active, but not trained population by Crisafulli et al. Finally it is possible that
differences at maximal exercise may be attributable to subjective factors. As described
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previously, maximal performance is dependent on both physical and mental attributes,
and communication between athletes and investigators regarding the testing and the
intervention might cause subjective bias. The aim in our investigation was to avoid bias
by randomising between sham and IPC cuff inflations, and maintaining blinding by not
discussing the rationale between high and low pressures until all visits were completed.
8.4.3. Study limitations
The results in this study might be attributable to IPC increasing muscle blood flow
during exercise, however this could not be detected in the current protocol design. Proof
of this requires additional investigations of flow such as by plethysmography. In
addition, NIRS as a technique has several limitations. It is likely that there is some
contribution to the signal by adipose tissue. However adipose tissue has a low blood
flow in comparison to skeletal muscle, and the desaturations during brief cuff inflations
closely match results from the thenar eminence (198). Furthermore the well-trained
study population had low a skinfold thickness compared to a sample from the general
population (75 ± 33 vs 123 ± 52 respectively; mean ± SD) (190), resulting in a
haemoglobin index that was within the acceptable range, and consistent with muscle
and not adipose tissue recordings. A general limitation of NIRS is the contribution to
the results by myoglobin and cytochrome C, which requires further investigation to
assess the contribution during exercise.
Despite an improvement in oxygenation, this was not reflected in an improvement in
power output. Specific testing is required to identify whether IPC improves oxygen
delivery or muscle efficiency and must be done using protocols that maintain blinding,
to offset the effect of assessment bias on subjective outcomes. This could be achieved
by greater analysis of ܸ̇O2 kinetics at a variety of exercise intensities, or by performing
muscle biopsies to investigate myocytes function and mitochondrial activity. Whilst an
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incremental exercise test is useful in detecting respiratory thresholds, ventilatory
efficiency and ܸ̇O2 max, there is only limited benefit in detecting exercise performance.
Performance in specific exercise tasks is related to numerous factors, and whilst aerobic
fitness is important, this does not account for techniques required to succeed in sport.
Specific performance directed tests, such as time trials, may be required to further
understand underlying processes and potential benefits of IPC. Furthermore, the study
investigated a homogeneous population of young, trained males, and is it unknown
whether the same effects would be observed in a group of elite athletes, in women, or of
younger or older subjects. The exact IPC protocol necessary to induce an effect is also
uncertain, and a dose-response study is required.
8.4.4. Application to clinical science and elite sport
The increase in oxygenation during exercise and recovery observed in the current study
suggests that IPC modifies oxygenation during IR injury. Further studies are required to
investigate whether local IPC improves oxygenation during experimental IR injury
using the vascular model characterised in chapter 4. In addition it is important to assess
whether this phenotype is observed in postconditioning and in remote ischaemic
preconditioning. Further studies using the current model could assess this.
These results could be of value in elite sport. Jacobs et al. performed a detailed
examination of physiological factors that contribute to time-trial performance in a group
of highly-trained cyclists (248). They observed that two of the factors most closely
associated with sustained power output during a cycling time trial included oxidative
phosphorylation capacity of the vastus lateralis, and maximal leg oxygenation. Given
this, an increase in oxygenation may improve sustained power output, despite being
unable to improve TTE in the current incremental exercise study. Given that marginal
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increases in performance can be the difference between success and failure in elite
sport, an investigation of the effect of IPC on time trial performance may be of value.
However, ischaemic cuff inflations as a method to improve performance should be
viewed with skepticism at present. Association between StO2 and power output may not
mean that they are causal, and current results did not show an improvement in maximal
power output during incremental exercise. Prospective studies are required to
investigate whether muscle oxygenation is reflected in performance over varying
exercise intensities. Furthermore, no evidence exists reporting the safety of repeated
high pressure cuff inflations for athletes. Given the volume of muscle bulk being
compressed at high pressure it is possible that tourniquet-induced neuromuscular
damage could occur, and as with any intervention, rigorous safety checks are required.
8.5. Conclusion
This study is the first to show that IPC might increase skeletal muscle oxygenation
during aerobic exercise and recovery but without a measureable increase in performance
and in contradiction with some of the published literature. Further work is needed to
understand the effects, if any, of IPC on exercise performance and the associated
underlying mechanisms.
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9. SUMMARY OF FINDINGS
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This thesis has described four in vivo models of ischaemia-reperfusion, which facilitated
investigations of the protective ischaemic preconditioning phenomenon. I first
investigated the effect of RIPC on cerebral IR using a transient rodent stroke model.
Secondly I characterised a human endothelial IR injury model, and investigated the
protective effect of IPC, RIPC and ExPC upon this. Thirdly I characterised a human
inflammatory blister model, and investigated the anti-inflammatory properties of IPC.
Finally I investigated the effect of IPC on muscle oxygenation and metabolism during
an incremental exercise test.
9.1. Remote ischaemic preconditioning as a treatment for
cerebral ischaemia-reperfusion injury
Chapter 3 investigated rodent cerebral IR injury. Manipulation of the surgical and
analysis techniques allowed for the definition of a robust, transient middle cerebral
artery occlusion model. In this model RIPC reduced infarct size, but only when using
inhaled anaesthesia. It was thus hypothesised that injectable anaesthesia inhibited RIPC,
the mechanism of which has been speculated.
Evidence of neuroprotection by RIPC from the experimental results in this thesis
complement findings in the literature (73,90), and suggest that RIPC could offer a
therapeutic potential against human stroke. Recently Jensen et al. furthered this
evidence by showing that RIPC can induce neuroprotection using a porcine model
(249). Given that this phenomenon exists in two mammalian species, it is plausible that
RIPC can protect the human brain from IR. Substantial interest in this has developed,
and recently a phase I clinical trial reported acceptable safety of RIPC in subarachnoid
haemorrhage, which indicates that larger trials will be undertaken to assess efficacy
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(250). Further studies in this thesis aimed to investigate the efficacy of RIPC in a human
IR injury model.
9.2. Ischaemic preconditioning as a treatment for IR injury in
humans
Human in vivo models are often used as a bridge between animal studies and clinical
trials, to validate efficacy and safety of novel therapies. Chapter 4 characterised an IR
injury model, which our group has used for a number of years. Results demonstrated
that L-FMC correlates with FMD, baseline diameter and the reduction in flow. This
suggests that L-FMC might be an additional component of vascular function,
complementing the work of others (154). Consistent with previous work, IR injury
reduced flow mediated dilatation (FMD), and the novel finding was made that IR
increases low-flow mediated constriction (L-FMC). Further experiments are required to
reveal whether L-FMC is dependent on the endothelium, and how it could complement
interventional or epidemiological studies.
In chapter 5 this model was then used to investigate IPC, RIPC and ExPC on human IR
injury. RIPC did not protect the endothelium from IR injury, contradicting findings
from previous studies (79,111). This inconsistency cannot be explained by results in this
thesis alone, but raises questions as to the robustness of RIPC as a protective phenotype
in humans. Whether or not RIPC attenuated IR injury in humans will depend on
forthcoming results from randomised phase III clinical trials that are adequately
powered to detect a clinically relevant effect (251).
In contrast to RIPC, IPC conferred protection in the brachial artery, yet this was not
complemented by observations in the radial artery. This was attributed to variation in
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the control of endothelial function between the two vessels. Additional chapters in this
thesis explored mechanism of IPC using alternative in vivo models.
9.3. Ischaemic preconditioning and inflammation
Experimental data has speculated an anti-inflammatory role for IPC. Chapters 6 & 7
reported a study aimed at determining whether IPC can reduce leukocyte trafficking
using an in vivo skin blister model. Chapter 6 characterised the blister model, and
observed that from 24 to 72 hours there was a clearance of granulocytes, and an increase
in three types of leukocyte that resembled myeloid-derived suppressor cells.
Furthermore receptor expression indicated an increase in cell activation, and the
possible adoption of a B cell phenotype by myeloid cells. These novel findings, in
combination with previous work by our group (174), have also identified two resolution
phenotypes in humans. Further work in this area aims to explore the function of myeloid
derived suppressor cells within the 72 hour blister, and in particular whether they show
specific suppressive features that contribute to the resolution of inflammation.
In chapter 7 this model was used to investigate the effects of aspirin and IPC on
inflammation. Aspirin attenuated the inflammatory response, but only in subjects with
an early resolver phenotype. There were no differences between control and IPC for
leukocyte trafficking, or for cytokine release in the collective group or in each group of
resolvers. The reported effects of IPC on leukocytes in vitro, were not replicated by
observations in vivo (15,72), and therefore it is unlikely that IPC modulates the
inflammatory response during IR. Further work aims to investigate whether IPC reduces
systemic mediators of inflammation during human IR injury, and to explore the humoral
and neural pathways of preconditioning in more depth.
241
9.4. Ischaemic preconditioning and muscle oxygenation during
exercise
Chapter 8 investigated whether IPC can be used to alter skeletal muscle oxygenation
and subsequent exercise performance in humans. This was achieved in a randomised
cross-over trial, using an incremental exhaustive cycling test to investigate the effect of
IPC on muscle oxygenation, the cardiorespiratory, and metabolic response. Results
showed that muscle oxygen saturation was improved during aerobic low-intensity
exercise and during recovery. This was however, not reflected in a modulation of other
factors, either during submaximal or maximal exercise. However, given the
discrepancies evident in the literature, this observation is unsurprising (126–129).
Further studies are required to understand how IPC influences oxygen delivery or
utilisation in humans, and whether this is also the case during IR injury. It has been
reported that muscle oxygenation is correlated with power output in a cycling time trial
(248). Thus an IPC-induced increase in skeletal muscle oxygenation might improve a
steady state power output. Further studies are required to investigate whether this exists
by performing specific exercise tests that are more reflective on performance than an
incremental test, such as a time trial.
9.5. Conclusion
This thesis has made novel investigations into the properties of ischaemic
preconditioning in rodents and humans. It suggests that local, but not remote ischaemic
preconditioning might offer potential therapy for the treatment of human ischaemia-
reperfusion injury. The mechanism of ischaemic preconditioning in humans appears
unlikely to be due to the inflammatory response, but may relate to modifications in
oxygen supply and utilisation.
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10. APPENDIX
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10.1. Gating strategy for lymphocytes in venous blood.
Figure 10.1 Lymphocyte gating strategy and fluorescence-minus-one controls for venous
leukocytes. Firstly single cells were isolated by the forward scatter / side scatter, and then an area /
height plot. Secondly T and B lymphocytes were isolated as CD3hi and CD19hi respectively, and
then NK cells as CD56hi. Remaining cells were separated into HLA-DRhi, or HLA-DRlo CD16hi/dim.
The remainder, mainly erythrocytes and debris were excluded.
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10.2. Gating strategy for non-lymphocytes and natural killer cells in venous blood.
Figure 10.2 Non-lymphocyte and natural killer cell gating strategy and fluorescence-minus-one
controls for venous leukocytes. Continuation from Figure 10.1. CD56hi NK cells were differentiated
into CD16hi and CD16lo cells (A). HLA-DRlo CD16hi/dim cells were then differentiated into MDSCs
(CD16dim) and granulocytes (CD16hi CD14lo) (B). MDSCs were differentiated as FSClo CD14hi and
CD14lo/dim. Granulocytes, were separated into neutrophils (FSCmid SSCmid) and eosinophils (FSChi
SSChi). HLA-DRhi cells were differentiated into monocytes (FSClo/mid SSClo) and macrophages
(remainder) and then by expression of CD14 and CD16 (C).
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10.3. Gating strategy for lymphocytes in 24 hr blisters.
Figure 10.3 Lymphocyte gating strategy and fluorescence-minus-one controls for 24 hour blister
leukocytes. Firstly single cells were isolated by the forward scatter / side scatter, and then an area /
height plot. Secondly T and B lymphocytes were isolated as CD3hi and CD19hi respectively, and
then NK cells as CD56hi. Remaining cells were separated as HLA-DRhi, or HLA-DRlo CD16hi/dim.
The remainder, mainly erythrocytes and debris were excluded.
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10.4. Gating strategy for non-lymphocytes and natural killer cells in 24 hr blisters.
Figure 10.4 Non-lymphocyte and natural killer cell gating strategy and fluorescence-minus-one
controls for 24 hour blister leukocytes. Continuation from Figure 10.3. CD56hi NK cells were
differentiated into CD16hi and CD16lo cells (A). HLA-DRlo CD16hi/dim cells were then differentiated
into MDSCs (CD16dim) and granulocytes (CD16hi CD14lo) (B). MDSCs were differentiated as FSClo
CD14hi and CD14lo/dim. Granulocytes, were separated into neutrophils (FSCmid SSCmid) and
eosinophils (FSChi SSChi). HLA-DRhi cells were differentiated into monocytes (FSClo/mid SSClo) and
macrophages (remainder) and then by expression of CD14 and CD16 (C).
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